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Abstract
The activation of leukocytes during inflammation results in the engagement of many related 
intracellular signalling pathways. The role of two key proteins families, phosphodiesterase 
(PDE) and Src kinase, has been assessed in these signalling pathways using specific 
inhibitors.
Inhibition of phosphodiesterase type 4 (PDE4) in lipopolysaccharide (EPS) stimulated 
human peripheral blood mononuclear cells (PBMC) resulted in the inhibition of TNF-a by 
an IL-10-independent mechanism. This is in contrast to other agents that elevate cAMP 
which in turn inhibit TNF-a synthesis by an IL-10-dependent mechanism. When PBMC 
were stimulated with EPS plus IFN-y, inhibition of PDE4 resulted in an altered effect on 
cytokine production, elevating IE-10 while still inhibiting TNF-a.
Inhibition of PDE4 in activated T cells only weakly inhibited cellular proliferation. In 
contrast, PDE4 inhibitors were potent but non-selective inhibitors of T-cell cytokine 
production. In contrast to studies in murine cells, inhibition of T-cell activation correlates 
with inhibition of binding to a high-affinity Rolipram binding site on the PDE4 protein.
Kinases from the Src family (Eck, Fyn and Eyn) have been implicated in signalling via the 
T-cell receptor (TCR) on lymphocytes and the high affinity IgE receptor (FceRI) on mast 
cells. Potent inhibitors of Src kinases blocked T-cell proliferation and cytokine generation in 
response to specific ligation of the TCR. However, activation of T-cells by multiple co­
stimulatory pathways was much more resistant to Src kinase inhibition. Inhibition of Src 
kinase in human cord blood-derived mast cells inhibited IgE-dependent degranulation of 
these cells. This indicates that Src kinase inhibitors may be useful in down-regulating 
allergic responses. Conversely, inhibitors of PDE4 and PDE type 7 (PDE7) did not prevent 
mast cell degranulation.
The observation that PDE4 inhibitors can regulate monocyte cytokine generation further 
supports the view that these agents could have therapeutic benefit in a number of 
inflammatory diseases such as asthma, arthritis and inflammatory bowel disease. The failure 
of Src kinase inhibitors to modify T cell signalling activated by multiple pathways indicates 
redundancy in these signalling pathways and therefore Src kinases may not represent good 
targets for immunomodulation. However, a selective Src kinase inhibitor could represent a 
good target for an anti-allergic drug.
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Chapter 1 
Introduction
1.1 General introduction
The discovery of cytokines approximately 50 years ago has opened the door to the 
understanding of the inflammatory process. The family of cytokines (which are described in 
more detail in section 1.3) has dramatically increased as the impact of genomics, proteomics 
and informatics has uncovered an ever expanding family tree. Cytokines have many 
activities; they can induce activation, differentiation, proliferation, migration and apoptosis 
of cells. The wide spectrum of responses controlled and induced by cytokines, makes them 
attractive targets for therapeutic intervention. Cytokines, such as tumour necrosis factor 
alpha (TNF-a) and interleukin-1 (IL-1), are regarded as excellent candidates and their 
blockade, using biological inhibitors, has already proved their importance in human clinical 
disease This thesis has examined how manipulation of enzymes that are involved in key 
intracellular signalling cascades can control cellular activation, particularly with respect to 
the control of cytokine production that is important in inflammation.
1.1.1 Acute inflammation
Since cytokines play an important role in inflammation it is necessary to define what is 
meant by ‘inflammation’. Inflammation is classically defined as the response of a living 
tissue to damage. This damage can be due to: infection, physical injury, chemical substances 
or hypersensitivity reactions among other causes. Acute inflammation requires the rapid 
recruitment of cells capable of dealing with foreign invaders. This infiltration of cells to the 
site of inflammation is a complex process. Neutrophils normally are the first cell type 
recruited to the site of inflammation. The neutrophil is responsible for mounting a 
phagocytic response against any foreign material, leading to its destruction and removal. The 
danger signals emitted by the injured tissue during inflammation also serve to summon other 
cell types. At later stages of the inflammatory response, cells such as: eosinophils, basophils.
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monocytes, T and B lymphocytes all appear at the site of injury. Resident tissue cells, such 
as mast cells, macrophages and dendritic cells also contribute to the innate and adaptive 
immune response. These cells are capable of mounting a sustained immune response to 
foreign bodies, resulting in the eventual control of the pathogen. The communication and co­
ordination of the cells involved in the inflammatory response is, for the large part, mediated 
by the action of cytokines. When inflammation and hence cytokine production persist over 
time a state of chronic inflammation may ensue.
1.1.2 Chronic inflammation
Chronic inflammation is defined as an inflammatory response of prolonged duration - weeks, 
months or indefinitely. The persistence of inflammatory disease is due to the inflammatory 
agent remaining, either at the site of the inflammatory reaction, or systemically. This 
continuous inflammatory insult inevitably causes tissue damage and consequently the body 
attempts to repair that damage. Chronic inflammation may develop in a number of ways. 
This may be as a progression from a state of acute inflammation, or develop following repeat 
episodes of acute inflammation or develop de novo. The aetiological agents that cause 
chronic inflammation are summarised in table 1.1.
1.2 Inflammatory disease
The broad definition of inflammation, as defined above, encompasses many biological 
processes and involves many different cell types and tissues. Inflammatory disease is too 
wide a topic to cover extensively in this introduction. Instead, two diseases each with their 
own distinct aetiology and pathology -  rheumatoid arthritis and asthma will be covered in 
some detail. These diseases will be used to introduce the concepts of inflammation, the cell 
types and cytokines involved in inflammation and as a general background to ideas 
introduced and studied throughout the thesis.
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Table 1.1: Aetiological agents responsible for eliciting chronic inflammatory responses.
I Infectious organisms that can avoid host defences and thus persist
for prolonged periods. E.g. Mycobacterium tuberculosis, fungi 
and parasitic infections. Such organisms survive by either being 
able to withstand phagocytosis, by existing within phagocytic 
cells or by inducing only a mild inflammatory response.
Infectious organisms that are not resistant to host defences but 
exist in areas protected from host defences. For example, bacteria 
that grow in the pus within an undrained abscess cavity.
III Irritant non-living and foreign material that cannot be removed by 
enzymatic breakdown or phagocytosis. For example, wood 
splinters, grit, metal and plastics. These foreign materials can be 
either:
Inhaled e.g. silica dust and other particles/fibres.
Introduced e.g. surgical prostheses etc.
IV Stimulation from usually normal tissue components. As in the 
case of auto-antigens.
V Where there is no other obvious cause, such as idiopathic 
diseases: Crohn’s disease, rheumatoid arthritis etc.
1.2.1 Rheumatoid Arthritis
Like most other chronic inflammatory diseases, rheumatoid arthritis (RA) is poorly 
understood. Although it is known that RA has an autoimmune component, its exact aetiology 
is unknown. What is known, is that the disease can be associated with a number of risk 
factors, some of which are genetic. Identical twin studies, which are normally powerful 
indicators of the genetic linkage of diseases, show a relatively low rate of concordance, in 
the range of 15-35% for RA This places a limit upon the possible contribution of a genetic 
element to the disease. Though, undoubtedly factors such as HLA subtype, age and sex are 
important predictors of the likelihood of disease; they are not the full explanation.
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RA is manifestly a disease of the joints, particularly the hands, wrists and feet. Despite this 
obvious outward phenotype, there is also clear evidence that RA has a systemic element. RA 
patients with active disease have elevated erythrocyte sedimentation rate (ESR), C reactive 
protein (CRP) and other acute phase proteins In more severe and prolonged cases there is 
an extra-articular disease, manifest as skin nodules which occur in regions prone to mild 
injury. Other features of RA include fibrosis, most commonly of the lung and in ~1% of 
cases ‘Feltys syndrome’  ^ (hypersplenism and increased white blood cell and platelet 
turnover).
The joints of patients with RA exhibit two main features; synovitis with hyperplasia and 
inflammation of the synovium inducing an inflammatory exudate into the joint causing 
erosion of bone and cartilage. Synovitis manifests itself symptomatically as joint pain, 
morning stiffness with swelling and tenderness of the joints. In RA there is a thickening of 
the synovium, the lining layer of the joint being 6-10 cells, as compared to 1-2 cells thick in 
a normal lining layer.
One consequence of synovitis is an increased vascularisation of the joint This ultimately 
leads to a large cellular infiltrate into and between the many newly formed small vessels. 
The most abundant infiltrating cells are T cells and macrophages with plasma cells, dendritic 
cells, activated fibroblasts and endothelial cells making up the rest of the cell mass As has 
been indicated, the majority of these cell types have trafficked to the joint and are blood- 
borne in nature. The erosion of cartilage and bone takes place mostly at the site where the 
fibrous capsule of the joint, lined by the synovium, abuts with the cartilage and bone. This 
region of synovium, known as the ‘pannus’, overlies and erodes the cartilage and invades the 
bone. Macrophages are the major cell type at this juncture with endothelial cells and 
fibroblasts (also known as synoviocytes) also present.
1.2.2 Asthma
The second disease used to illustrate the role that cytokines play in inflammation is asthma. 
Asthma is an inflammatory disease of the airways of the lung. In asthma, narrowing of the
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airways occurs because of inflammation and hypersecretion of mucus. This is exacerbated as 
the smooth muscle of the bronchi become hyperresponsive to non-specific stimuli This 
intermittent airway constriction leads to wheeze, cough, tightness and shortness of breath. In 
the long term, this may lead to fibrosis and scarring of the bronchioles, and obstruction of the 
airways may become permanent.
Asthma is a disease whose prevalence has markedly increased over the last twenty years 
This increase has been postulated to be caused by such things as passive smoking 
vaccination programmes (e.g. BCG) viral infections diet and the length of time an 
individual spends indoors Either together, or on their own, none of these factors can truly 
explain the inexorable rise in the number of asthma cases.
Asthma has, like many diseases, been shown to have a genetic component with genetic loci 
being mapped as disease susceptibility factors. These have been associated with human 
chromosomes 4, 5, 6, 7, 11, 13 and 16 Genome screening techniques have been used 
to try to map individual genes or sectors of chromosomes that have either positive or 
negative effects upon asthma. Two such candidates are CD 14 and the high-affinity IgE 
receptor.
A linkage with the CD 14 gene was mapped to the short arm of chromosome 5 
Interestingly this is the same location as the IL-4 gene and a number of other Th2 cytokines. 
CD 14 acts as a co-receptor for lipopolysaccharide (EPS) so it’s linkage, albeit as a negative 
regulator of disease, was a surprise. Baldini et al discovered that a C-^T base change 159 
bases upstream of the transcription start site for CD 14 was associated with high levels of 
soluble CD14 (sCD14) and low levels of IgE. This adds weight to the theories of those who 
think that exposure to allergens and the immune milieu encountered during infancy, 
programs immunity to asthma. Thus, exposure to bacterial antigens and stimulation of 
monocytes and macrophages (in particular the production of IL-12) may prime for cytokine 
responses that counteract IgE production.
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The other gene product strongly linked to asthma is the high affinity IgE receptor (FceRI) (3- 
chain The P-chain of FceRI, although not essential for IgE signalling, acts to amplify 
signals through the receptor. Regulating its expression may therefore be a way of modifying 
cell function and disease. Unlike CD 14 there have been few changes identified in the FceRIp 
chain and those that have been discovered are conservative and do not seem to alter the gene 
function
Although, like rheumatoid arthritis, asthma does have a genetic component, the disease can 
be best understood by examining the cell types and cell-cell interactions that occur both in 
normal and diseased states. At the centre of the asthmatic process lies the CD4 positive T 
helper memory cell These cells are critical because they produce an array of cytokines 
that programme the behaviour of other leukocytes, and ultimately control acute and chronic 
allergic inflammation in the airway (the role of cytokines in the pathogenesis of asthma will 
be covered in more detail in section 1.3.2). The various cell types and their interactions in 
asthma can be seen in fig 1.1.
Asthma exhibits a two stage progression from an immediate response, which starts in 
minutes, to a delayed response, which starts hours after the initial insult. The immediate 
response is mediated by acute phase components involved in classical immediate-type 
hypersensitivity responses. This is induced by allergen cross-linking specific IgE bound to 
mast cells via the high-affinity IgE receptor Mast cells release a range of granule- 
associated preformed mediators which are responsible for the immediate symptoms of the 
acute allergic response and which contribute to the late phase response Mast cells also 
produce a variety of chemokines and cytokines which contribute to the recruitment and 
activation of a second wave of response, in particular the recruitment and survival of 
eosinophils The late phase response is characterised by airway perivascular oedema, 
mucus plugging and activated Th2 cells which sustain the recruitment and activation of 
eosinophils.
7
Chapter 1
Allergen Allergen
peptides0 0 1  tidi
I #
MHC d a ss  II ■  B7.2
Peptide 
TCR/CD4 I I
IL-4
IL-13
1
CD40L CD40 
Basophil B cell
J
CD40L CD40
Activated CD4 
helper T cell
Th2 cell B cell
Eosinoptiil Mast cell Basophil
Immediate phase response 
Histamine, P G ,  IT  
and PAF release
Asthma symptoms 
/ \
Bronchioles
Late phase response  
Eosinophil and m ast cell 
Degranulation products
Figure 1.1: The cells co-ordinating the asthmatic response. Allergen is processed as peptides 
and presented to CD4 T helper cells in the context o f MHC class II. IL-4 released by mast cells, basophils and 
eosinophils facilitates the differentiation of Th2 cells, which upon stimulation produce IL-4, IL-5, IL-10 and IL- 
13. Activated Th2 cells then interact with B cells via TCR, BCR and CD40/CD40L, and in the presence of IL-4 
and IL-13 switch Ig synthesis in favour of IgE. IgE binds to IgE receptors (including FceRI on mast cells and 
basophils) and is cross-linked by allergen to activate IgE receptor positive cells. Amplification of B cell Ig class 
switching may occur from interactions of basophils with CD40 positive B cells (see box). Activation of mast 
cells, basophils and eosinophils leads to the release of pro-inflammatory, vasoactive and fibrogenic factors 
(histamine, tryptase, chymase, LT, PG, PAF) that are responsible for the symptoms of bronchial asthma. 
Abbreviations: APC, antigen-presenting cell, BCR, B cell receptor, CD40L, CD40 ligand, Ig, immunoglobulin, 
LT, leukotrienes, MHC, major histocompatability complex, PG, prostaglandins, PAF, platelet activating factor, 
TCR, T cell receptor. Adapted from a diagram by Marone
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1.3 Cytokines and inflammation
Cytokines are often viewed as the hormones of the immune system. They bind to target 
receptors which are expressed at the cell surface but which can also be expressed in a 
secretable form. Cytokines are potent molecules that typically act at concentrations in the 
pico- to nano-molar range and can act in three separate ways. They can act upon the cell 
producing the cytokine in an autocrine manner, act locally on neighbouring cells in a 
paracrine manner or act over longer distances in an endocrine manner. Unlike classical 
endocrine hormones, cytokines are often pleiotropic in action. This can be exemplified by 
the actions of TNF-a, fig 1.2, an important pro-inflammatory cytokine involved in the 
pathogenesis of many diseases
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Figure 1.2: Overview of the effects of tumour necrosis factor-alpha. Abbreviations, Ag, 
antigen, HLA, human leukocyte antigen, MMP, matrix-metalloproteinases, PGE2, prostaglandin E?, ROS, 
reactive oxygen species.
Cytokines rarely act in isolation but form complex and interdependent regulatory pathways,
termed ‘cytokine networks’ Individually cytokines have been shown to have distinct and
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potent effects upon many cellular activities. These in vitro actions have not always been 
manifest when tested in vivo. To understand how cytokines act in vivo it is necessary to 
know how they interact with other cytokines in their local network. To understand how these 
networks are altered in diseases the examples of RA and asthma will again be used. RA will 
introduce the concept of a cytokine imbalance between pro- and anti-inflammatory cytokines 
that perturbs the cytokine network in the rheumatoid synovium and asthma will introduce the 
Thl/Th2 paradigm and how inappropriate cytokine production can lead to disease.
1.3.1 Cytokines and rheumatoid arthritis
In a chronic autoimmune diseases, such as RA, it can be predicted that cytokines will be 
expressed at high levels at the site of inflammation. From early studies measuring both 
mRNA and protein, in culture and in situ, it became apparent that the rheumatoid synovium 
was an abundant site of cytokine expression these cytokines are shown in table 1.2. As 
can be seen from this list of cytokines, both pro- and anti-inflammatory cytokines can be 
found in the inflamed joint, and although informative it gives no indication as to which 
cytokines may be critically involved in the pathogenesis of the disease.
Using the knowledge that cytokines act within connected networks, researchers analysed the 
pattern of cytokine production in the hope of finding an immune bias to the cytokine 
network. It was discovered that macrophage derived proteins TNF-a, IL-1, IL-6 and IL-8 
were found at high levels in the synovium These proteins, in particular TNF-a, IL-1 and 
IL-6, have many effects on different cells and organs of the body and were thought likely to 
play some role in the disease. T cell derived cytokines, such as IL-2 and IFN-y were found to 
a lesser extent at the protein level, though were found to be more abundantly expressed at the 
mRNA level This imbalance in cytokine production formed the basis of a theory to 
explain the joint destruction seen in RA, Fig 1.3.
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Table 1.2; The expression of cytokines in the rheumatoid synovium. *
Cytokines Monocytes Fibroblasts T cells
IL-1 + +
TNF-a + +
IL-6 + +
LIF + +
GM-CSF + +
PDGF + +
bFGF +
IL-lRa +
TGF-P + +
IL-10 + +
IL-13 +
MCP-1 + 4-
M IP-la + +
RANTES +
IL-8 + +
ENA-78 + +
VEGF -t-
IFN-y ±
IL-2 ±
IL-4 ?
* Abbreviations, ENA-78, epithelial cell-derived protein 78, bFGF, basic fibroblast growth factor, GM-CSF, 
granulocyte/macrophage colony stimulating factor, LIE, leukaemia inhibitory factor, MCP-1, monocyte 
chemoattractant protein 1, M IP-la, macrophage inflanunatory protein 1 alpha, PDGF, platelet derived growth 
factor, RANTES, regulated and normal T cell expressed, TGF-|3, transforming growth factor beta, VEGF, 
vascular endothelial growth factor.
The pattern of cytokine expression described in figure 1.3 however, does not completely 
describe the network of cytokines involved in rheumatoid arthritis. Other cytokines, such as 
IL-11, IL-12, IL-15, IL-17 and IL-I8 which are also found to be expressed in the 
rheumatoid synovium are likely to play some role in the pathogenesis of the disease. Despite 
this obvious complexity, the key finding that inhibition of individual cytokines could alter 
the global cytokine profile has aided both the understanding and the therapy of RA. Work in 
animal models of arthritis and ultimately in clinical trials has shown that blockade of 
TNF-a can reduce disease severity.
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Figure 1.3: The balance of pro- and anti-inflammatory cytokines in the rheumatoid 
synovium. The overall outcome of cytokine production in the rheumatoid synovium can be seen as a balance 
of the actions of the cytokines produced in that environment. Many cytokines are pro-inflammatory and 
contribute to the pathogenesis of the disease, e.g. TNF-a and IL-1. Other cytokines are anti-inflammatory, and 
can antagonise the action of pro-inflammatory cytokines, e.g. soluble TNF receptors and IL-1 receptor antagonist. 
A third class of cytokines, that has both pro- and anti-inflammatory action can influence both arms of the 
inflammatory response, e.g. TGF-P. Adapted from a diagram by Feldmann and Brennan .
1.3.2 Cytokines and asthma
The adaptive immune response involves both humoral and cellular immunity. These twin 
arms of adaptive immunity are largely regulated by T cells and in particular the cytokines 
they produce. Pioneering work by Mosmann and Cofmann led to the proposal that T 
helper (Th) cells could be separated into different subsets according to the cytokines they 
released. This distinction was also subsequently made for cytotoxic T cells The discovery 
of Th subsets has provided great insight into the probable disease mechanisms underpinning 
atopic inflammation and hence asthma. Th subsets are thought to be derived from a common 
precursor and, in response to environmental stimuli, differentiate into different populations 
with distinct cytokine secretion profiles, Fig 1.4. The so-called Thl subset of cells secrete 
IL-2, IFN-y, TNF-a and LT, i.e. cytokines involved in cellular defence mechanisms and lytic 
antibody responses against intracellular pathogens The other major subset, called Th2 
cells, in contrast to Thl cells produce an entirely different spectrum of cytokines including, 
IL-4, IL-5, IL-6, IL-9 and IL-13 These cytokines are involved in the immune response to
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combat extracellular pathogens, e.g. parasitic worms. Th2 cytokines critically prime the 
immune response to make IgE antibodies. The presence of IgE and Th2 cytokines are 
strongly associated with asthma
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Figure 1.4; The balance of T helper subsets and cytokine production. Naive CD4 positive T 
cells when experiencing antigen for the first time are not pre-committed to either a Thl or Th2 lineage. Thp (T 
helper precursor cells) cells expand when stimulated with antigen under the influence of IL-2. The dominant 
differentiating cytokines, IL-12 (Thl) and IL-4 (Th2), skew T helper cells to becoming either Thl or Th2 cells. 
These cells upon restimulation, produce distinct patterns of cytokines. Thl cells produce, IL-2, IFN-y, LT and 
TNF-a and Th2 cells produce, IL-4, IL-5, IL-10 and IL-13. IFN-y is responsible for amplifying Thl responses 
and IL-4 is responsible for amplifying Th2 responses. Thl cells mediate delayed type hypersensitivity reactions 
and Th2 cells mediate allergic inflammatory reactions.
A major breakthrough in our understanding of asthma came about by the discovery that, in 
response to allergens, T lymphocytes produce a restricted array of cytokines The study of 
T cell lines and clones produced in response to such allergens lead to the discovery of a 
distinct cytokine production profile, dominated by cytokines that are pro-inflammatory for 
allergic inflammation It is the over-production of Th2 cytokines such as, IL-4, IL-5 and 
IL-13 (Fig 1.1), which contributes to events such as the production of IgE and recruitment of 
eosinophils to the asthmatic lung. A number of factors are thought to select for the Th2 
response in asthma. These include low binding affinity of allergenic peptides in the groove
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of MHC class II, selective engagement of CD28 with CD86 but not CD80 and low IL-12 
or IL-18 production in the microenvironment, which normally biases T cell/dendritic cell 
interactions to prime for Thl responses
1.4 Signal transduction pathways involved in inflammation
The activation of cells to produce factors, such as cytokines, requires the transduction of 
extracellular signals, usually through the binding of a ligand to a receptor, which leads to the 
transcription of genes and production of proteins. These activation pathways, in different cell 
types, while sharing common elements are distinct. Key signal transduction pathways 
activated in cells involved in RA and asthma will be emphasised. These signalling pathways 
can be activated in vitro and share common elements with those pathways likely to be 
activated during inflammation.
1.4.1 Activation of monocytes and macrophages with bacterial endotoxin (LPS)
Monocytes and macrophages are responsible for producing large amounts of inflammatory 
cytokines, e.g. TNF-a, IL-1 and IL-6. These cytokines, which are produced in large 
quantities in the rheumatoid synovium, play a role in joint destruction. To date the best 
established in vitro model of monocyte/macrophage activation utilises bacterial products 
such as LPS. Although there is no definitive evidence for the role of infection in rheumatoid 
arthritis, the signalling pathways activated by LPS are likely to be shared by cells in the 
synovial environment. The understanding of how LPS transduces downstream signals has 
recently undergone a paradigm shift
In 1968 Sultzer et al, demonstrated that the C3H/HeJ inbred mouse strain was naturally 
tolerant to LPS These mice were able to withstand an LPS challenge 20-40 times the 
median lethal dose for most other laboratory strains This trait mapped to the major urinary 
protein (mupl) locus on chromosome 4 and was designated as the Ips locus The Ips
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mutation not only manifests itself at a system level but also at the individual cell level and 
renders many diverse cell lineage’s hypo-responsive to the effects of LPS.
Virulent Gram-negative bacteria induce inflammation by the shedding of their outer 
membrane Within the aqueous environment of the host’s vascular compartment, 
amphipathic LPS molecules spontaneously aggregate as micelles These micelles, via a 
plasma LPS-binding protein, are catalytically transferred as monomers to the surface 
receptor CD 14 CD 14 is recognised as both a myeloid differentiation factor and a receptor 
for LPS and can either be glycosylphosphatidylinositol-linked into the plasma membrane or 
a soluble protein. Both the cell surface and soluble CD 14 moieties facilitate LPS signalling 
despite the absence of a transmembrane domain This has led to speculation that a co­
receptor is recruited to the LPS/CD14 complex and mediates signal transduction
Recently the gene responsible for the Ips phenotype in C3H/HeJ mice was discovered. A 
mis-sense mutation in the Toll-like receptor 4 (TLR4) was discovered and was found to 
result in a Pro 712—>His amino acid substitution The Toll-like receptors are signalling 
receptors that, although initially thought to be involved in embryogenesis in Drosophila, 
were subsequently found to be implicated in innate immune defence responses against 
pathogens The mammalian homologues of Toll have a characteristic leucine rich repeat 
extracellular domain and a cytoplasmic domain responsible for signal transduction. Nine 
human Toll receptors have been cloned thus far but only one, TLR4, has been implicated in 
LPS signal transduction. The transfection of constitutively active TLR4 into a recipient cell 
line induces expression of cytokines and co-stimulatory molecules in a similar manner to 
endotoxin Wild-type TLR4 transfection alone is insufficient to confer LPS sensitivity, but 
in the presence of another protein, MD-2 it forms a complex at the cell surface which confers 
LPS sensitivity upon TLR4 negative cell lines Confusion regarding which toll receptor is 
responsible for mediating LPS signalling has recently been clarified as LPS preparations 
from distinct bacterial species {Leptospira) were found to activate cells through TLR2 and
notTLR4T
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The cytoplasmic domain of the Toll-family proteins is homologous to the cytoplasmic 
domain of the lL-1 receptor and both receptors share many of the same signal transduction 
pathways The cytoplasmic domain of the Toll/lL-1 receptor (TIR) is referred to as a 
TIR domain. The TIR domain also resides in a second protein, known as myeloid 
differentiation factor 88 (MyD88). MyD88 is postulated, via its TIR domain, to interact with 
Toll-like receptor complexes In lL-1 signal transduction MyD88 immunoprecipitates with 
the functional IL-IR complex (IL-lRl, IL-IR accessory protein and IL-IR associated kinase 
(IRAK)) In MyD88 deficient mice, responses to lL-1, lL-18 and endotoxin are all 
deficient indicating its central role in all three pathways
The death domain of MyD88 recruits the down stream serine/threonine kinase IRAK, in its 
unphosphorylated state IRAK is also a key molecule in the signalling cascade, as 
dominant-negative mutants of IRAK inhibit nuclear factor-KB (NF-kB) activation by 
upstream components of the cascade IRAK becomes autophosphorylated when the IL-IR 
is stimulated, but as yet no substrate for IRAK has been identified. IRAK interacts with a 
downstream protein, a member of the TNFR (tumour necrosis factor family receptor)- 
associated factors (TRAFs), known as TRAF6 The TRAF family of adapter proteins 
promotes protein oligomerisation and facilitates protein-protein interactions. TRAF6 is 
unique amongst the TRAF factors in that, apart from its association with CD40 it is the 
only TRAF not to engage a receptor complex. LPS activates the production of both TNF and 
lL-1, the common elements between the two receptor signalling pathways are shown in fig 
1.5. TRAF6 immunoprecipitates with the mitogen activated protein kinase kinase kinase 
(MAPKKK), NIK (NF-KB inducing kinase), this activates the IkB kinase complex and these 
enzymes are responsible for degrading the NF-kB inhibitor IkB Another MAPK, MEKK- 
1 (mitogen activated protein kinase Erk kinase kinase 1), is thought to activate IKK’s but as 
yet this has no proven role in Toll receptor signalling. Finally the phosphorylation of IkB 
releases NF-kB and it translocates to the nucleus where it induces the expression of specific 
genes, many of which are cytokines involved in the inflammatory response
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Figure 1.5: The similarities in signalling pathways of Toll/IL-IR and the TNFR family.
Abbreviations, TNFR, TNF-a receptor, TRADD, TNFR 1-associated death domain protein, RIP, receptor 
interacting protein, IRAK, IL-1 receptor-activated kinase, TRAF, TNF receptor-associated factors, NIK, NF-kP 
inducing kinase, IKK, IkP kinase.
1.4.2 Activation of T cells through the T cell receptor
Alongside monocytes, activated T cells are critically involved in inflammatory cytokine 
production. The primary activation signal of T lymphocytes is one that is transduced via the 
T cell receptor (TCR), which recognises antigenic peptides in the binding groove of the 
major histocompatibility complex (MHC). Although there are many other pathways that can 
be activated in T cells, only a limited number of such pathways will be discussed in this 
introduction. The TCR is a complex multi-subunit structure composed of a ligand binding 
heterodimer (a^ or yô) that can recognise peptides bound to MHC molecules. This complex 
also contains the CD3e, y, ô and TCRÇ (zeta) chains The role of these chains is to target
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the fully functional TCR complex to the cell surface. The CD3 and zeta chains contain 
immunoreceptor tyrosine-based motifs (ITAMs), three in the zeta chain and one in each of 
the CD3 chains These IT AMs may either be involved in amplification of signalling 
through the TCR, or determine signal specificity as they are thought to differentially bind 
intracellular signalling proteins, Zap-70 (Zeta associated protein -  70 kDa), phospholipase 
Cyl (PLCyl), phosphatidylinositol 3-kinase (P13 kinase) and she (Sh2 containing sequence)
85-88
Members of at least four families of tyrosine kinases are involved in the transduction of the 
signal generated by engaging the TCR. Src kinase members, p56^‘^*' (Lck) and p59^^" (Fyn) 
are two proteins that play an important role in TCR signalling. The role of Lck in TCR 
signalling was elucidated using a mutant of the Jurkat cell line, termed JCAMl Upon 
TCR stimulation, these cells failed to give a calcium flux. Analysis of these cells revealed a 
defect in tyrosine phosphorylation, which was due to a defect in functionally active Lck 
Reconstitution of JCAM-1 cells with wildtype Lck restored functionality to the cell line. 
TCR signalling was also antagonised by the micro-injection of Lck antibodies into T cells 
Finally, Lck deficient mice were shown to have sub-optimal T cell proliferative responses, 
when T cells were stimulated through the TCR Fyn is also associated with the TCR 
directly, being co-expressed with the cytoplasmic domains of CD3e and y and TCR Ç and T) 
chains. The role of Fyn in TCR signalling is not as clear as that of Lck. This is exemplified 
by the fact that overexpression of Fyn in T cells augments TCR stimulation, as measured by 
tyrosine phosphorylation and lL-2 production
A member of the Syk (spleen tyrosine kinase) class of protein tyrosine kinases, Zap-70 is the 
dominant family member in T cells. Zap-70 is known to be a critical molecule in TCR 
signalling, as a rare Zap-70 immunodeficiency exists in humans, and such individuals exhibit 
a severely immunocompromised phenotype In transfection studies, Zap-70 associates 
with the zeta chain and its activation is dependent upon either Lck or Fyn In the JCAM-1 
cell line Zap-70 is neither phosphorylated nor recruited to the T cell receptor complex Syk
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augments TCR-triggered tyrosine phosphorylation of zeta and unlike Zap-70 was able to 
stimulate tyrosine phosphorylation of zeta when transfected into Cos-1 cells Another cell 
line P116 (which has defects of protein tyrosine phosphorylation, calcium flux and lL-2 
transcription), that is also derived from Jurkat cells, is defective for both Syk and Zap-70. 
When either catalytically active protein was reintroduced into these cells their defects were 
reversed
Csk (c-Src tyrosine kinase), another tyrosine kinase family protein, has a negative regulatory 
role upon Src kinase activation and as such upon T cell activation. Csk phosphorylates the 
carboxy-terminal of Lck and Fyn maintaining them in an inactive state The phosphatase 
CD45, (also associated with the TCR complex), dephosphorylates Lck and Fyn allowing 
their activation upon TCR engagement Another tyrosine kinase family member Tec 
(tyrosine kinase expressed in hepatocellular carcinoma), expressed as Itk (lL-2 inducible T 
cell kinase) and Tec, are also involved in TCR signalling. Itk signals downstream of Lck and 
is recruited to different signalling complexes when CD28 or the TCR are engaged In 
Itk-deficient mice T cell signal impairment is modest and hence its contribution to TCR 
signalling may not be as great as the Src family kinases Tec when activated by TCR/CD3 
or CD28 ligation interacts with the CD28 receptor. Tec can phosphorylate p62°°^ (a substrate 
of CD28), whereas Itk cannot. These differences may indicate different roles for these 
tyrosine kinases in T cell activation
Further down stream events, in the TCR signalling cascade, occur via tyrosine 
phosphorylation of Slp-76 (SH2 domain leukocyte protein), a Zap-70 substrate, which 
mediates association with Vav. TCR stimulation induces tyrosine-phosphorylated proteins 
including Slp-76, pl20™ and She which associate with the Grb-2/Sos complex which is 
known to be involved in the regulation of Ras The Ras/MAPK pathway is an
important pathway activated upon TCR stimulation. The expression of T cell cytokines, such 
as lL-2, is largely inducible and is initiated by the cross-linking of the T cell receptor plus 
the activation of other co-stimulatory molecules. The signal transduction pathways detailed
19
Chapter 1
above, ultimately leads to the activation of many transcription factors. The complex interplay 
between these factors, controls the cytokine production in T cells. In T cells these signal 
transduction pathways include a calcium-dependent/cyclosporin-sensitive pathway that 
regulates the nuclear factor of activated T cells (NFAT), a protein kinase C-dependent 
pathway that regulates activator protein-1 (AP-1), (NF-kB) and a p21/Ras activated MAPK 
cascade that affects AP-1 amongst other transcription factors
1.4.3 Activation of mast cells through the high-affinity IgE receptor
As described earlier, mast cells are important in the pathogenesis of asthma and allergic 
disease. IgE, and more specifically the IgE that is cross-linked on the cell surface of a mast 
cell by antigen, is an important trigger of many of the symptoms of asthma. The receptors 
that bind IgE on mast cells are termed high-affinity IgE receptors or FceRI.
FceRI belongs to a family of multi-subunit immune receptors that do not have intrinsic 
kinase activity but associate reversibly with protein tyrosine kinases. FceRI is expressed on 
mast cells as a heterodimeric complex comprising of a, P and two y chains. IgE binds to the 
alpha chain, which is the major extracellular component of FceRI The P and y sub-units 
are responsible for down-stream propagation of signals through phosphorylation of their 
ITAM’s (as seen in the TCR, section 1.4.2) The P chain has been ascribed an amplifying 
role within the signalling pathway and the y units are essential for targeting the receptor to 
the cell surface and for signal transduction
Upon receptor aggregation signals are transduced via an unknown mechanism to the p and 
y-chain signalling subunits. The Src family tyrosine kinase, Lyn, is activated, or deactivated, 
via tyrosine phosphorylation or dephosphorylation at its carboxy terminus by Csk kinase and 
the phosphatase CD45 respectively Activated Lyn then phosphorylates the P and y- 
chain ITAM’s, the y-chains are then able to selectively recruit Syk which in turn is activated 
by Lyn Targets of these tyrosine kinases include the activation of PI(3) kinase to
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produce phosphotidylinositol (3,4,5)P3 or PIP3, phosphorylation of Bruton’s tyrosine kinase 
(Btk) and phosphorylation of the membrane localised adapter protein (LAT)
These pathways critically activate mobilisation of intra and extracellular calcium, Btk, when 
localised to the cell membrane by its binding to PIP3, contributes to the activation of PLCyl, 
which in turn is brought to the membrane by phosphorylated LAT. PLCyl acts upon 
membrane inositol phospholipids to generate Ins(l,4,5)P3 or IP3 and diacylglycerol (DAG) 
120:121. d a g  targets various protein kinase C (PKC) ispforms, whereas IP3 binds to IP3 
receptors on the surface of the endoplasmic reticulum containing calcium stores 122. This 
leads to a depletion of intracellular calcium stores and an elevation of cytoplasmic calcium 
levels. The depletion of calcium stores leads to an opening of the plasma membrane channels 
required for calcium influx. The calcium release activated current is mediated by the store- 
operated calcium channels and is responsible for sustained elevations in cytosolic calcium 
and replenishment of ER (endoplasmic reticulum) calcium stores
Activation of FceRI also leads to the involvement of adapter proteins required to activate 
down-stream targets of the small GTP-binding protein and kinase cascades. Syk targets the 
membrane bound adapter LAT, which anchors further adapters Grb-2 and Slp-76 *26.127 
These adapters respond by recruiting and localising guanine nucleotide exchange factors for 
the Ras family of GTPases 2^^ .
The Erk (extracellular signal-regulated kinase). Ink (c-Jun N-terminal protein kinases) and 
p38 MAP kinases are downstream components of the signal cascade initiated by engagement 
of the high affinity IgE receptor *29;i30^  The consequence of activation of these pathways is 
the nuclear import of a range of transcription factors including, NF-kB, ATF-2 (activating 
transcription factor 2), Elk-1, Jun and SRF (serum response factor) plus the activation of 
nuclear proteins, e.g. c-jun and c-fos. These transcription factors act in concert so the final 
effect on protein transcription depends upon their overall pattern of expression.
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Finally, the activation of the signalling cascades described results in cytokine production and 
degranulation, with the subsequent release of pre-formed and newly synthesised 
inflammatory mediators. Purified lung mast cells constitutively express mRNA for IL-5, IL- 
6, IL-8 and TNF-a and upon stimulation with anti-IgE induce expression of IL-4 and GM- 
CSF, whilst increasing the expression of IL-5 and TNF-a *21-133 conjunction with 
pathways already described, a transient rise in free calcium and cyclic AMP enables the 
microtubular apparatus of the cell to mobilise and allow fusion of the secretory granules with 
the plasma membrane.
1.5 Inhibitors of cytokine production and signal transduction
The hypothesis that blockade of specific cytokines could be of therapeutic benefit has now 
been supported by clinical findings. This is especially true for TNF-a, where biological 
inhibitors may revolutionise the treatment of both RA and Crohn’s disease *:*24435 ^he 
effectiveness of such an approach, has been to some extent limited by the expense of such 
treatments, which may curtail their eventual use. Orally available, small molecule inhibitors 
of signal transduction pathways, offer a cheaper alternative to biological inhibitors and as 
such are being pursued as alternative therapies.
1.5.1 Phosphodiesterase inhibitors
The phosphodiesterase (PDF) family of enzymes was discovered over thirty years ago by 
Butcher and Sutherland These enzymes were found to degrade the second messengers 3’, 
5’- cyclic adenosine monophosphate (cAMP) and 3’, 5’- cyclic guanine monophosphate 
(cGMP), to 5’-AMP and 5’-GMP respectively. Both cAMP and cGMP act as second 
messengers propagating signals delivered by hormones, neurotransmitters and cytokines into 
the cell 2^2. The family of PDE enzymes contains at least eleven isozymes with different 
selectivity for cAMP and cGMP. The type 4 of the PDE family, termed PDE4, is known to 
specifically hydrolyse cAMP in preference to cGMP and is an abundant isoform in 
inflammatory cells, smooth muscle and vascular endothelium ^^9 The PDE4 enzyme is
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further split into four subtypes (A-D). These subtypes themselves are further divided, as 
alternative splicing of the PDE4 A-D genes produces additional splice variants
The archetypal PDE4 inhibitor. Rolipram, was first described twenty five years ago 
Rolipram is a relatively weak competitive inhibitor of PDE4 (Kd -0.5-1 pM) and binds to an 
alternative conformation of the PDE4 enzyme in a steroselective manner and with a high 
affinity (Kd-lnM). This high-affinity confomer is often referred to as the high-affinity 
Rolipram binding site or HARBS *"*2;i43 typified by Rolipram, the first generation of 
PDE4 inhibitors had dose limiting side effects in both animals and humans the greatest 
manifestation of these side effects was the induction of a strong emetic response 
Second generation PDE4 inhibitors have been developed over the last ten years, which have 
reduced side effects and it is these inhibitors, plus Rolipram, that have been used to validate 
the therapeutic potential of PDE4 inhibitors
PDE4 inhibitors have been proposed as being useful in treating chronic inflammatory 
conditions such as RA. PDE4 is an abundant enzyme in monocytes and PDE4 inhibitors 
have proved potent modulators of some monocyte functions, such as the inhibition of LPS 
stimulated TNF-a production in humans and mice *"*2-151 This reduction in TNF-a protein 
levels is mirrored by a decrease in TNF-a mRNA levels In rat models of arthritis, where 
anti-TNF-a antibodies are effective at stopping disease, PDE4 inhibitors had strong 
suppressive effects *22^ 53^
At the present time the main therapeutic target of PDE4 inhibitors has been asthma. PDE4 
inhibitors effect diverse components of the allergic response from recruitment of eosinophils 
to the activation of T cell cytokines and show promise in many animal models of the disease, 
these are summarised in table 1.3. In man CDP840 (a specific PDE4 inhibitor) was well 
tolerated by volunteers and, although showed no effect on the early phase response in 
asthma, gave a 30% reduction in the late phase response
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Table 1.3: A list of the pharmacologically active PDE4 inhibitors tested in animal 
models of airway eosinophilia. *
Compound Species Route Model Refs.
CDP840 Rat p.o. IL-5 induced pleural eosinophilia 158
Guinea
pig
i.p. OVA- sensitised and challenge (aerosol)
158
Monkey s.c. Atopic challenge with ascaris suum
159
CP-80633 Guinea p.o. OVA sensitised and 160
pig challenge
Monkey s.c. Atopic challenge with ascaris suum
160
D-22888 Guinea
pig
p.o.
OVA sensitised and 
challenge, late phase 
pulmonary eosinophilia
161
T-440 Guinea
pig
p.o.
Allergen induced challenge 
early and late phase 
measurements
162
KF19514 Guinea
pig
p.o. PAF-induced lung eosinophilia 78;163;164
SB207499 Guinea p.o. LTD4 and OVA induced 165
pig eosinophilia
* Abbreviations; OVA, ovalbumin, PAF, platelet activating factor, LTD4, leukotriene D4, p.o., per oral, i.p., intra- 
peritonealy, s.c., sub-cutaneously.
1.5.2 Tyrosine kinase inhibitors
Signalling through the T cell receptor and high-affinity IgE receptor are both known to 
recruit tyrosine kinase enzymes to the receptor upon its engagement. The 
immunosuppression of T cell mediated immunity has been one of the driving forces behind 
the successful treatment of autoimmune disease and organ transplantation, in the modem era. 
The ‘gold-standard’ T cell immunosuppressive drug, cyclosporin A (CsA) has revolutionised 
the treatment of transplantation, being more efficient, effective and having fewer side-effects 
than treatments that preceded it *25;i56 (^ s^A despite being a very effective treatment does 
however show dose-limiting side effects, particularly nephrotoxicity and a higher incidence
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of cancer, that precludes the broader use of the drug. Other macrolide drugs such as FK-506 
and Rapamycin, though effective, also suffer from dose-limiting side effects .
Newer T cell immunosuppressive drugs have emerged that target the IL-2R (monoclonal 
antibodies daclizumab and basiliximab) and though useful in treating certain conditions 
efficacy and cost prohibit their widespread use. Thus the search has been to replace 
cyclosporin with a synthetic inhibitor of T cell receptor signal transduction. Candidate 
targets, excluding the cyclophilins which are targeted by drugs such as CsA, include proteins 
such as Lck, Fyn, ZAP-70/Syk and MAP kinase, as well as non-TCR transduced signalling 
proteins such as those of the JAK/STAT cytokine receptor pathway. The Src-kinase family, 
which in T cells is represented by, Lck, Fyn and p62^^  ^(Yes), are attractive targets as they 
have a relatively restricted expression and in the case of Lck and Fyn are important in TCR 
signalling *^2-no Src-like family of enzymes is also thought to be involved in the 
activation of mast cells through the high-affinity IgE receptor.
A number of inhibitors of Src kinases exist with varying potencies and specificities, these are 
summarised in table 1.4. The most potent and selective inhibitors described to date are a 
series of pyrazolopyrimidines, which have specificity for Lck, Fyn, Src and p59"^  ^ (Hck) 
over epidermal growth factor (EGF) receptor kinase, with selectivity against ZAP-70 and 
protein kinase A (PKA). These inhibitors, named PPl and PP2, inhibited tyrosine 
phosphorylation of a number of proteins in human T cells stimulated through the TCR 
PPl also inhibited the proliferation of peripheral blood lymphocytes (PEL) in response to 
anti-CD3 antibodies but not PMA/IL-2 dependent p r o l i f e r a t i o n ^ ^ !
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Table 1.4: The action of Src kinase inhibitors in in vitro assays.
Compound IC50 Lck Specificity Effects upon cell function
WIN61651 18-24pM Selective compared 
to PKC and PKA, 
erb2, EGF kinase 
and Insulin receptor 
kinase
i  tyrosine phosphorylation of cellular 
proteins
i  IL-2 production in CD3/CD4/CD28 or 
CD3/PMA stimulated T cells 
i  proliferation to antigen and in MLR
A-125800 l-7pM 50-100 fold 
selectivity over 
MAPK but 
equipotent 
inhibition of Zap-70
i  tyrosine phosphorylation and calcium flux 
i  proliferation to alloantigen and CD3/CD28 
induced IL-2 production in T cell cultures 
Irreversible binding to Lck
PPl & PP2 4-6nM Selective over 
EGFR kinase 
Inactive against 
Jak-2, Zap-70 and 
PKA
i  proliferation of T cells stimulated with CD3, 
influenza (antigen) and MLR 
Weakly active against PMA/IL-2 dependent 
proliferation
Support Th2 differentiation in mice
* References, •174
1.6 Aim of project
PDE4 and Src kinase enzymes are known to play a role in intracellular signalling processes. 
This project has capitalised on the fact that potent and specific inhibitors of these enzymes 
exist. Using such inhibitors it has been possible to assess the role played by PDE4 and Src in 
the activation of inflammatory cells.
Inhibiting PDE4 is known to block TNF-a production from LPS activated monocytes. To 
understand how this regulation occurs the effect of PDE4 blockade on the cytokine network 
induced by LPS activation of human PBMC was investigated.
The aims were:
• To investigate the effect of PDE4 inhibition on the overall pattern of cytokine production 
from LPS activated human PBMC.
• To investigate if the effect of inhibiting PDE4 blocks pro-inflammatory cytokine 
production via the elevation of anti-inflammatory cytokines, e.g. IL-10.
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• To determine whether altering the stimulus delivered to PBMC, alters the effect PDE 
inhibitors have on cytokine production.
Inhibition of PDE4 is also thought to disrupt T cell function. To test this, the effect of PDE4 
blockade on activated T cells was investigated.
The aims were:
• To investigate the effect of PDE4 inhibition on T cell proliferation.
• To investigate the effect of PDE4 inhibition on T cell cytokine production.
• To assess if the effect of PDE4 inhibitors on T cell function correlates with inhibition of 
the PDE4 enzyme in either its low-or high-affinity conformation.
Src kinase enzymes are implicated in transducing signals through the T cell receptor.
The aims were:
• To investigate the effect that Src kinase inhibition has on T cell proliferation induced by 
various stimuli.
• To investigate the effect of Src inhibition on T cell cytokine production.
• To investigate the point at which Src kinase inhibitors block TCR signal transduction.
Finally, to determine the role that Src kinase and phosphodiesterase type? (PDE7) may play 
in mast cell activation.
The aims were:
• To develop a model of cord blood-derived mast cell activation.
• To investigate the effect of Src kinase and PDE7 inhibition on the IgE-dependent 
degranulation of mast cells.
27
Chapter 2
Chapter 2
Materials and Methods
28
Chapter 2
Chapter 2
Materials and Methods
2.1 General reagents and equipment
Unless stated otherwise all chemical and biological reagents were obtained from Sigma 
Chemical company, Poole, UK. All tissue culture plastic ware was obtained from Falcon, 
Becton Dickinson labware, NJ, with the exception of ‘U’ bottomed 96 well tissue culture 
plates which were obtained from Costar, NY. Centrifugation was performed using bench top 
centrifuges 8R and GP8R, lEC, MA. All biological buffers, including tissue culture media 
were obtained from Gibco, Paisley, UK, unless stated otherwise. Foetal calf serum (FCS) 
was sourced from Helena Biosciences, #NS3005, lot 7329-2-NS31 (USA herd).
2.1.1 Recombinant proteins
Protein Expression system Source
IL-la E.coli R&D systems, Oxford, UK
IL-P E.coli Biosource, UK
IL-2 E.coli R&D systems, Oxford, UK
IL-4 E.coli R&D systems, Oxford, UK
IL-6 E.coli R&D systems, Oxford, UK
IL-8 E.coli R&D systems, Oxford, UK
IL-10 SF21 R&D systems, Oxford, UK
IL-12p40 SF21 R&D systems, Oxford, UK
TNF-a E.coli Celltech, UK
IFN-y E.coli R&D systems, Oxford, UK
2.1.2 Antibodies
Antibody Isotype Conjugate Clone Source
CCRl
CCR2
Mouse
IgG2b
Mouse
IgG2b
Biotinylated
Biotinylated
53504.11
48607.121
R&D systems, Oxford, UK 
R&D systems, Oxford, UK
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Cont.
CCR3 Rat IgG2a PE 61828.111 R&D systems, Oxford, UK
CCR5 MouseIgG2b Biotinylated 45549.111 R&D systems, Oxford, UK
CCR6 MouseIgG2b PE 53103.111 R&D systems, Oxford, UK
CD117 MouseIgGl FITC YB5.B8 Pharmingen, San Diego, CA
CD 14 MouseIgG2a PE M5E2 Pharmingen, San Diego, CA
CD16 MouseIgGl FITC 3G8 Pharmingen, San Diego, CA
CD25 MouseIgGl PE 2A3 BD, San Jose, CA
CD3 MouseIgGl FITC/PE SK7 BD, San Jose, CA
CXCRl MouseIgG2b PE 5A12 Pharmingen, San Diego, CA
CXCR2 MouseIgGl PE 6C6 Pharmingen, San Diego, CA
CXCR3 MouseIgGl FITC 49801.111 R&D systems, Oxford, UK
CXCR4 MouseIgG2a PE 12G5 Pharmingen, San Diego, CA
CXCR5 MouseIgG2b Biotinylated 51505.111 R&D systems, Oxford, UK
IFN-y (c)
Mouse
IgGl Unconjugated NIB42 Pharmingen, San Diego, CA
IFN-Y (d) MouseIgGl Biotinylated 4S.B3 Pharmingen, San Diego, CA
IL-10 MouseIgG2b Unconjugated 23738.111 R&D systems, Oxford, UK
IL-10 (c) Rat IgG2a Unconjugated JES3-19F1 Pharmingen, San Diego, CA
IL-10 (d) Rat IgG2a Biotinylated JES3-12G8 Pharmingen, San Diego, CA
IL-IOR MouseIgGl Unconjugated 37607.11 R&D systems, Oxford, UK
IL-12p40 (c) MouseIgGl Unconjugated A08E6E5 Biosource, UK
IL-12p40 (d) MouseIgGl Biotinylated A25C4B6 Biosource, UK
IL -la (c) MouseIgGl Unconjugated 36-3B3-14 Pharmingen, San Diego, CA
IL-la (d) MouseIgGl Biotinylated 284 Pharmingen, San Diego, CA
IL-lp (c) MouseIgGl Unconjugated 508A7G8 Biosource, UK
IL-ip (d) MouseIgGl Biotinylated 508A3H12 Biosource, UK
IL-2 (c) MouseIgGl Unconjugated 419A-7A3 Biosource, UK
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IL-2 (d) MouseIgG2b Biotinylated 297C16G2 Biosource, UK
IL-4 (c) MouseIgGl Unconjugated 8D4-8 Pharmingen, San Diego, CA
IL-4 (d) Rat IgGl Biotinylated MP4-25D2 Pharmingen, San Diego, CA
IL-6 (c) Rat IgGl Unconjugated MQ2-13A5 Pharmingen, San Diego, CA
IL-6 (d) Rat IgGl Biotinylated MQ2-39C3 Pharmingen, San Diego, CA
IL-8 (c) MouseIgG2b Unconjugated G265-5 Pharmingen, San Diego, CA
IL-8 (d) MouseIgG2b Biotinylated G265-8 Pharmingen, San Diego, CA
mlgGl
control
Mouse
IgGl FITC/PE A112-2 Pharmingen, San Diego, CA
mIgG2a
control
Mouse
IgGl PE G115-178 Pharmingen, San Diego, CA
V mIgG2b 
control
Mouse
IgGl Biotin/PE MPC-11 Pharmingen, San Diego, CA
rIgG2a
control Rat IgG2a PE 35-95 Pharmingen, San Diego, CA
TNF-a (c) MouseIgGl Unconjugated MABl Pharmingen, San Diego, CA
TNF-a (d) MouseIgGl Biotinylated MABll Pharmingen, San Diego, CA
Notes : (c) = ELISA coating antibody, (d) = ELISA detection antibody, FITC 
= Fluorescein isothiocyanate, PE = Phycoerythrin.
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2.2 Chemical structures
All chemical inhibitors used throughout this thesis were synthesised by the medicinal 
chemistry department Celltech ( Slough, UK).
2.2.1 PDE4 inhibitors
o
R-Rolipram
O
CT1730 (CDP840)
SB207499 (Ariflo)
NC
COgH
O
O
CT1881(RP73401)NH
CT2396 (RS25344)
O
All PDE4 inhibitors were synthesised by the medicinal chemistry department of Celltech 
(Slough, UK) according to the details given in the references I4i;i58;i75-i79^  Compounds were 
kept as frozen stock solutions at a concentration of 20mM in DMSO, the repeated freeze 
thawing of compounds was avoided.
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Chapter
CT5102-00
CT5215-10
CH,
T
.  N
S
'CH3
,CH,
N C H 3 
'C H ,
L,
N-[3,5-D im ethyl-4-(2-
dim ethylam inoethyloxy)phenyl]-9-
methoxybenzo[h]-
5,6-dihydroquinazoline-2-am ine
N-[3-(D iethylam inoethoxy)-4,5-
dim ethoxyphenyl]-4-(3-
methoxyphenylsulfanyl)
dihydrochloride
CT5227-10
C H .
• C H ,
H3C.
C K
H3C
N-[3,4-D im ethoxy-5- 
(dim ethylam ino)ethoxyphenyl]-4- 
(3-m ethoxyphenylsuifanyl)pyrim idine 
2-am ine dihydrochloride
CT5263-00
H3C
CT5264-10
N 
S
'CH3
, C H ,
H,C
' O
6,6-D im ethyl-9-m ethoxy-N-2-[3-
methoxy-4-(2-
pyrroldinyl)ethoxyphenyl]-
benzo[h]-5,6-dihydroquinazoline-2-
am ine
N-[3,4-D im ethoxy-5-(2-pyrrolidin-1- 
yl)ethoxyphenyl]-4- 
(3-m ethoxyphenylsulfanyl)pyrim idine 
2-am ine hydrochloride
CT5269-10
H3C CH3
N-[3-(2-D iethylam inoethoxy)-4,5-
dim ethoxyphenyl]-9-methoxy-6,6-
dim ethylbenzo[h]5,6-
dihydroquinazoline-2-am ine
dihydrochloride
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CT5276-00
N-[3,5-Dimethoxy-4-(2-
diethylaminoethoxy)phenyl]-9-
methoxy-6,6-dimethyl-
benzo[h]-5,6-dihydroquinazoline-2-
amine
CT5378-10
CH3
N-{3,5-dimethoxy, 4-[2-(4- 
methoxypiperazin-1- 
yl)ethoxy]phenyl}-4 
-(3-methoxyphenylthio)pyrimidine-2- 
amine dihydrochloride salt
CT5474-00
CT5475-00
CT5605-10
0 '  'N H
KC
CT5651-00
N-[3,5-Dimethyl-4-(2-
isopropylaminoethoxy)phenyl]-6,6-
diemthyl-9-methoxy-
benzo[h]-5,6-dihydroquinazoline-2-
amine
4-(3-carboxamidophenylthio)-N-
[3,4-dimethoxy-5-
(isopropoxycarbonyloxy)phenyl]py
rimidine-2-amine
N-(3-hydroxymethylphenyl) 4-(3- 
methoxyphenylthio)pyrimidine-2- 
amine hydrochloride
9-methoxy-6,6-dimethyl-N-(2-
methylbenzimadazol-5-yl)benzo[h]-
5,6-dihydroquinazoline-2-amine
CT5733-00
9-methoxy-6,6-dimethyl-N-(2-
aminobenzothiazol-6-yl)benzo[h]-
5,6-dihydroquinazoline-2-amine
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6,6-Dimethyl-9-methoxy-N-(2-
methylbenzimidazol-5-yl)-4-
methylthio-benzo[h]-5,6-
dihydroquinazoline-2-amine
CT6236-00
N-(6-Benzothiazolyl)-6,6-dimethyl-9-
methoxy-4-methylthio-benzo[h]-5,6-
dihydroquinazoline-2-amine
All kinase/PDE7 inhibitors were synthesised by the medicinal chemistry department of 
Celltech (Slough, UK) according to the details given in patents WO 9841512, 9719065, 
9828281, 9858926 Compounds were kept as frozen stock solutions at a concentration 
of 20mM in DMSO, the repeated freeze thawing of compounds was avoided.
2.3 Cell based assays
2.3.1 Purification of human PBMC
Peripheral blood mononuclear cells were isolated from normal healthy volunteers. Whole 
blood was taken by venous puncture using heparinised vacutainers (Becton Dickinson), 
diluted 1 in 4 in RPMI 1640 (Gibco, UK) and centrifuged at 400g for 35 min over a Ficoll- 
paque gradient (Amersham-Pharmacia Biotech, UK). Cells at the interface were removed 
and washed once followed by a low speed spin to remove platelets. Unless stated otherwise, 
cells were then resuspended in RPMI 1640 containing 10% FCS and penicillin 100 units 
ml \  streptomycin 50|ig mP’ and glutamine 2mM (Gibco, UK).
2.3.2 LPS stimulation of PBMC
PBMC were resuspended at a density of 2x10  ^ cells/well in flat bottomed 96 well tissue 
culture treated plates. Cells were stimulated with an optimal dose of LPS {E.coli strain
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B5:055, Sigma, at lp.g ml'^) and incubated at 37°C in 5%C02/95% air. Cytokine production 
was measured from cell free supernatants by sandwich ELISA (Chapter 2.4.).
2.3.3 Antigen stimulation of human PBMC
PBMC were resuspended at a density of 2x10  ^cells/well in round bottomed 96 well tissue 
culture treated plates. Assays were performed in RPMI 1640 with 10% pooled human AB 
serum as a replacement for FCS. Healthy volunteers were chosen for their potential 
reactivity to tetanus toxoid and house dust mite antigen prior to use in assays. Only reliable 
and strong responders to each antigen were chosen. Cells were stimulated with an optimal 
dose of tetanus toxoid (Wellcome Laboratories, Beckenham, UK, at l|Lig ml'^) and incubated 
for five days at 37° in 5%C02/95% air. Cellular proliferation was measured by the 
incorporation of ^H-thymidine. Cells were harvested onto glass fibre filter mats using a 
Skatron 96 well harvester (Molecular Devices, Sunnyvale, CA) and ^H-thymidine 
incorporation measured using a (3-plate counter (Wallac-Perkin Llmer, UK). Cells were also 
stimulated with an optimal dose of house dust mite antigen (part purified preparation of 
Dermataphagoides pterrenyssinus, ALK, Denmark, at 5000 units ml'^) and incubated for 
five days at 37°C in 5%C02/95% air. Cellular proliferation was measured by the 
incorporation of ^ H-thymidine.
2.3.4 Superantigen stimulation of human PBMC
PBMC were resuspended at a density of 2x10^ cells/well in round bottomed 96 well tissue 
culture treated plates. Cells were stimulated with an optimal dose of superantigen (an equal 
mixture of staphylococcal enterotoxins A, B, D and E, Toxin Technologies, Sarasota, FL, at 
0.1 ng mf^) and incubated at 37°C in 5%C02/95% air. Cellular proliferation was measured 
by the incorporation of ^ H-thymidine.
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2.3.5 Anti-CD3 stimulation of human PBMC
PBMC were resuspended at a density of 2x10  ^cells/well in round bottomed 96 well tissue 
culture treated plates. Cells were stimulated with an optimal dose of the anti-CD3 antibody, 
OKT3, (Celltech, UK, at 0.05pg ml'^) and incubated at 37°C in 5%C02/95% air. Cellular 
proliferation was measured by the incorporation of ^H-thymidine. Where indicated, cells 
were resuspended in DMEM (Gibco, UK) containing 10% FCS and penicillin, streptomycin 
and glutamine (Low biotin preparation). The cytokine production from such cultures was 
measured using a multiplex cytokine assay (Section 2.4.4).
2.3.6 Concanavalin A (Con A) stimulation of human PBMC
PBMC were resuspended at a density of 2x10  ^cells/well in round bottomed 96 well tissue 
culture treated plates. Cells were stimulated with an optimal dose of Con A (at lp,g ml'^) and 
incubated at 37°C in 5%C02/95% air. Cellular proliferation was measured by the 
incorporation of ^ H-thymidine.
2.3.7 Phytohaemagglutinin (PHA) stimulation of human PBMC
PBMC were resuspended at a density of 2x10^ cells/well in round bottomed 96 well tissue 
culture treated plates. Cells were stimulated with an optimal dose of PHA (derived from 
Phaseolus vulgaris, at l|ig ml'^) and incubated at 37°C in 5%C02/95% air. Cellular 
proliferation was measured by the incorporation of ^ H-thymidine.
2.3.8 Phorbol 12- myristate-13-acetate (PMA) and ionomycin stimulation of 
human PBMC
PBMC were resuspended at a density of 2x10^ cells/well in round bottomed 96 well tissue 
culture treated plates. Cells were stimulated with an optimal dose of PMA (at l[ig ml'^) and 
ionomycin (Ca"^ "^  ionophore derived from Streptomyces conglobatus, at 10 ng ml'^) and 
incubated at 37°C in 5%C02/95% air. Cellular proliferation was measured by the
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incorporation of ^H-thymidine. IL-2 production was measured in cell free supernatants by 
sandwich ELISA (Chapter 2.4).
2.3.9 Mixed lymphocyte reaction (MLR)
PBMC from two HLA mismatched donors were selected for use in a MLR. The first donor’s 
cells, referred to as the ‘responder’, were resuspended at a density of 1x10  ^ cells/well in 
round bottomed 96 well tissue culture treated plates. These cells were stimulated with the 
second donors cells, referred to as the ‘stimulator’, which had been irradiated for a period of 
45 min with a total dose of 2500 rads. These cells had no proliferative capacity but were 
determined to be alive by staining with trypan blue and propidium iodide. The stimulator 
cells were added to the responder cells at a density of 1x10  ^in an equal volume. This gave a 
ratio of 1:1 responders to stimulators. Cells were was incubated for five days at 37°C in 
5%C02/95% air. Cellular proliferation was measured by the incorporation of ^ H-thymidine.
2.3.10 Isolation of human mast cells derived from cord blood precursors
The purification of human mast cells was adapted from a technique developed by Saito et al 
Either heparin- or citrate-treated cord blood was taken from the umbilical cord vein of 
placental tissue (performed with parental consent). Cord blood was always used within 12 
hours of collection. Cord blood mononuclear cells were separated over Ficoll-paque 
gradients as detailed in section 2.3.1. Briefly, cord blood was diluted 1 in 4 with RPMI 1640 
and centrifuged at 400g for 35 min. Cells at the interface were removed and washed once 
followed by a low speed spin to remove platelets. Red cells were removed by suspension in 
red cell lysis buffer (155mM NH4CI; lOmM KHCO3 and O.lmM EDTA, in H2O pH = 7.4) 
for 5 minutes. Cells were then resuspended at a concentration of 1x10  ^cells ml'* in a 75cm^ 
tissue culture flask in mast cell media (RPMI1640, 10% FCS, penicillin, streptomycin, 
glutamine, transferrin 5pg ml'  ^ , insulin 5pg m l'\ sodium selinite 5ng ml'* and HEPES 
25mM). Cells were treated with a cocktail of human recombinant stem cell factor (SCF) 
4.3nM (R&D Systems, Oxford, UK), interleukin-6 (lL-6) 2.5nM (R&D systems, Oxford, 
UK) and 300nM PGE2 (prostaglandin E2) and incubated at 37°C in 5%C02/95% air. Growth
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factors were added at weekly intervals to cultures to which fresh mast cell media had also 
been added. Cellular viability was assessed weekly using trypan blue and cellular 
morphology was assessed using cytospin preparations stained with Giemsa/May-Grünwald.
2.3.11 Anti-IgE stimulated human mast cell degranulation
Cord blood derived mast cells (cbMC) were grown in a cocktail of SCF, IL-6 and PGE2 for 
70 days prior to harvest. cbMC were resuspended at a density of 2x10“^ cells/well in flat 
bottomed 96 well tissue culture treated plates. Cells were preincubated with lOpg ml'  ^ of 
human IgE protein (Serotec, Oxford, UK) for 2 hours in mast cell media. Cells were then 
stimulated with an optimal dose of mouse anti-human IgE antibody (Pharmingen, at 5pg 
ml'h, either in the presence or absence of SCF (lOng ml'h, for 30 mins at 37°C in 5% 
C02/95% air. Plates were then spun at 200g for 3 minutes and supernatants taken and frozen 
at -70°C. The concentration of histamine and peptido-leukotriene was determined in 
supernatants by EIA (Section 2.4.5 and 2.4.6).
2.3.12 PMA and ionomycin stimulated human mast cell degranulation
cbMC were resuspended at a density of 2x10"^  cells/well in flat bottomed 96 well tissue 
culture treated plates. Cells were stimulated with an optimal dose of PMA (Ipg ml'h and 
ionomycin (lOng ml'h and incubated for 30 min at 37°C under conditions of 5% C02/95% 
air. Plates were then spun at 200g for 3 minutes and supernatants taken and frozen at -70°C. 
The concentration of histamine and peptido-leukotriene was determined from supernatants 
by EIA (Section 2.4.5 and 2.4.6).
2.3.13 Preparation of rat pleural mast cells
Mature Sprague-Dawley rats were killed according to an approved Home Office schedule. 
The underside of the rat was sprayed with 70% ethanol to reduce contamination by hair. Skin 
was removed from belly to ribs. The diaphragm was cut near the sternum and injected with 
2mls of DPBS+ (Dulbecco’s PBS with 0.1%BSA and 0.1%glucose); the pleural cavity
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massaged and the washout placed into a 50ml centrifuge tube. Rat pleural lavages were 
centrifuged at 150g for 8 minutes. Pelleted cells were resuspended in 40ml cDMEM 
(DMEM + 10%FCS + glutamine + pen/strep) and centrifuged at 150g for 8 minutes. Pelleted 
cells were resuspended in 7.5 mis of 72.5% isotonic Percoll (Amersham Pharmacia Biotech) 
and placed into a 15ml centrifuge tube. 1ml of cDMEM was layered on top of the cell 
suspension and the tube centrifuged at 300g for 10 minutes. Cells at the interface and in the 
supernatant were discarded and the pellet resuspended in lOmls of cDMEM. Cells were 
washed once more in lOmls of cDMEM prior to use in assays.
2.3.14 Anti-IgE stimulated rat pleural mast cell degranulation
Rat pleural mast cells were resuspended in 1ml of cDMEM containing 2.5jLtg mP* of rat IgE 
(Zymed, San Francisco, CA) incubated overnight at 37°C in 5% C02/95% air. Cells were 
then washed and resuspended in cDMEM at a density of 2.5x10"^  cells/well in round 
bottomed 96 well tissue culture treated plates. After 15 minutes incubation at 37°C, cells 
were stimulated with l[ig ml'  ^ anti-rat IgE and incubated for a further 30 minutes at 37°C. 
Plates were then centrifuged at 200g for 5 minutes and supernatants harvested. The 
concentration of histamine was determined from supernatants by EIA (Section 2.4.5).
2.4 Immunoassays
2.4.1 Assay buffers (ELISA)
Coating buffer : 4.3g NaHCOs, 5.3g Na2 COs made up to 1 litre with distilled H2 O,
pH 9.4.
Blocking buffer: 8.0g NaCl, 1.42g Na2HP04.2H20, 0.2g KH2PO4, 0.2g KCl, 5.0g
bovine serum albumin (fraction V) made up to 1 litre with distilled 
H2O, pH 7.4.
Assay buffer: 8.0g NaCl, 1.42g Na2HP0 4 .2H20, 0.2g KH2PO4, 0.2g KCl, 5.0g
bovine serum albumin (fraction V), 1ml Tween20 made up to 1 litre 
with distilled H2O, pH 7.4.
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Wash Buffer: 9.0g NaCl, 1ml Tween20 made up to 1 litre with distilled H2O, pH
7.4.
Stop solution : 1.8M H2SO4
2.4.2 Cytokine sandwich ELISA protocol 1
Nunc Maxisorb plates (Nalge Nunc, Rochester, NY) were coated with 2.5 \ig ml'  ^of capture 
antibody (anti-IL-la, -lL-4, -lL-6, -IL-8, -IL-10, -TNF-a and-IFN-y) overnight at 4°C in 
coating buffer. Wells were then aspirated and blocking buffer added whilst plates were 
rotated (250rpm on an orbital shaker (Stuart Scientific, Bibby Sterilin, Staffordshire, UK)) at 
room temperature (RT) for 1.5h. Plates were then washed four times with wash buffer, using 
a Denley Wellwash 4 plate washer (Denley,Thermoquest). Standards were diluted in assay 
buffer and added along with samples to plates and incubated at RT for 2 h. The plates were 
washed a further four times and biotinylated detection antibody added at a concentration of 
2.5 pg ml'  ^ in assay buffer. Plates were incubated at RT for a further 1.5 h. The plates were 
washed a further four times and streptavidin conjugated to horseradish peroxidase (Amdex, 
Amersham, UK) added at a concentration of 1 in 500 in assay buffer. The plates were 
incubated at RT for a further 30 min. Plates were washed four times and 
tetramethylbenzidine (TMB, Intergen, CA) substrate added. Plates were allowed to develop 
for between 10 to 30 min and the reaction terminated using stop solution. Plates were read at 
450nm with a reference reading taken at 630nm using a Labsystems Multiskan Ex plate 
reader (Labsystems, Thermo Labsystems, UK). Standard curves were constructed and data 
analysed using Genesis II software (Labsystems, Thermo Labsystems, UK). Minimum 
detection limits of each assay were determined to be at least two standard deviations above 
background readings.
2.4.3 Cytokine sandwich ELISA protocol 2
As for cytokine sandwich ELISA protocol 1 except, capture antibodies (anti-IL-ip, -IL-2
and-IL-12p40) were used at a concentration of 5pg m l'\ plates blocked for 2 h and the
concentration of detection antibody used was 0.4 pig m l'\
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2.4.4 Multiplex cytokine assay (Upstate biotech #48-001)
Cytokine production was measured from 0KT3 stimulated PBMC as indicated in chapter 
2.3.5. All assays were performed in 96 well ‘U’ bottomed polypropylene plates (Costar, 
NY). Recombinant standards, which contained 5000 pg ml'  ^of IL-2, IL-4, TNF-a, IFN-y and 
GM-CSF, were reconstituted with DMEM and diluted over a range from 5000 to 31.25 pg 
ml"\ 50pil of standards and samples were added to 25pil of Luminex beads. Separate beads 
were conjugated to monoclonal antibodies that specifically recognised IL-2, IL-4, TNF-a, 
IFN-y and GM-CSF. Standards and samples were vortexed gently and incubated at room 
temperature (RT) for 2 hours in the dark. 25jLil of biotin-conjugated antibodies that 
specifically recognised IL-2, IL-4, TNF-a, IFN-y and GM-CSF, were then added to samples, 
vortexed gently and incubated at RT for 1.5 hours in the dark. 25pil of a 20pig ml'  ^ solution of 
streptavidin-phycoeiythiin (PE) (Pharmingen, SanDiego, CA) was added and samples 
incubated at RT for 30 minutes in the dark to reveal the presence of bound antibody on bead. 
The reaction was terminated by adding 25pil of a 0.2% (v/v) solution of formaldehyde in 
PBS. The fluorescence of each bead set was assayed at an emission wavelength of 532nm 
using a Luminex 100 analyser (Luminex, Austin, TX). 50 beads were counted per assay 
point and sample concentrations were determined by linear regression analysis of standard 
curves, using Graphpad-prism 3 software (Graphpad software, San Diego, CA).
2.4.5 Histamine EIA (IBL kit #RE 59221)
Standards and samples were added to soda glass tubes with an equal volume of indicator 
buffer. Samples were acetylated for 30 min by treatment with acetylating agent (acetic 
anhydride). Samples were then diluted 1 in 20 in assay buffer and added to 96 well plates. 
Tracer (histamine-HRP) was then added to the wells and anti-histamine anti-serum. Plates 
were then incubated for 3 h at RT and then washed four times in wash buffer. TMB substrate 
was added and the reaction terminated with stop solution 20 minutes after the addition of
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substrate. Plates were read at an optical density of 450nm with a reference reading taken at 
630nm. Standard curves were constructed and data analysed using GenesisII software.
2.4.6 Peptido-Leukotriene and leukotriene C4 (kit # 520501, 520211) and 
prostaglandin D2 (Kit # 512011) EIAs (Cayman Chemical Co.)
Assays for peptido-leukotrienes were determined to cross react with the following; 
Leukotriene C4 (100%), D4 (100%), E4 (67%), D5 (61%), C5 (54%), E5 (41%), A3 (<0.01 %), 
A4 (<0.01%), B3 (<0.01 %), B4 (<0.01%). Leukotrienes C4, D4 and E4 are collectively termed 
peptido-leukotrienes. Plates pre-coated with mouse anti-rabbit IgG were treated with 
standards and samples plus peptido-leukotriene tracer (peptido-leukotriene linked to 
acetylcholinesterase) and peptido-leukotriene polyclonal antiserum. Plates were incubated 
for 18 hours at RT in the dark. Plates were then washed four times and Ellman’s reagent 
added (acetylthiocholine and 5,5’-dithio-bis-(2-nitrobenzoic acid)) and colour allowed to 
develop in the dark for between 60 to 90 min. Plates were read at a wavelength 405nm and 
total and non-specific binding calculated to allow for the estimation of peptido-leukotriene 
levels. Due to the rapid degradation of PGD2 methoxylamine (MOX) hydrochloride was 
added to cultures which formed stable PGD2 -  MOX derivatives, these were measured using 
specific antiserum raised against PGD2 -  MOX. Standard curves were constructed and data 
analysed using GenesisII software (Thermo Labsystems, UK).
2.4.7 cAMP EIA (Amersham kit #RPN225)
5x10^ human PBMC were suspended in DPBS (0.1% glucose and 0.1% bovine serum 
albumin in Dulbecco’s PBS). Cells were added to a 1.5ml Eppendorf tubes and mixed with 
inhibitor and incubated in a 37°C water bath for 10 minutes. l|ig  ml'  ^Con A was added and 
samples incubated at 37°C prior to harvesting cAMP. cAMP was retrieved from samples by 
firstly cooling cells on ice. Tubes were then micro-centrifuged and the assay supernatant 
discarded. Cell pellets were resuspended in assay buffer (0.05M sodium acetate buffer, pH
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5.8 containing 0.02% BSA) and boiled for 10 minutes using a boiling water bath. Samples 
were snap frozen prior to assay using cAMP ELISA.
2.5 Flow cytometry
2.5.1 General procedure
1x10  ^ cells were spun down in 5ml polypropylene Falcon tubes (Becton Dickinson, San 
Jose, CA). Cells were then washed once in PBS and then washed once more in 3ml of 
staining buffer (PBS, 0.5% heat-inactivated FCS and 0.1% sodium azide, pH 7.4). Cells were 
resuspended in 50jal of staining buffer with between 0.1 and 0.5pg pl'  ^ of either 
fluorochrome or biotinylated conjugated antibody added in a reaction volume of lOpl. Tubes 
were incubated at 4°C for 30 min in the dark. Cells treated with biotinylated antibodies were 
washed twice in 3ml of cold staining buffer and incubated with streptavidin-PE (0.1 pg pl'^) 
in a reaction volume of 50pl. These tubes were incubated for a further 30 min at 4°C . Before 
analysis, all cells were washed twice in cold PBS and resuspended in 500pl of PBS without 
azide. Cell staining data was acquired using CellQuest software (Becton Dickinson) on either 
a FACScan or FACSCalibur flow cytometer (Becton Dickinson). Specific antibody staining 
was compared to staining with isotype antibody controls. PMT (photo-multiplier tube) 
voltage, threshold and compensation settings were adjusted using calibrite beads™ (Becton 
Dickinson). Positivity was assessed using histogram markers for single stains and quadrant 
markers, on dot plots, for double stains.
2.5.2 IL-2 receptor alpha chain expression on OKT3 stimulated human PBMC
1x10  ^Human PBMC in round bottomed 96 well plates were stimulated with 0KT3 (0.05pg 
ml'^). Cells were assessed for the expression of CD25 (IL-2 receptor alpha chain) after 1, 2, 3 
or 4 days post-stimulus. 0KT3-stimulated cells were stained with CD3-FITC (fluorescein 
isothiocyanate) and CD25-PE according to the general staining protocol (Chapter 2.5.1). 
Lymphocytes were gated according to their characteristic forward and side light scattering 
properties. Lymphocytes that were deemed to be positive for CD3, using quadrant markers,
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were also assessed for CD25 expression. CD25 positivity was expressed in mean 
(geometrical) fluorescent units.
2.5.3 CD14 and CD16 expression on LPS and LPS plus IFN-y stimulated human 
PBMC
1x10  ^human PBMC in 24 well plates (Costar, UK) were stimulated with LPS (Ipg ml'^) or 
LPS (Ipg ml'*) plus IFN-y (Ing ml'*) or left untreated. PBMC were harvested by scraping all 
cells from the bottom of each well. Cells were assessed for the expression of CD 14 and 
CD 16, using CD14-PE and CD16-FITC directly conjugated antibodies, according to the 
general staining protocol (section 2.5.1). Monocyte/macrophages were gated according to 
their characteristic forward and side light scattering properties. Monocyte/macrophages were 
assessed for both CD 14 and CD 16 expression using quadrant gates, and CD14/CD16 
positivity was assessed in terms of the percentage cells that stained double positive for both 
markers.
2.5.4 The expression of chemokine receptors on human cord blood derived mast 
cells
2.5.4.1 Light Scatter properties
Cord blood mast cells were analysed using flow cytometry to determine their physical 
phenotype. Cord blood mononuclear cells stimulated with SCF, IL-6 and PGE2 (section 
2.3.10) were assessed using flow cytometry at weekly intervals. Cellular light scattering 
properties, forward light scatter (a measure of cell size) and side or 90° light scatter (a 
measure of cell granularity) were measured. Forward and side scatter were plotted using dot 
plots and distinct populations were assessed using polygon gates applied to dot plots.
2.5.4.2 Chemokine receptor staining on cord blood mast cells
Distinct cbMC populations as determined in section 2.5.4.1. were stained with biotinylated 
antibodies against human CCRl, 2, 5 and CXCR5 and directly conjugated antibodies against 
human CCR3, 6 and CXCRl, 2, 3 and 4 according to the general staining protocol (section
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2.5.1). Chemokine receptor expression was assessed on distinct cbMC populations at weekly 
intervals. Expression was assessed using histogram plots and positivity was expressed in 
mean (geometrical) fluorescent units.
2.6 Enzyme assays
2.6.1 Reagents
Staurosporin, ATP (Tris salt), DTT, HEPES, pEY (polyglutamic acid tyrosine ratio of 4:1), 
manganese chloride were obtained from Sigma, protein kinase C assay kit, streptavidin-SPA 
beads and ^^P-yATP were obtained from Amersham. Brij-35 was obtained from Pierce and 
magnesium chloride was obtained from BDH. Microtitre plates for SPA were purchased 
from Wallac. 6-amino hexanoyl AEEIYGVLAKKK Lck substrate was synthesised by IBMS 
Southampton.
2.6.2 Enzymes
GST (glutathione S-transferase) -Lck (GST fusion proteins refer to enzymes expressed with 
a GST affinity tag to aid enzyme purification), was cloned from a Jurkat cDNA library and 
expressed as a GST fusion protein in mammalian NSO cells. GST-Lyn was produced in- 
house as a GST catalytic domain fusion by a Baculovirus-SF9 expression system. GST-Fyn 
was produced in-house as a GST catalytic domain fusion by a Baculovirus-SF9 expression 
system. PKC was purchased from Boehringer Mannheim. EGFR was produced in-house as a 
GST catalytic domain fusion by a Baculovirus-SF9 expression system. Zap-70 was produced 
in-house as a GST fusion by a Baculovirus-SF9 expression system, cdc-2 was purchased 
from Amersham. Full length PDE4A was harvested from baculovirus infected SF9 insect 
cells, partially purified from crude cell lysates using a Resource Q column with a 0 - 0.5M 
salt gradient. Truncated PDE4A enzyme, AQ44-L329, containing only the catalytic domain 
(without the high affinity Rolipram binding site (HARBS)) was purified from transfected 
COS cells
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2.6.3 GST-Lck enzyme assay
Reactions were carried out in a total volume of 200pl at room temperature in 96 well 
microtitre plates. The reaction mixture contained 20mM HEPES pH7.4, lOmM magnesium 
chloride, lOmM manganese chloride, 0.05% Brij 35, 0.5pM 6-amino hexanoyl 
AEEIYGVLAKKK peptide substrate, 0.6pM ATP (Tris salt) and 5pCi/ml 33P y-ATP. The 
compounds were added in DMSO so that the final DMSO concentration was 1%. The assay 
was run for 15 minutes before being stopped with 50pl stop solution; 3mM ATP in 125mM 
EDTA. 200pl of the final mixture is then transferred to a Millipore MAPH filtration plate 
containing lOOpl 75mM phosphoric acid. The plate was then left for at least 60 minutes at 
room temperature. The plate was then washed lOOpl x6 with 75mM Phosphoric acid and 
then lOOpl scintillant (Packard Ultima Gold) was added prior to counting in a Wallac 
Microbeta plate counter.
2.6.4 GST-Lyn enzyme assay
Reactions were carried out in a total volume of200jxl at room temperature in 96 well 
microtitre plates. The reaction mixture contained 20mM HEPES pH7.4, 2mM magnesium 
chloride, 2mM manganese chloride, 0.05% Brij 35, 5mM DTT, IpM 6-amino hexanoyl 
AEEIYGVLAKKK peptide substrate, 0.6pM ATP (Tris salt) and 5pCi/ml 33P y-ATP. The 
compounds were added in DMSO so that the final DMSO concentration was 1%. The assay 
was run for 15 minutes before being stopped with 50pl stop solution; 3mM ATP in 125mM 
EDTA. 200|xl of the final mixture was then transferred to a Millipore MAPH filtration plate 
containing lOOpl 75mM phosphoric acid. The plate was then left for at least 60 minutes at 
room temperature. The plate is then washed lOOpl x6 with 75mM Phosphoric acid and then 
lOOpl scintillant (Packard Ultima Gold) was added prior to counting in a Wallac Microbeta 
plate counter.
2.6.5 GST-FynT enzyme assay
Reactions were carried out in a total volume of 200pl at room temperature in 96 well 
microtitre plates. The reaction mixture contained 20mM HEPES pH7.4, 2mM manganese
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chloride, 0.05% Brij 35, lOpM 6-amino hexanoyl AEEIYGVLAKKK peptide substrate, 
0.6pM ATP (Tris salt) and 5pCi/ml 33P y-ATP. The compounds were added in DMSO so 
that the final DMSO concentration was 1%. The assay was run for 15 minutes before being 
stopped with 50pl stop solution; 3mM ATP in 125mM EDTA. 200|xl of the final mixture 
was then transferred to a Millipore MAPH filtration plate containing lOOpl 75mM 
phosphoric acid. The plate was then left for at least 60 minutes at room temperature. The 
plate was then washed lOOpl x6 with 75mM Phosphoric acid and then lOOpl scintillant 
(Packard Ultima Gold) is added prior to counting in a Wallac Microbeta plate counter.
2.6.6 Zap-70 enzyme assay
Reactions were carried out in a total volume of 200|il at room temperature in 96 well 
microtitre plates. The reaction mixture contained 20mM HEPES pH7.4, lOmM magnesium 
chloride, lOmM manganese chloride, 5mM DTT, 0.05% Brij 35, 5pg/ml pEY, 0.6pM ATP 
(Tris salt) and 5pCi/ml 33P y-ATP. The compounds were added in DMSO so that the final 
DMSO concentration was 1%. The assay was run for 10 minutes before being stopped with 
50|xl stop solution; 3mM ATP in 125mM EDTA. 200pl of the final mixture was then 
transferred to a Millipore MAFC filtration plate containing lOOpl 30% cold TCA which was 
left at 4°C overnight. The plate was then washed lOOpl x6 with 10% cold TCA, lOOpl x3 
with 100% ethanol and then lOOpl scintillant (Packard Ultima Gold) was added prior to 
counting in a Wallac Microbeta plate counter.
2.6.7 PKC (Amersham Kit RPN77) enzyme assay
Reactions were carried out in a 30pl reaction volume 50mM Tris pH 7.5 buffer containing 
ImM Ca2+, 15mM Mg2+, 0.6mole L-a phosphatidyl-L-serine and 2pg/ml'* PMA, 2.25pM 
peptide, 2.5mM DTT, 1.2pM ATP, 0.2pCi 33P y-ATP. For reactions that contained 
staurosporin, this was added in a DMSO solution and the final DMSO concentration did not 
exceed 1%. This was shown not to interfere with enzyme activity. (Data not shown.) The 
reaction was initiated with enzyme, either mix or individual isozymes and run for 10 minutes
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at room temperature before being stopped with 20pl 0.5M phosphoric acid containing IpM 
staurosporin. 30pl of the final mixture was then transferred to a Millipore MAPH filtration 
plate containing lOOpl 75mM phosphoric acid. The plate was then left for at least 60 minutes 
at room temperature. The plate was then washed lOOpl x6 with 75mM phosphoric acid and 
then lOOpl scintillant (Packard Ultima Gold) was added prior to counting in a Wallac 
Microbeta plate counter.
2.6.8 EGFR enzyme assay
Reactions were carried out in a total volume of 200pl at room temperature in 96 well 
microtitre plate. The reaction mixture contained 20mM HEPES pH7.4, 25mM magnesium 
chloride, ImM manganese chloride, 5mM DTT, 0.05% Brij 35, 5pg/ml pEY, IpM ATP 
(Tris salt) and 5pCi/ml 33P y-ATP. The compounds were added in DMSO so that the final 
DMSO concentration was 1%. The assay was run for 30 minutes before being stopped with 
50pl stop solution; 3mM ATP in 125mM EDTA. 200jxl of the final mixture was then 
transferred to a Millipore MAFC filtration plate containing lOOpl 30% cold TCA and then 
this is left at 4°C overnight. The plate was then washed lOOpl x6 with 10% cold TCA, lOOpl 
x3 with 100% ethanol and then lOOpl scintillant (Packard Ultima Gold) was added prior to 
counting in a Wallac Microbeta plate counter.
2.6.9 cdc-2 (Amersham SPA kit RPNQ 0170) enzyme assay
Reactions were carried out in a 40pl reaction volume containing, 50mM Tris-HCl pH 8.0 
buffer, lOmM Mg2+, lOOmM NazVOg, ImM DTT, 0.75pM (biotin-PKTPKKAKKL) 
peptide, 0.5pM ATP and 0.2pCi 33PyATP. For reactions that contained inhibitors, this was 
added in a DMSO solution and the final DMSO concentration did not exceed 1%. This was 
shown not to interfere with enzyme activity. The reaction was initiated with enzyme, and run 
for 30 minutes at room temperature before being stopped with 200pl streptavidin - PVT 
beads 5mg/ml in 50pM ATP in 5mM EDTA. The plate was left to stand for 30 minutes 
before being spun at 2000rpm for 10 minutes in a centrifuge and then read in the Wallac 
Microbeta plate counter.
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2.6.10 PDE enzyme assay
PDE (3, 4 or 7) enzymatic activity was assayed in a homogeneous scintillation proximity 
assay (SPA) using yttrium silicate SPA beads (Amersham, UK). The buffer used for dilution 
of substrate and enzyme contained 50nM TES pH 7.6 with lOmM MgCl2. Substrate was
[^H] cAMP/cGMP (Amersham) at 0.1 pm final concentration and the enzyme was titrated to 
give approximately 20% substrate hydrolysis at the 30 minute time-point. The inhibitors 
were added to the enzyme substrate in a DMSO solution prior to the addition of the enzyme. 
The reaction mixture was incubated at room temperature for 30 minutes then the reaction 
was terminated by the addition of PDE SPA beads at 20mg ml * in HPLC grade water. 
Samples were quantified in a Wallac Microbeta scintillation counter and IC50 values 
calculated using XL Fit (Microsoft) with a log dose inhibition curve. Background was given 
by the addition of an excess quantity of a potent reference PDE inhibitor.
2.6.11 [^H]-Rolipram binding to guinea-pig membranes
R-Rolipram was iodinated and dispatched to Amersham International, where it was titrated 
by catalytic reduction with palladium charcoal to a specific radioactivity of 851 Gbq/mmof*. 
The ability of compounds to inhibit the binding of [^ H] R-Rolipram to guinea-pig 
membranes was investigated using the method devised by Schneider et al *^ .^ For saturation 
binding experiments , the concentration of [^ H] R-Rolipram was varied from 0.01 to 30nM. 
Sufficient enzyme was used to bind 10% of the total label at 5nM. Non-specific binding was 
assayed in the presence of 2pM unlabelled Rolipram. Specific binding was calculated by 
subtracting non-specific from total binding.
2.7 Statistical analysis of results
Where appropriate statistical analysis of data was performed using Graphpad-Prism version 
3 (Graphpad software, San Diego, CA). To determine if parametric or non-parametric 
analysis of data was required Bartletts test of homogeneity of variance was performed. If the 
data was Gaussian or approximately Gaussian (using larger sample numbers) then parametric
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analysis of variance (ANOVA) was performed. For sample comparisons data was analysed 
using a two-tailed student’s T-test to which a P-value of =<0.05 was assigned as significant. 
To investigate the statistical relationship between two sets of data a Pearson correlation, 
assuming Gaussian distribution, was performed. The p-value for such correlation’s was set at 
=/<0.05. The coefficient of determination (r )^ was derived from such calculations and used to 
explain the shared variance between two sets of data. If the data set was small, then no 
assumption of Gaussian distribution was made and a nonparametric (Spearman’s) correlation 
was made. Spearman’s (r) was calculated instead of an r^  value. A two-tailed p-value of 
=/<0.05 was assigned as significant.
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Chapter 3
Evaluation of the effect of inhibition of phosphodiesterase 
type 4 on human monocyte function
3.1 Introduction
Human monocytes are a rich source of both pro-inflammatory cytokines; TNF-a, IL-la, IL- 
1(3, IL-6, IL-8 and IL-12 and anti-inflammatory cytokines; IL-10, IL-lRa (IL-1 receptor 
antagonist) and sTNF-R (Soluble TNF receptor). Regulation of the balance of these two 
types of mediator determines whether a response to infection or invasion by foreign material 
is either normal or inappropriate.
The elevation of cAMP is a key regulatory step in controlling inflammatory cell activation, 
and is an important mechanism for controlling the balance between pro- and anti­
inflammatory responses. This need for control has resulted in many co-operative systems 
which act in unison to safeguard the production of cAMP. For instance many G protein 
coupled receptors, such as the histamine receptors, mediate intracellular signalling by 
controlling cAMP levels These pathways control the synthesis of cAMP by acting upon 
the enzyme, adenylyl cyclase, which is responsible for the synthesis of cAMP from AMP 
188:189 also be controlled by another family of enzymes, the phosphodiesterases,
which are responsible for the degradation of cAMP It is the eventual balance of the 
action of the phosphodiesterase and the adenylyl cyclase enzymes which determines the 
level of intracellular cAMP.
The cAMP dependent type 4 phosphodiesterase (PDE4) is abundantly present in 
inflammatory cells Thus the regulation of its activity has been proposed as a
therapeutic target to control the level of cAMP in these cells PDE4 inhibitors potently 
inhibit TNF-a production by activated human and murine monocytes both in vitro and in
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vivo *47;150;176 i48;149 i99;200 ^he inhibition of TNF-a by PDE4 inhibitors has implications for 
their use in inflammatory diseases, such as rheumatoid arthritis, where blockade of TNF-a 
has been validated as a therapy for this disease
The aim of the work presented in this chapter was to clarify how inhibition of PDE4 controls 
the production of cytokines from activated human peripheral blood mononuclear cells. 
Varying effects on the production of pro-inflammatory cytokines by elevating cAMP levels 
have been reported in the literature These variations, in both human and murine
experiments, have suggested that apart from TNF-a, regulation of IL-1, IL-6 and IL-10 by 
cAMP is complex. The work in this chapter has attempted to quantify the effect PDE4 
inhibition has on inflammatory cytokine synthesis. The concept that different activation 
signals delivered to the monocyte may alter the effect of PDE4 inhibition on cytokine release 
has also been explored.
3.2 Results
3.2.1 The effect of PDE4 inhibition on TNF-a release from human PBMC
In order to deduce the exact kinetics of cytokine production from activated human 
monocytes human PBMC were stimulated with purified EPS derived from E.coli (strain 
055:B5) and the production of TNF-a, IL-1 a, IL-lp, IL-6, IL-8 and IL-10 proteins was 
measured over a period of up to four days post stimulus, fig 3.1.
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Figure 3.1: The production of cytokines from LPS stimulated human PBMC. ixlOf 
human PBMC, were stimulated with l|ig  ml ' of LPS derived from E.coli (055:B5 strain). TNF-a, IL-1 a, IL-ip, 
IL-6 , IL- 8  and IL-10 were measured at the times indicated in cell free supernatants by sandwich ELISA. The 
amount of cytokine produced was quantified relative to standard curves for all cytokines tested. The data shown 
is representative of at least seven other experiments. The values shown are the mean of three separate points, 
standard deviations were omitted to allow the nature of the curves to be fully represented.
The maximum production of cytokines varied markedly. IL-8 was produced in the greatest 
quantities with a maximum concentration found in the culture fluid of 122.3 ng ml'\ In 
contrast only 853 pg ml * of IL-Ia was found to be produced.
When human PBMC were pre-treated with the potent PDE4 inhibitor RP73401 (Chapter
2.2.1) prior to stimulation with LPS, RP7340I blocked the production of TNF-a. Figure 3.2 
indicates that RP73401 potently, and dose dependently, inhibited TNF-a protein production 
from LPS stimulated human PBMC. RP7340I inhibited the production of TNF-a for the 
duration of the experiment.
55
Chapter 3
LPS alone 
0 - - L P S  + 0.1nMRP73401 
LPS + InM  RP73401 
X— LPS + lOnM RP73401 
LPS + lOOOOnM RP73401
T 2000
a 1500
0 5 10 15 20 25 30 35 40 45 50
Time in hours
Figure 3.2: The effect of the PDE4 inhibitor RP73401 on the LPS stimulated release of 
TNF-a from human PBMC. IxlO^ human PBMC were incubated with the PDE4 inhibitor RP73401 at 
the concentrations indicated for 30 min prior to stimulation with Ijag ml ’ of LPS derived from E.coli (055:B5 
strain). TNF-a was measured at the times indicated in cell free supernatants by sandwich ELISA. The experiment 
shown is representative of six others. Mean values are indicated ± SD.
3.2.2 The effect of PDE4 inhibition on the production of IL-1 a , XL-(3, IL-6 and 
IL-8 by human PBMC
The effect of RP73401 on LPS induced IL-1 a  production by human PBMC was evaluated, 
fig 3.3. Pre-treatment of cells with RP73401 strongly inhibited the production of IL-1 a. The 
effect of RP73401 was dose-dependent. The highest concentration of RP73401 (lOpM) 
inhibited IL-1 a  production by 84 ± 5.1% when measured 9 hours after cytokine induction.
The effect of RP73401 on the other IL-1 family member, IL-lp, was also tested, fig 3.4. 
Unlike its effect on IL-1 a, RP73401 inhibited IL-lp production to a lesser extent. However, 
the effect of RP73401 was dose-dependent. The highest concentration of RP73401 (lOpM) 
inhibited IL-1 (3 production by 39.1 ± 2.5%, 7 hours after LPS challenge.
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Figure 3.3: The effect of the PDE4 inhibitor RP73401 on the LPS stimulated release of 
IL-loC from human PBMC. IxlO^ human PBMC were incubated with the PDE4 inhibitor RP73401 at the 
concentrations indicated for 30 min prior to stimulation with Ipg ml ' of LPS derived from E.coli (055:B5 strain). 
IL-1 a  was measured at the times indicated in cell free supernatants by sandwich ELISA. The experiment shown 
is representative of four others. Mean values are indicated ± SD.
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Figure 3.4: The effect of the PDE4 inhibitor RP73401 on the LPS stimulated release of 
IL-IP from human PBMC. Ixlof human PBMC were incubated with the PDE4 inhibitor RP73401 at the 
concentrations indicated for 30 min prior to stimulation with Ipg ml ' of LPS derived from E.coli (055:B5 strain). 
IL-ip was measured at the times indicated in cell free supernatants by sandwich ELISA. The experiment shown 
is representative of three others. Mean values are indicated ± SD.
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In contrast to its effects on TNF-a and IL-1, RP73401 did not inhibit IL-6 production by 
LPS stimulated human PBMC, fig 3.5. Even at the highest concentration tested (lOpM), 
RP73401 showed no statistically significant inhibition of IL-6, p=0,799.
Like IL-6, RP7340I was unable to inhibit the production of IL-8 by LPS stimulated human 
PBMC cultures, fig 3.6, Even at the highest concentration tested (lOpM), RP7340I showed 
no statistically significant inhibition of IL-8 production, p=0.720.
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Figure 3.5; The effect of the PDE4 inhibitor RP73401 on the LPS stimulated release of 
IL-6 from human PBMC Ixiof human PBMC were incubated with the PDE4 inhibitor RP73401 at the 
concentrations indicated for 30 min prior to stimulation with Ipg ml * of LPS derived from E.coli (055:B5 strain). 
IL-6 was measured at the times indicated in cell free supernatants by sandwich ELISA. The experiment shown is 
representative of four others. Mean values are indicated ± SD.
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Figure 3.6: The effect of the PDE4 inhibitor RP73401 on the LPS stimulated release of 
IL-8 from human PBMC. IxIO  ^ human PBMC were incubated with the PDE4 inhibitor RP73401 at the 
concentrations indicated for 30 min prior to stimulation with Ipg mf* o f LPS derived from E.coli (055:B5 strain). 
IL-8 was measured at the times indicated in cell free supernatants by sandwich ELISA. The experiment shown is 
representative of three others. Mean values are indicated ± SD.
3.2.3 The role of IL-10 in PDE4 inhibitor-mediated blockade of TNF-a 
production
To investigate if elevated levels of IL-10 were responsible for the blockade of TNF-a 
caused by inhibition of PDE4, exogenous human recombinant (hr) IL-10 (hrIL-IO) was 
added to human PBMC at the time of LPS challenge. The effect of the addition of hrIL-IO 
on TNF-a, IL-1 (3 and IL-6 was measured and compared to the effect of RP73401 on the 
same cytokines (figs 3.2, 3.4 and 3.5). Figure 3.7a shows that hr IL-10 suppressed the 
production of TNF-a by LPS activated human PBMC. Ing ml'  ^ of IL-10 inhibited TNF-a 
production for the duration of the experiment, blocking 73.4 ± 8.3% of TNF-a released 20 
hours after stimulation. Figure 3.7b indicates that hrIL-10 also suppressed the production of 
IL-ip by LPS activated human PBMC. Ing ml * of hrIL-10 inhibited IL-1(3 production for 
the duration of the experiment, blocking 55.8 ± 2.7% of IL-ip released 20 hours after 
stimulation. Figure 3.7c indicates that hr IL-10 weakly suppressed the production of IL-6 by
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LPS activated PBMC. Ing ml'  ^ of hr IL-10 inhibited IL-6 production for the duration of the 
experiment, blocking 21.8 ± 0.4% of IL-6 released 20 hours after stimulation, however this 
inhibition was not statistically significant, p=0.749. The effect of hrIL-IO on LPS induced 
cytokine production was similar to the effect RP7340I had on TNF-a production. To test if 
IL-10 mediated the effect of RP7340I on TNF, the IL-10 produced in LPS stimulated PBMC 
cultures was neutralised using an anti-fL-IO receptor antibody capable of neutralising 
bioactive IL-10.
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Figure 3.7: The effect of human recombinant IL-10 on the LPS stimulated release of 
TNF-a, IL-ip and TNF-a from human PBMC. Ix lof human PBMC were incubated with human 
recombinant IL-10 (Ing ml'h for 30 min prior to stimulation with Ipg ml'  ^ o f LPS derived from E.coli (055:B5 
strain). TNF-a (A), IL-ip (B) and IL-6 (C) were measured at the times indicated in cell free supernatants by 
sandwich ELISA. The experiment shown is representative o f three others. Mean values are indicated ± SD.
The antibody specifically recognised the IL-10 receptor, and at a dose of 5pg ml'  ^ blocked 
total IL-10 biological activity (according to the manufacturers data). Table 3.1 indicates that 
at a dose of 5pg ml ' an anti-IL-IO receptor antibody was unable to effect the ability of
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RP73401 to inhibit TNF-a production. This effect was not dependent on the antibody used, 
as both neutralising monoclonal and polyclonal antibodies against IL-10 protein (as well as 
the anti-IL-10 receptor antibody used in this study) had no effect on the ability of RP73401 
to block LPS stimulated TNF-a release (data not shown).
Table 3.1: The effect of an anti-IL-10 receptor antibody on the PDE4 inhibitor- 
mediated inhibition of TNF-a release from LPS stimulated human PBMC. *
Concentration of 
RP73401 (nM)
Anti-IL-10 receptor 
antibody (5|ig ml ')
SEM±
M0PC21 control 
antibody (5pg ml ')
SEM±
1000 88.9% 5.5% 89.2% 4.6%
100 87.3% 5.0% 82.9% 4.4%
* IxlOf human PBMC were incubated with 1000 and lOOnM of the PDE4 inhibitor RP73401 for 30 min prior to 
the addition of either 5jxg ml'* of a mouse anti human IL-10 receptor antibody or 5pg ml'  ^ o f an isotype control 
antibody (M 0PC2I) and Ipg ml'  ^ o f LPS derived from E.coli (055:B5 strain). TNF-a was measured after 24 
hours from cell free supernatants by sandwich ELISA. The values shown are expressed as percentage inhibition 
of total specific TNF-a produced in the absence of any drug. The experiment shown is the mean of four other 
experiments ± SEM.
RP73401 was also tested to see if it effected IL-10 levels in LPS stimulated cultures of 
human PBMC. Figure 3.8 indieates that RP73401 weakly inhibited IL-10 production. The 
effect of RP73401 on IL-10 levels was greatest between 20 and 40 hours after LPS stimulus. 
In the experiment shown the highest concentration of RP73401 (lOpM) inhibited IL-10 
production by between 48 ± 3.6% 20 hours after LPS challenge. In other experiments the 
effect of RP73401 was weaker, by 48 hours post LPS challenge RP73401 did not inhibit IL- 
10 production (fig 3.12).
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Figure 3.8: The effect o f the PDE4 inhibitor RP73401 on the LPS stim ulated release of 
IL-10 from hum an PBMC. Ixlof human PBMC were incubated with the PDE4 inhibitor RP73401 at the 
concentrations indicated for 30 min prior to stimulation with l^ig ml'  ^o f LPS derived from E.coli (055;B5 strain). 
IL-10 was measured at the times indicated in cell free supernatants by sandwich ELISA. Experiments shown is 
representative of five others. Mean values are indicated ± SD.
3.2.4 The effect o f LPS plus IFN-y on the phenotype o f hum an m onocytes and the effect 
of PDE4 inhibition on pro-inflammatory cytokine production by LPS plus IFN-y 
stimulated hum an PBMC
In order to test if different activation conditions altered the phenotype of monocytes, the 
expression of two surface proteins, CD14 (co-receptor for the recognition of LPS) and CD16 
(low-affinity receptor for IgG), was measured. Figure 3.9 shows the effect of LPS, or LPS 
plus IFN-y, or tissue culture media (containing 10% PCS) on the surface expression of CDI6 
in CD 14 positive cells, measured over a six day period. After 2 days in culture 89.7 ± 1.9% 
of untreated CD 14 positive cells expressed CD 16, 43.7 ± 0.5% of LPS treated cells and 22.8 
± 4.6% of LPS plus IFN-y treated cells expressed CD 16. By day 4 these percentages had 
altered so, 77.4 ± 4.8% of untreated cells were positive, 62.2 ± 7.8% of LPS treated cells 
were positive and 18.1 ± 6.3% of LPS plus IFN-y treated cells were positive. On the sixth 
day 53.9 ± 1.5% of untreated cells were positive, 22.4 ± 2.1% of LPS treated cells were 
positive and 10.9 ± 4.6% of LPS plus IFN-y treated cells were positive.
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Figure 3.9: The effect o f LPS plus IFN-y on the maturation of CD14/CD16 double 
positive monocytes. IxlOf human PBMC were incubated with l|ag ml ' o f LPS derived from E .coli (055:B5 
strain), l|ag ml ' of LPS derived from E.coli (055:B5 strain) plus Ing ml ' of human recombinant IFN-y or left 
untreated. Prior to stimulation monocytes (identified using flow cytometry) were analysed for the dual expression 
of the surface markers CD 14 and CD 16. CD 14/CD 16 levels were enumerated using a mouse anti-human CD 14 
FITC antibody and a mouse anti-human CD 16 PE antibody. Positivity for these markers was assessed by 
comparison with isotype control antibodies and the percentage o f CD14 positive cells staining for CD16 was 
calculated. CD 14 and CD 16 expression were monitored daily. The values shown are the mean o f six separate 
experiments ± SEM.
Using the same experimental conditions the effect of RP73401 (20pM) on CD16 expression 
in CD 14 positive monocytes was investigated. Figure 3.10a shows the effect of 20p,M 
RP73401, on CD 16 expression in CD 14 positive cells treated with tissue culture medium. 
After 2 days in culture 89.7 ± 1.9% of untreated CD14 positive cells expressed CD16 
compared to 42.3 ± 11.7% of cells treated with RP73401. After 4 days in culture 77.4 ± 
4.8% of untreated CD 14 positive cells expressed CD16 compared to 54.3 ± 16.3% of cells 
treated with RP73401. On the sixth day in culture 53.9 ± 1.5% of untreated CD 14 positive 
cells expressed CD16 compared to 38.4 ± 10.8% of cells treated with RP73401. Figure 
3.10b shows the effect of 20pM RP73401, on CD16 expression in CD 14 positive cells 
treated with LPS. After 2 days in culture 43.7 ± 0.5% of LPS treated CD 14 positive cells 
expressed CD 16 compared to 11.5 ± 4.0% of cells treated with RP73401. After 4 days in 
culture 62.2 ± 7.8% of LPS treated CD 14 positive cells expressed CD 16 compared to 12.1 ± 
1.8% of cells treated with RP73401. On the sixth day in culture 22.4 ± 2.2% of LPS treated
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CD 14 positive cells expressed CD16 compared to 3.9 ± 1.2% of cells treated with RP73401. 
Figure 3.10c shows the effect of 20|xM RP73401, on CD16 expression in CD 14 positive 
cells treated with LPS plus IFN-y. After 2 days in culture 22.7 ± 4.6% of LPS plus IFN-y 
treated CD 14 positive cells expressed CD 16 compared to 8.3 ± 1.7% of cells treated with 
RP73401. After 4 days in culture 18.1 ± 6.3% of LPS plus IFN-y treated CD 14 positive cells 
expressed CD16 compared to 3.2 ± 1.3% of cells treated with RP73401. On the sixth day in 
culture 10.9 ± 4.6% of LPS plus IFN-y treated CDI4 positive cells expressed CD16 
compared to 4.8 ± 0% of cells treated with RP73401.
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Figure 3.10; The effect of RP73401 on the maturation of CD14/CD16 double positive 
monocytes. IxlOf human PBMC were incubated with Ipg ml ' of LPS, Ipg ml ' of LPS plus Ing ml ' o f IFN- 
Y or left untreated. Cells were either incubated with or without 20pM of RP73401. Prior to stimulation monocytes 
(identified using flow cytometry) were analysed for the dual expression of the surface markers CD14 and CD 16. 
CD 14/CD 16 levels were enumerated using a mouse anti-human CD 14 FITC antibody and a mouse anti-human 
CD 16 PE antibody. Positivity for these markers was assessed by comparison with isotype control antibodies and 
the percentage of CD 14 positive cells staining for CD 16 was calculated. CD 14 and CD 16 expression were 
monitored daily. The values shown are the mean o f three separate experiments ± SEM.
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The PDE4 inhibitor RP73401 was compared in terms of its ability to alter the production of 
TNF-a and IL-10 from LPS and LPS plus IFN-y stimulated human PBMC. Figure 3.11 
shows the percentage inhibition of TNF-a production by human PBMC stimulated with 
either LPS or LPS plus IFN-y (Ing ml *). 48 hours after stimulation RP73401 inhibited LPS 
induced TNF-a production more potently and to a greater extent than LPS plus IFN-y 
induced release. Using lOnM of RP7340I to compare effects, 90.9 ± 2.6% of LPS induced 
TNF-a was inhibited compared to 70.2 ± 2.6% of LPS plus IFN-y induced TNF-a. The IC50 
for RP73401 also shifted, being 0.4nM in LPS stimulated cultures and 3.5nM in LPS plus 
IFN-y stimulated cultures. These differences were statistically significant, p<0.05.
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Figure 3.11: The effect of the PDE4 inhibitor RP73401 on LPS and LPS plus IFN-y 
stimulated release of TNF-a from human PBMC. IxlOf human PBMC were incubated with the 
PDE4 inhibitor RP73401 at the concentrations indicated for 30 min prior to stimulation with Ipg ml ' of LPS 
derived from E .coli (055:b5 strain) or Ipg ml ' of LPS derived from E .coli (055:b5 strain) plus Ing ml ' of human 
recombinant IFN-y. TNF-a was measured after 48 hours from cell free supernatants by sandwich ELISA. The 
values shown are expressed in terms of percentage inhibition of total specific TNF-a produced in the absence of 
any drug. The data shown is the mean of seven experiments ± SEM. A single asterisk denotes a statistically 
significant difference in the ability of the same dose of RP73401 to inhibit TNF-a production from LPS versus 
LPS plus IFN-y stimulated human PBMC, p<0.05. A double asterisk denotes a statistically significant difference 
in the ability of the same dose of RP73401 to inhibit TNF-a production from LPS versus LPS plus IFN-y 
stimulated human PBMC, p<0.01.
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The effect of RP73401 on LPS and LPS plus IFN-y stimulated IL-10 release was also 
compared in the same way. Figure 3.12 shows that 48 hrs after LPS stimulation RP7340I 
had little overall effect on IL-10 production by human PBMC, however RP7340I inhibited 
IL-10 production when measured at earlier time points (as indicated in fig 3.8). In contrast, 
RP7340I dose-dependently augmented IL-10 production by LPS plus IFN-y stimulated 
human PBMC cultures. At a concentration of lOnM, RP73401 inhibited 2.4 ± 9.4% of LPS 
induced IL-10 compared to a stimulation of IL-10 levels by 83.9 ± 25.6 % in LPS plus IFN-y 
stimulated cells. This effect was also seen at earlier time points (data not shown).
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Figure 3.12: The effect of the PDE4 inhihitor RP73401 on the LPS and LPS plus IFN-y 
stimulated release of IL-10 from human PBMC. IxlOf human PBMC were incubated with the 
PDE4 inhibitor RP73401 at the concentrations indicated for 30 min prior to stimulation with Ipg ml ' o f LPS 
derived from E.coli (055;b5 strain) or Ipg ml * of LPS derived from E.coli (055:b5 strain) plus Ing ml * o f human 
recombinant IFN-y. IL-10 was measured after 48 hours from cell free supernatants by sandwich ELISA. The 
values shown are expressed in terms of percentage stimulation of total specific IL-10 produced in the absence of 
any drug. The data shown is the mean of seven experiments ± SEM.
To evaluate if this increased IL-10 production caused by inhibiting PDE4 in LPS plus IFN-y 
stimulated cells played a role in modulating TNF-a, bio-active IL-10 was neutralised using a 
monoclonal antibody to the IL-10 receptor. Figure 3.13, indicates that 5pg ml'  ^ of an anti- 
IL-10 receptor antibody did not alter the ability of RP73401 to inhibit TNF-a production 24 
hours after human PBMC were stimulated with LPS plus IFN-y. At a concentration of lOnM,
66
Chapter 3
RP73401 inhibited 93.7 ± 0.6% of TNF-a in the presence of 5pg mf^ of an anti IL-10 
receptor antibody and inhibited 95.4 ± 0.7% of TNF-a in the presence of 5pg ml ' of 
M0PC21 (isotype matched control antibody).
In contrast to PBMC stimulated with LPS alone, cells stimulated with LPS plus IFN-y 
synthesised appreciable amounts of the pro-inflammatory cytokine lL-12. Figure 3.14 
indicates that RP73401, potently and dose dependently inhibited lL-12 p40 protein 
production by LPS plus IFN-y stimulated human PBMC. RP73401 inhibited the production 
of lL-12 p40 for the duration of the experiment, lOpM of RP73401 inhibiting 81.8 ± 7.1% of 
lL-12 p40 released 7 hours after LPS plus IFN-y challenge.
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Figure 3.13: The effect of an anti IL-10 receptor antibody on the ability of RP73401 to
block production of TNF-a from LPS plus IFN-y stimulated human PBMC. ixlOf human 
PBMC were incubated with the PDE4 inhibitor RP73401 at the concentrations indicated for 30 min prior to the 
addition of either 5gg ml ' of a mouse anti human IL-10 receptor antibody or 5pg ml ' o f an isotype control 
antibody (M0PC21) and Ipg ml ' of LPS derived from E.coli (055:B5 strain) plus Ing ml ' of human 
recombinant IFN-y. TNF-a was measured after 24 hours in cell free supernatants by sandwich ELISA. The values 
shown are expressed in terms of percentage inhibition of total specific TNF-a produced in the absence of any 
drug. The experiment shown is the mean of three other experiments ± SEM.
Elevated levels of IL-10, as well as being known to control TNF-a, have also been 
implicated in the control of lL-12 production from human monocytes The effect of
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R f73401 on lL-12 production was tested in the presence of an anti-IL-10 receptor antibody 
that had previously been used to neutralise bioactive IL-10. Figure 3.15 indicates that Spg 
ml ' of an anti-IL-10 receptor antibody did not alter the ability of RP73401 to inhibit lL-12 
p40 production 24 hours after human PBMC were stimulated with LPS plus IFN-y. At a 
concentration of lOnM, RP73401 inhibited 77.9 ± 5.5% of 1L-I2p 40 in the presence of 5|ig 
ml ' of an anti IL-10 receptor antibody and inhibited 87.0 ± 2.2% of lL-12 p40 in the 
presence of 5pg ml ' of MOPC21 (isotype matched control antibody). These differences 
were not statistically significant, p=0.595.
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Figure 3.14: The effect of the PDE4 inhibitor RP73401 on the LPS plus IFN-y 
stimulated release of IL-12 p40 from human PBMC. ixlOf human PBMC were incubated with 
the PDE4 inhibitor RP73401 at the concentrations indicated for 30 min prior to stimulation with Igg ml ' of LPS 
derived from E.coli (055:B5 strain) plus Ing ml ' of human recombinant IFN-y IL-12(p40) was measured at the 
times indicated in cell free supernatants by sandwich ELISA. The experiment shown is representative o f three 
others. Mean values are indicated ± SD
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Figure 3.15: The effect of an anti-IL-10 receptor antibody on the ability of RP73401 to 
block production of IL-12p40 by LPS plus IFN-y stimulated human PBMC. ixio^ human 
PBMC were incubated with the PDE4 inhibitor RP73401 at the concentrations indicated for 30 min prior to the 
addition of either 5pg ml ’ of a mouse anti human IL-10 receptor antibody or 5pg ml ’ of an isotype control 
antibody (M0PC21) and Ipg ml ’ of LPS derived from E.coli (055:35 strain) plus Ing ml ’ of human 
recombinant IFN-y. IL-12p40 was measured after 24 hours in cell free supernatants by sandwich ELISA. The 
values shown are expressed in terms of percentage inhibition of total specific TNF-a produced in the absence of 
any drug. The experiment shown is the mean of three other experiments ± SEM.
3.3 Discussion
Inhibitors of phosphodiesterase type 4 are currently being evaluated in a number of diseases 
and are showing clinical efficacy i54;i96;)98;209-2i4 inhibitors, which are non-
discriminatory for the four PDE4 subtypes, have a wide range of action on cellular function. 
Particular interest has surrounded the capacity of PDE4 inhibitors to block TNF-a
production from activated monocytes 147-150;176;199, as biological inhibitors of TNF-a are
efficacious in the treatment of rheumatoid arthritis and Crohn’s disease Both
IL-10-dependent and-independent mechanisms have been implicated to explain how PDE4 
inhibitors might regulate TNF-a production. In light of these contradictions the effect of 
PDE4 inhibitors on key cytokines involved in inflammation was studied.
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Using in vitro activation of human PBMC with LPS studies were undertaken to detail the 
exact effect of a potent and specific PDE4 inhibitor upon pro- and anti-inflammatory 
cytokine production from activated cells. Human peripheral blood mononuclear cells 
activated with LPS release cytokines in an ordered and reproducible fashion. TNF-a is 
produced before either IL -la and IL-ip which precede the release of lL-6 and lL-8 which in 
turn is followed by the production of IL-10. In accordance with literature reports this 
study showed that, the potent selective PDE4 inhibitor RP73401, strongly and dose- 
dependently, blocked the production of TNF-a from LPS stimulated PBMC and this effect 
was sustained over the whole time course of the assay. This effect was not specific to this 
particular chemical class of PDE4 inhibitor (data not shown).
The inhibition of another key inflammatory regulator, lL-1, by either elevating cAMP levels 
directly or via inhibiting PDE4 has yielded conflicting data in the literature. In human 
monocytes or PBMC studies have shown either a suppression of IL-ip production or a 
neutral effect on IL-lp production To confirm and extend these findings, experiments 
were performed to distinguish the inhibition of both IL -la and IL-ip, as evidence points to 
distinct biological roles for these two proteins IL -la production was, strongly and dose- 
dependently, blocked by RP73401 in a similar manner to TNF-a. In contrast IL-ip 
production, though blocked by RP73401, was inhibited to a lesser extent than IL-la. IL-ip 
is thought to be a more physiologically important cytokine than IL -la and its
overexpression may be responsible for some of the destructive effects seen in diseases such 
as rheumatoid arthritis The differential effect of RP73401 on IL -la  and P may relate 
to their different secretion pathways, both molecules are synthesised as pre-cursors with 
calpain cleaving pro-lL-la and IL-ip converting enzyme (ICE, also known as caspase-1) 
cleaving pro IL-lp
The pro-inflammatory cytokine IL-6 can be induced by lL-1 which is thought to play 
a regulating role in controlling lL-6 synthesis. Conflicting reports exist regarding the effect
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of elevated (intracellular) cAMP on the production of lL-6 from LPS activated monocytes. 
These indicate that elevated cAMP (by PDE-dependent and-independent mechanisms) can 
either inhibit or have no effect on IL-6 production 168:202:221:232 ^he work in this thesis has 
indicated that the PDE4 inhibitor RP73401 had no statistically significant effect on lL-6 
production from LPS stimulated PBMC. This could be due to the weak effect on IL-ip 
caused by PDE4 inhibition and, since lL-1 is known to induce IL-6 may mean that 
production of IL-ip rather than IL-la controls the production of lL-6 in LPS stimulated 
human PBMC. In accordance with literature reports the PDE4 inhibitor RP73401 had no 
effect on lL-8 production from LPS stimulated human PBMC
LPS stimulated PBMC produce IL-10 in response to increasing levels of TNF-a and as such 
TNF-a and IL-10 are reciprocally responsible for activating and deactivating gene 
transcription and protein production of each other Since IL-10 is a potent anti­
inflammatory agent that is capable of controlling TNF-a the elevation of IL-10 could be an 
effective mechanism for inhibiting TNF-a production. This elevation in IL-10 has been 
shown to directly control TNF-a production One mechanism to increase IL-10
production in inflammatory cells is via the elevation of intracellular cAMP. The same 
hypothesis has been extended to explain why PDE4 inhibitors are such potent blockers of 
TNF-a production. In these studies IL-10 at low physiological doses was a potent suppresser 
of TNF-a production when added to PBMC at the time of LPS challenge, confirming 
literature findings In addition it also suppressed IL-ip production, inhibiting its 
production to the same extent as the PDE4 inhibitor RP73401. lL-6 production was only 
weakly inhibited by exogenous addition of IL-10.
The similarity between the effect of hrlL-10 and RP73401 on the inhibition of cytokine 
production gives credence to the hypothesis that an elevation of IL-10 may mediate the 
effect of PDE4 inhibition upon cytokine production. However, PDE4 inhibitors have been 
shown to inhibit TNF-a by both IL-10-dependent and-independent mechanisms 6^i;205:24i
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this study the potent PDE4 inhibitor RP73401, did not induce increased IL-10 production. 
RP73401 at concentrations as low as lOnM inhibited IL-10 production from LPS stimulated 
PBMC, in contrast to the published observations of the effects of PDE4 inhibitors on IL-10 
production This implies that elevated IL-10 did not mediate the inhibitory effect of 
PDE4 inhibition of TNF-a production. The IL-10-independent mechanism of RP73401 was 
confirmed, as it inhibited TNF-a production in the presence of an excess quantity of an anti- 
IL-10 receptor neutralising antibody. Thus, PDE4 inhibitors potently inhibit TNF-a 
production by an IL-10-independent mechanism.
Monocytes, like many other leukocytes, cannot be clearly defined as a single uniform 
population of cells. Indeed human blood derived monocytes can be defined as different types 
depending upon their relative expression of certain surface receptors. One population, typical 
of the majority of blood monocytes, expresses high levels of the LPS binding protein, CD14, 
but little or no low-affinity IgG receptor (CD 16 or FcyRllla) The other population,
which represents the minor sub-set in whole blood, expresses lower amounts of CD 14 but 
much higher levels of CD 16.
The occurrence of these two monocyte/macrophage phenotypes can be altered in disease and 
according to anatomical location, e.g. alveolar macrophages are CD14^/CD16^ whereas 
peritoneal macrophages are CD 14"  ^ and pleural macrophages are intermediate between 
the two phenotypes In diseases, such as sepsis and renal disease the
circulating levels of CD14^/CD16^ and CD 14^ monocytes are altered and may contribute to 
the specific pathogenesis of those diseases. As well as differing phenotypically these 
monocyte sub-sets also differ functionally. Although both sub-sets transcribe TNF-a mRNA 
and produce TNF-a protein in response to LPS they differ in their regulation of IL-10. 
CD 14^ monocytes regulate IL-10 normally at both message and protein level, but cells that 
express CD 16 produce little or no IL-10 protein when stimulated with LPS
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In light of the contradictory findings surrounding the action of PDE4 inhibitors on cytokine 
production, the contribution of monocyte phenotype on the effect of PDE4 inhibitors was 
investigated. Although certain cytokines, such as TGF-j3 and GM-CSF can regulate 
CD16 expression, the effect of different activating agents on the maturation of CD14^/CD16^ 
monocytes is untested. In the present studies when monocytes were cultured in medium 
containing serum, they up-regulated CD 16 expression in accordance with literature accounts 
242:243 However, when cells were stimulated with serum and LPS (stimulating through 
TLR4), cells initially suppressed CD 16 expression but later reverted back to the phenotype 
of serum treated cells. In contrast, when LPS plus IFN-y were added to human PBMC 
cultures, CD 16 expression was strongly suppressed. This effect was not observed when IFN- 
Y alone was administered to monocytes
CD14VCD16'*' and CD 14^ monocyte/macrophages as well as differing in their production of 
cytokines in response to LPS, also regulate their expression of phosphodiesterases 
differently. In blood, as monocytes mature (and increase CD 16 expression) they also up- 
regulate the transcription of PDEl and PDE3 whilst down-regulating the transcription of 
PDE4 ^^ 4. This is in contrast to CD 14^ monocytes which maintain PDE4 activity ^^ 4 and are 
susceptible to the action of PDE4 inhibitors. Since PDE induction may be linked to 
monocyte phenotype, the effect of PDE4 inhibition on CD 16 expression was investigated. 
Inhibition of PDE4 suppressed the expression of CD 16 on serum, LPS and LPS plus IFN-y 
treated monocytes. Paradoxically this would suggest that active PDE4 may be required for 
CD 16 expression, though CD 16 expressing cells are known to down-modulate PDE4 activity 
^^ 4, However, in cells treated with serum, for five days, RP73401 was unable to suppress 
CD 16 expression. This fits with the known PDE expression profile of such cells, which lack 
PDE4 In both LPS and LPS plus IFN-y treated cells the regulation of phosphodiesterases 
is unknown. Further studies will be required to see if such cells do regulate their PDF’s 
differently, and if this accounts for the effect that PDE4 inhibitors have on CD 16 expression.
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Since LPS and LPS plus IFN-y stimulated monocytes differ with respect to surface 
phenotype and may differ in PDE expression profile, the effect of PDE4 inhibition on 
cytokine release from such cells was studied. In contrast to LPS stimulated PBMC, cells 
stimulated with LPS plus IFN-y were shown to produce large amounts of IL-12. RP73401 
potently suppressed IL-12 production from PBMC stimulated with LPS plus IFN-y, an effect 
seen in endotoxemic animals treated with PDE4 inhibitor This effect may be critical to 
the ability of PDE4 inhibitors to block inflammation since inhibiting IL-12 production can 
suppress Thl mediated disease
PDE4 inhibitors also inhibited TNF-a production by PBMC stimulated with LPS plus IFN-y. 
However, this inhibition of TNF-a production was weaker than from PBMC stimulated with 
LPS alone. Expressed in terms of IC50 RP73401 was almost ten-fold weaker at inhibiting 
LPS plus IFN-y than LPS induced TNF-a release. PDE4 inhibition also had markedly 
different effects on the regulation of IL-10 production from LPS versus LPS plus IFN-y 
stimulated cells. Inhibition of PDE4 had no significant effect on IL-10 production from LPS 
stimulated PBMC measured 48 hours after LPS stimulation, though it did inhibit the 
production of IL-10 at earlier time points. However, it caused a dose-dependent elevation in 
IL-10 synthesis 48 hours after stimulation of PBMC with LPS plus IFN-y.
It could be postulated that the increase in IL-10, caused by PDE4 inhibition, in LPS plus 
IFN-y stimulated PBMC was responsible for the suppression of pro-inflammatory cytokines, 
such as TNF-a. However, despite the up-regulation of IL-10 caused by PDE4 inhibition this 
study found that the blockade of TNF-a production was independent of IL-10 release, as the 
inhibitor RP73401 worked equally well in the presence of excess amounts of an anti-IL-10 
receptor antibody. Likewise, it was discovered that, as was the case for TNF-a, the inhibition 
of IL-12 production by PDE4 inhibitors was independent of any effect on IL-10 production.
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To summarise, the results in this chapter confirm that PDE4 inhibitors have potent anti­
inflammatory effects in vitro. They suppress the production of TNF-a by both LPS and LPS 
plus IFN-y-stimulated PBMC. As well as TNF-a, they also suppress the production of IL-la 
and to a lesser extent IL-ip. In addition, the suppression of IL-12 by PDE4 inhibitors 
represents an important point of blockade of Thl (cellular) mediated immune responses. In 
contrast to other agents that elevate cAMP, PDE4 inhibitors do not inhibit TNF-a production 
by enhancing the synthesis of IL-10. It has been shown that PDE4 inhibitors, as well as 
suppressing cytokine production, can also suppress the expression of surface proteins, such 
as those of the B7 family To this list should be added the low-affinity IgG receptor, 
which is suppressed in CD 14 positive cells. This may have important implications as CD16 
expressing monocytes have been associated with specific diseases, e.g. sepsis 4^^ . The 
stimulation of monocytes with LPS plus IFN-y, which results in a well documented effect on 
cytokine production, and now also an increase in CD 14^  ^cells, alters the pattern of cytokine 
inhibition achieved by PDE4 inhibitors. In such cells PDE4 inhibitors can up-regulate IL-10, 
though IL-10 is not responsible for the TNF-a inhibitory action of PDE4 inhibitors. The next 
results chapter will discuss the impact of inhibiting PDE4 upon T cell activation and 
cytokine release. This will focus on the therapeutic potential of PDE4 inhibitors to act as 
immunosuppressive or immunomodulatory agents.
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Chapter 4
Evaluation of the effect of inhibition of phosphodiesterase 
type 4 on human T cell function
4.1 Introduction
The effect of elevation of cAMP in T cells has been well documented. Elevating cAMP in T 
cells has a suppressive function, inhibiting both the production of IL-2 and cellular 
proliferation 253-261 jjowever, these suppressive effects are complex, and under certain 
circumstances cAMP can augment T cell responses, as in the case for the production of Th2 
cytokines by Th2 cells or clones 262-265
The elevation of cAMP through activation of adenylyl cyclase has emphasised the important 
role that cAMP plays in modulating T cell responses. Research aimed at defining the effect 
of PDE4 inhibition, as a means to elevate cAMP levels, has attracted far less study and has 
yielded some conflicting and contradictory data ^^ =^^66-269 ^he archetypal PDE4 inhibitor. 
Rolipram, was the first PDE4-specific tool used to elucidate the effect of PDE4 in T cells 
but further studies using PDE4 inhibitors to block T cell function have been compounded by 
a number of factors. The first of these relates to the pharmacological profile of PDE4 
inhibitors. Rolipram binds, with a high affinity, to a site on the PDE4 enzyme. This binding 
was first ascribed to a phosphodiesterase species in brain membranes and is often termed 
HARBS (high affinity Rolipram binding site). Rolipram binds to the catalytic site of the 
PDE4 enzyme, in what is thought to be an alternative conformation, with approximately 100- 
fold lower affinity. The pharmacological profile of inhibitors differs with respect to their 
inhibition at the catalytic (low-affinity) and HARB sites and inhibition at these sites 
correlates with distinct physiological sequelae. This distinction occurs for inhibition of TNF- 
a  production in LPS stimulated monocytes 4^7;i50 thg inhibition of eosinophil superoxide 
production^^ ,^ which correlate with inhibition at the catalytic site. However, many of the so- 
called side effects of PDE4 inhibitors, such as the induction of emesis *^6 and gastric acid
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hyper-secretion correlate with displacement of ^H-Rolipam binding to the PDE4 enzyme 
(in its high-affinity state).
The pharmacological effect of PDE4 inhibitors is further complicated by the existence of 
sub-types of the PDE4 enzyme. The PDE4 enzyme can be transcribed by four distinct genes 
coding for four separate subtypes termed A, B, C and D. The expression patterns of these 
isoforms are tissue specific 2^ 5-277 jjuman CD4 and CD8 positive T cells, in various studies, 
have been shown to express subtypes A, B and D but not C; this expression profile can be 
altered upon T cell activation i40;i99;276 studies on resting human T cells messenger RNA 
for PDE4A was dominantly expressed. Upon activation both PDE4B and D were induced 
but not PDE4C These isoform expression patterns are complicated by the presence of 
many splice-variants *4°, the expression patterns of which remain largely unknown.
These two factors, the unknown mode of binding to the PDE4 enzyme and the existence of 
PDE4 enzyme isoforms, have combined to confuse the studies evaluating the effect of PDE4 
inhibitors on T cell function. Many studies conducted with PDE4 inhibitors have used either 
pan-specific PDE4 inhibitors or inhibitors of unknown specificity. Conclusions from such 
experiments have been interpreted without the consideration of which PDE4 isoforms or 
splice variants were involved. Work using inhibitors that preferentially inhibit PDE4A and B 
showed that inhibition of these subtypes correlated with inhibition of T cell activation 
though a contribution of the PDE4D enzyme could not be ruled out. However PDE4D does 
not seem to be involved in controlling T cell proliferation as mice lacking PDE4D (PDE4D 
''' knockout mice), showed no impairment of their T cell responses to antigen
The differences in modulation of T cell responses by PDE4 inhibitors are most obvious when 
comparing in vitro and in vivo data between mammalian species. Elevation of cAMP has 
been shown to skew the Th cell cytokine profile toward a Th2 phenotype, yet in animal 
models PDE4 inhibitors have been shown to be efficacious in both Thl and Th2 disease 
models i52;i58;280;28i human in vitro experiments Rolipram inhibited Th2 cell proliferation
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more potently than Thl However, the effect of inhibition of PDE4 on Thl/Th2 cytokine 
production suggested Thl cytokines may be inhibited to a greater extent than Th2 
cytokines^^^’^ ^^ ’^ ^^ . In contrast, inhibiting the action of PDE4 in murine T cell clones resulted 
in a skewed cytokine response in favour of Th2 cytokine production
PDE4 inhibitors are currently undergoing clinical trials to test their efficacy in a number of 
diseases, such as asthma and chronic obstructive pulmonary disease (COPD) These
diseases, particularly asthma, are either mediated or influenced by T cell activity and in 
particular the T helper cytokines produced by T cells. In light of the limited and 
contradictory studies on the effects of PDE4 inhibitors on human T cell function, this thesis 
has attempted to understand the therapeutic potential of inhibiting T cell PDE4. Using in 
vitro models of human T cell activation the contribution of PDE4, to both T cell proliferation 
and cytokine production, was studied in detail. This work has addressed how the 
pharmacological activity of PDE4 inhibitors may account for their inhibition of different T 
cell functions. In particular it addresses whether inhibition of the PDE4 enzyme in its low- or 
high-affinity state correlates with inhibition of T cell activation.
4.2 Results
4.2.1 The effect of PDE4 inhibitors on T cell activation
In order to assess the effect of PDE4 inhibitors on T cell activation initial experiments were 
carried out to determine the effect on cAMP levels in activated cells of PDE4 inhibition. 
Human PBMC were stimulated with the mitogen Con A for a period of 24 hours. The potent 
PDE4 inhibitor RS25344 (refer to chapter 2.2.1), when added to Con A stimulated PBMC 
cultures elevated the level of cAMP. Figure 4.1 indicates that lOjitM of RS25344 elevated 
cAMP levels by 303 ± 8% at thirty minutes and by 217 ± 31% at 24 hours after Con A 
stimulation of PBMC. The effect of RS25344 was dose-dependent as lOOnM of RS25344 
elevated cAMP levels by only 180 ± 12% thirty minutes after stimulation and by 21 ±31% 
24 hours after stimulation.
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Figure 4.1: The effect of the PDE4 inhibitor RS25344 on intracellular cAMP 
accumulation in Con A stimulated human PBMC. IxlO^ human PBMC were incubated in the 
presence of IGp-M and lOOnM of the PDE4 inhibitor RS25344 prior to stimulation with Ipg ml ' of Con A. The 
intracellular levels of cAMP were measured at the intervals indicated, using a RIA. The graph is representative of 
four other experiments, each point is the mean of four separate determinations ± SD.
In order to test if PDE4 inhibitors blocked T cell proliferation six phosphodiesterase 
inhibitors; CDP840, R-Rolipram, S-Rolipram, RS25344, RP73401 and SB 207499 (refer to 
Chapter 2.2.2) were used to inhibit the antigen specific proliferation of human PBMC. 
Figure 4.2 shows that all six inhibitors evaluated inhibited tetanus toxoid stimulated human 
PBMC proliferation in a dose-dependent fashion. No compound achieved total inhibition of 
proliferation, maximal inhibition was in the range of 75 to 90%.
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Figure 4.2: The effect of PDE4 inhibitors on tetanus toxoid induced proliferation of 
human PBMC. IxlO^ human PBMC were incubated in the presence of six PDE4 inhibitors; CDP840, R- 
Rolipram, S-Rolipram, RS25344, RP73401 and SB 207499 for 30min prior to stimulation with lp.g mP  ^ of 
tetanus toxoid. PBMC were incubated for five days and ^H-thymidine incorporation was measured for the last 
12h of culture. PDE4 inhibitor inhibition of proliferation was expressed as a percentage of total proliferation 
induced by tetanus toxoid alone. The graph is a mean of three separate experiments ± SEM.
The same compounds also inhibited antigen proliferation of human PBMC in response to 
Dermataphagoides pteronyssinus (a Th2-like stimulus as opposed to tetanus toxoid which is 
a Thl-like stimulus) in a dose-dependent manner (data not shown). Inhibition of tetanus 
toxoid-and D. pteronyssinus-mducQd proliferation was compared in terms of the 
concentration of compound needed to inhibit 25% of the maximal proliferative response 
(IC25) induced by each antigen. IC25 instead of IC50 values were used as not all compounds 
consistently achieved 50% inhibition of maximal proliferation. Table 4.1 compared these 
IC25 values and indicates that all PDE4 inhibitors tested showed no significant differences in 
potency between tetanus toxoid-or D. pteronyssinus-'mductd PBMC proliferation.
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Table 4.1: Tbe effect of PDE4 inhibitors on Thl-and Th2-Iike antigen-induced 
proliferation of human PBMC. *
Compound TT (IC25) nM SEM +/- HDM (IC25) nM SEM +/-
S-Rolipram 3333 1333 3250 577
R-Rolipram 916 308 650 122
CDP840 2250 749 2625 509
RP73401 29 20.7 80 57.2
RS25344 8.53 4.21 10 0
SB207499 375 96 1000 288
* 1x10^ human PBMC were incubated in the presence of six PDE4 inhibitors; CDP840, R-Rolipram, S-Rolipram, 
RS25344, RP73401 and SB 207499 for 30min prior to stimulation with Ipg ml'* o f tetanus toxoid or 1x10^ units 
of D.pteronyssinus major antigen Der PL PBMC were incubated for five days and ^H-thymidine incorporation 
was measured for the last 12h of culture. PDE4 inhibitor inhibition of proliferation was expressed as a percentage 
of total proliferation induced by tetanus toxoid alone or D.pteronyssinus. The table is a mean of four separate 
experiments ± SEM. Abbreviations: TT, tetanus toxoid and RDM, house dust mite antigen.
The PDE4 inhibitor RP73401 was tested to see if it inhibited human PBMC proliferation 
induced by an equal mixture of the staphylococcal enterotoxins A, B, D and E (termed 
superantigen). RP73401 only weakly inhibited proliferation induced by superantigen, fig 4.3. 
At the highest concentration tested (lOpM), RP73401 inhibited 77.5% of the response after 
36 hours but only gave 17.8% inhibition 78 hours post-stimulus.
The inhibition of Con A stimulated PBMC proliferation by the PDE4 inhibitors CDP840, R- 
Rolipram, S-Rolipram, RS25344, RP73401 and SB 207499, like the effect on superantigen 
induced proliferation, was also transitory. IC25 values for each compound, when measured 24 
and 48 hours after Con A stimulation, showed a decrease in potency in the range of 1.5 to 10 
fold. The addition of lOOnM of PGE2 (which by itself elicited no effect upon PBMC 
proliferation) enhanced the anti-proliferative effects of the PDE4 inhibitors when measured 
48 hours after stimulation table 4.2.
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Figure 4.3: The effect of the PDE4 inhibitor RP73401 on superantigen induced 
proliferation of human PBMC. IxlO^ human PBMC were incubated in the presence of RP73401 for 
30min prior to stimulation with lOOpg ml * of an equal mixture of the staphylococcal enterotoxins A, B, D and E. 
^H-thymidine incorporation was measured at the intervals indicated for a period of 92h. The graph is a 
representative of three others; mean values are indicated ± SD.
Table 4.2: The effect of PGE2 on the PDE4-mediated inhibition of Con A stimulated 
human PBMC proliferation. *
Compound
Con A 
24hrs 
(IC25) nM
SEM
±
Con A 48hrs 
(IC25) nM
SEM
±
Con A 48hrs 
+ PGE2(IC25) 
nM
SEM
±
S-Rolipram 500 218 2733 1246 550 1 2 2
R-Rolipram 253 130 1000 252 138 92
CDP840 33 19 46.7 27 15 7.5
RP73401 <2 .2 / 5.3 1.8 <6.3 /
RS25344 <2 / 10.7 4.7 <3.8 /
SB207499 87 13 833 338 355 176
* 1x10 human PBMC were incubated in the presence of six PDE4 inhibitors; CDP840, R-Rolipram, S-Rolipram, 
RS25344, RP73401 and SB 207499 for 30min prior to stimulation with Ipg ml ' of Con A. ^El-thymidine 
incorporation was measured after 24 and 48 h in culture. In separate experiments compounds were also incubated 
with lOOnM of PGE? for 30min prior to stimulation with Con A and ^H-thymidine incorporation was measured 
after 48h in culture. PDE4 inhibitor inhibition of proliferation was expressed as the concentration of compound 
needed to inhibit 25% of the total proliferation induced by Con A only. The table is a mean o f four separate 
experiments ± SEM. Where ‘ < ‘ is shown this indicates values below lower detection limits of the assay.
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4.2.2 The effect of PDE4 inhibition on T cell cytokine production and cytokine 
receptor expression.
Human PBMC were induced to produce cytokines using the mitogenic anti-CD3 antibody, 
0KT3. GM-CSF, IL-2, IFN-y, IL-4 and TNF-a levels were then monitored at regular time 
intervals for a period of 72 hours. Figure 4.4a shows that RP73401 inhibited the OKT3 
stimulated production of GM-CSF in a dose-dependent manner. At the highest concentration 
(IpM), 70.3 ± 7.4% of GM-CSF was inhibited 24 hours after 0KT3 stimulation. In addition 
to GM-CSF, IL-2 levels were also inhibited by RP73401, fig 4.4b. However, IL-2 was only 
produced over the first 48 hours after 0KT3 stimulation and its production peaked after 8 
hours. The effect on IL-2 was again dose-dependent. The highest concentration of RP73401 
blocked 69.5 ±6.1% of IL-2 released 24 hours after 0KT3 stimulation.
The cytokines IFN-y and IL-4, are responsible for amplifying Th cytokine production and so 
are important immunomodulatory cytokines. Figures 4.4c and d indicate that RP73401 
inhibited IFN-y and IL-4 production in a dose-dependent manner, with the highest 
concentration of RP73401 inhibiting 72.1 ± 16.9% of IFN-y and 53.2 ± 3.4% of IL-4 
produced 24 hours after 0KT3 stimulation. These differences were not statistically 
significant, p=0.211.
Finally, RP73401 potently blocked TNF-a production from 0KT3 stimulated human PBMC 
cultures, fig 4.4e. Like its effect on other cytokines, RP73401 inhibited TNF-a production in 
a dose-dependent way. The highest concentration of RP73401 inhibited 94 ± 3.2% of TNF-a 
produced 24 hours after 0KT3 stimulation. It should be noted that at later time points the 
inhibition of TNF-a production was total, though this was not the case for any of the other 
cytokines tested.
To test the effect of PDE4 inhibitors on cytokine receptor expression, human PBMC were
induced to express the IL-2 receptor alpha chain (CD25) by stimulation with superantigen.
Figure 4.5 indicates that RP73401 weakly inhibited the expression of CD25 on CD3 positive
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T cells. At the highest concentration tested (lOpM), RP73401 inhibited 59 ± 20% of CD25 
expression measured 18 hours after superantigen challenge. After 72 hours in culture 
RP73401 did not inhibit the expression of CD25 on CD3 positive cells.
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Figure 4.4; The effect of PDE4 inhibitor RP73401 on OKT3-induced cytokine (GM-
CSF, IL-2, IFN-y, IL-4 and TNF-a) production from human PBMC. ixio^  human PBMC 
were incubated in the presence of RP73401 for 30min prior to stimulation with 0KT3 (40ng ml '*)• GM-CSF 
(Figure 4.4a), IL-2 (Figure 4.4b), IFN-y (Figure 4.4c), IL-4 (Figure 4.4d), and TNF-a (Figure 4.4e) production 
was monitored at regular intervals over a 72h period. Cytokine levels were measured in cell free supernatants by 
multiplex cytokine assay. The graphs shown are representative of five other experiments. The data shown 
represents mean values ± SD.
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Figure 4.5: The effect of the PDE4 inhibitor RP73401 on superantigen induced 
expression of CD25 (IL-2 receptor alpha chain) on human PBMC. ixio^  human PBMC were 
incubated in the presence of RP73401 for 30min prior to stimulation with lOOpg ml'  ^o f an equal mixture o f the 
staphylococcal enterotoxins A, B, D and E. CD25 (IL-2 receptor alpha chain) levels were monitored at regular 
intervals for a period of 72h. CD25 levels were determined on CD3 positive cells using a FACScan flow 
cytometer. The data shown is the mean of three separate experiments ± SEM.
4.2.3 PDE4 inhibition of superantigen stimulated PBMC proliferation: Data 
analysed for a correlation with inhibition of PDE4 in its high-affinity or low- 
affinity conformation.
Six PDE4 inhibitors; CDP840, R-Rolipram, S-Rolipram, RS25344, RP73401 and RS 14203 
were tested for their ability to block the activity of PDE4 enzyme preparations in an in vitro 
assay. Table 4.3 indicates the IC50 values for each compound tested for their inhibition of the 
catalytic activity of PDE4A derived from SF9 cells, a truncated PDE4 enzyme PDE4A330 
(A330 mutant lacking HARBS, ^^ )^ which was purified from COS cells and inhibition of ^H- 
Rolipram binding to guinea pig brain membranes (a PDE4 preparation demonstrated to 
exhibit the high-affinity Rolipram binding site). The IC50 values for all six compounds varied 
in potency from 0.26nM to 325nM against PDE4A, from 0.4nM to 753nM against 
PDE4A330 and from 1 to 9InM against antagonism of ^H-Rolipram binding to guinea-pig 
membranes.
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Table 4.3; The inhibition of PDE4 enzymatic activity and competition for ^H-Rolipram 
binding by a selection of PDE4 inhibitors.*
Compound
PDE4A (SF9) 
IC50 (nM)
PDE4A330 (COS) 
IC50 (nM)
^H-Rolipram binding to brain 
membranes IC50 (nM)
S-Rolipram 325 605 91
R-Rolipram 66 501 5
CDP840 2.7 3.9 60
RP73401 0.26 0.4 5
RS25344 37.4 753 1
RS14203 0.87 39 64
* PDE4 enzyme activity was assayed in a homogeneous scintillation proximity assay. Full length PDE4A was 
harvested from baculovirus infected SF9 cells and truncated PDE4A (AQ44-329) was harvested from transfected 
COS cells. Inhibitors were added to the enzyme substrate prior to enzyme addition. The reaction was incubated at 
room temperature for 30 min prior to termination of the reaction. Antagonism of ^H-Rolipram binding to guinea 
pig brain membranes was measured using liquid scintillation counting The IC50 values shown represent the mean 
of five different experiments.
Figure 4.6a shows the relationship of the inhibition of PDE4A (derived from SF9 cells) by 
the six compounds CDP840, R-Rolipram, S-Rolipram, RS25344, RP73401 and RS 14203 
correlated against the inhibition of superantigen-induced human PBMC proliferation 
(measured after 36 hrs). The correlation between these two parameters was good 
(Spearman’s r = 0.714) and though the result showed a trend towards significance it was not 
significant, p= 0.136. Figure 4.6b shows the relationship of the inhibition of ^H-Rolipram 
binding to guinea-pig membranes for the same six compounds correlated against the 
inhibition of superantigen-induced human PBMC proliferation proliferation (measured after 
36 hrs). The correlation between these two parameters was good (Spearman’s r = 0.927) and 
the result was statistically significant, p= 0.007. Figure 4.6c shows the relationship of the 
inhibition of PDE4A330 (derived from COS cells) for the six compounds CDP840, R- 
Rolipram, S-Rolipram, RS25344, RP73401 and RS 14203 correlated against the inhibition of 
superantigen-induced human PBMC proliferation proliferation (measured after 36 hrs). 
There was no correlation between these two parameters (Spearman’s r = 0.143) and the result 
was not significant, p= 0.801.
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Figure 4.6a: Correlation of inhibition of superantigen induced proliferation and 
FDE4A enzyme activity by inhibitors of PDE4. PBMC were preincubated with PDE4 inhibitors 30 
minutes prior to stimulation with lOOpg mb' of staphylococcal enterotoxins A, B, D and E. Proliferation was 
measured after 36 h by incorporation of [^H] thymidine. An IC25 was taken as not all responses consistently 
reached 50% inhibition. Independently the compounds were assayed for activity against the PDE4A enzyme 
derived from SF9 cells. These two data sets were plotted against each other using Prism-3. This graph represents 
the data from three separate experiments.
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Figure 4.6b: Correlation of inhibition of superantigen induced proliferation and H- 
Rolipram binding to brain membranes by inhibitors of PDE4. PBMC were preincubated with 
PDE4 inhibitors 30 minutes prior to stimulation with lOOpg ml'  ^ of staphylococcal enterotoxins A, B, D and E. 
Proliferation was measured after 36 h by incorporation of [^H] thymidine. An IC25 was taken as not all responses 
consistently reached 50% inhibition. Independently the compounds were assayed for ability to displace [^H] R- 
Rolipram from guinea-pig brain membranes. These two data sets were plotted against each other using Prism-3. 
This graph represents the data from three separate experiments.
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Figure 4.6c: Correlation of inhibition of superantigen induced proliferation and 
PDE4A330 enzyme activity by inhibitors of PDE4. PBMC were preincubated with PDE4 inhibitors 
30 minutes prior to stimulation with lOOpg ml ' of staphylococcal enterotoxins A, B, D and E. Proliferation was 
measured after 36 h by incorporation of [^H] thymidine. An IC25 was taken as not all responses consistently 
reached 50% inhibition. Independently the compounds were assayed for activity against the PDE4A330 truncated 
enzyme. These two data sets were plotted against each other using Prism-3. This graph represents the data from 
three separate experiments.
4.3 Discussion
As the results in this chapter indicate, PDE4 inhibitors were able to elevate cAMP levels in 
mitogen stimulated human PBMC. cAMP levels were still elevated in PDE4 inhibitor-treated 
cells 24 hours after Con A stimulation but overall cAMP levels were diminished by 86%. 
This may indicate that inhibition of PDE4 alone is insufficient to maintain cAMP levels as 
they are in resting cells and may require additional stimulatory signals, for example those 
delivered via adenylyl cyclase. This phenomenon (a decrease in cAMP following 
stimulation) is intriguing and may hint at the fact that PDE4 activity dominates over adenylyl 
cyclase stimulation in activated T cells.
The elevation of cAMP, as a result of inhibition of PDE4 in T cells, was manifest as an 
inhibition of PBMC proliferation in response to the recall antigen, tetanus toxoid. However, 
PDE4 inhibitors did not achieve total inhibition of tetanus toxoid induced proliferation. Since 
research has indicated that Th2 cells may be more susceptible to elevated levels of cyclic
89
Chapter 4
AMP than Thl cells, this possible effect was investigated ^^ =^ 7^:282 jjowever, the results for 
these experiments did not substantiate literature reports as all PDE4 inhibitors tested 
inhibited tetanus toxoid (Thl priming) or Dermataphagoides pteronyssinus (Th2 priming) 
primed responses to the same extent.
In this study PDE4 inhibitors were unable to totally inhibit T cell proliferation induced by 
Con A or superantigen. Inhibition of mitogen-driven PBMC proliferation (or antigen, data 
not shown), became progressively weaker as time increased following the initial stimulation. 
This is in contrast to some the reported effects of PDE4 inhibitors i48;i76;i97;266^  though none 
of these studies used human PBMC. It was postulated that the reduced potency of PDB4 
inhibitors may be due to a reduced adenylyl cyclase stimulation. PGE2 (which stimulates 
adenylyl cyclase), at a dose which did not interfere with PBMC proliferation, enhanced the 
potency of PDE4 inhibitors to block proliferation. PGE2 production is known to be activated 
in human PBMC but work in this chapter indicates that this may not be sufficient to 
maintain inhibition of T cell proliferation. Thus a lack of adenylyl cyclase stimulation could 
explain why PDE4 inhibitors are only transitory blockers of T cell proliferation.
As well as being anti-proliferative, PDE4 inhibitors have also been postulated to block 
cytokine production, either inhibiting Thl responses or antagonising Thl responses by 
augmenting Th2 responses 266-268:282 of PDE4 function, as exemplified by the
inhibitor RP73401, was able to block the production of cytokines from PBMC activated via 
the T cell receptor. This inhibition of the PDE4 enzyme non-selectively blocked the 
production of GM-CSF, IL-2, IL-4 and IFN-y. Unlike other studies inhibition of PDE4 
did not selectively enhance or diminish Th-polarising cytokines, in particular IFN-y and IL- 
4. This evidence would indicate that, at least in human in vitro experimental models, PDE4 
inhibitors do not bias Th cytokine expression but are general suppressants of cytokine 
production.
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In contrast to the incomplete inhibition of IL-2, IL-4, IFN-y and GM-CSF production, PDE4 
inhibition completely blocked TNF-a production. This may indicate that TNF-a, produced 
by T cells stimulated through the TCR, lies on a pathway that is regulated by cAMP and 
hence PDE4. Further studies will need to establish that this effect on TNF-a production is 
solely directed at the T cell. These studies are needed as activated T cells, via the production 
of such factors as IL-17 can induce monocytes to synthesise TNF-a. Regardless, this 
effect emphasises the potent anti-TNF-a activity of PDE4 inhibitors and reinforces their 
potential therapeutic benefit in TNF-a-mediated disease.
Inhibition of PDE4, as was the case for other cytokines with exception of TNF-a, did not 
completely block the production of IL-2. However, unlike the effect on proliferation, 
inhibition of cytokine production was maintained over the course of the experiment. To 
address if PDE4 inhibition altered cytokine receptor expression, CD25 levels on activated T 
cells were also measured. RP73401 only blocked CD25 expression for the first 24 hours 
following T cell activation. This may indicate that, as well as IL-2 receptor expression, 
signalling through the IL-2 receptor is unable to be blocked by inhibiting PDE4. Further 
studies are needed to distinguish the exact T cell signalling pathways that are PDE4 
dependent. It is known that activation of certain pathways, e.g. using CD3, CD28 and PMA 
in combination, can overcome the inhibitory effect that cAMP has on T cell proliferation 
Thus it may be possible, using purified T cells, to distinguish PDE-sensitive and-insensitive 
signalling pathways.
The partial inhibition of T cell proliferation, by PDE4 inhibitors, is at odds with their potent 
suppressive effect in many other inflammatory cells I47;i76;i98;273;2g6 of these effects
correlate with inhibition of the enzyme in its low-affinity conformation jjowever, a
proportion of the biological effects of PDE4 inhibitors, including many unwanted side- 
effects, correlate with their ability of inhibitors to compete with Rolipram binding to the 
PDE4-HARB site but not the enzyme in its low-affinity conformation.
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It was discovered that, in contrast to studies that measured the production of IL-2 from 
activated murine T cells PDE4-mediated inhibition of mitogen stimulated human PBMC 
proliferation correlated with displacement of ^H-Rolipram binding to PDE4 and not 
inhibition of the low-affinity enzyme confomer. This was exemplified by a strong correlation 
with inhibition of superantigen-stimulated human PBMC proliferation and inhibition of ^H- 
Rolipram binding to brain membranes. In an enzyme which is unable to adopt the high- 
affinity conformation (PDE4A330) inhibition of proliferation did not correlate with 
inhibition of the enzyme. This effect is the opposite to that seen when correlating murine T 
cell cytokine production and may indicate that inhibition of cytokine production and T cell 
proliferation by PDE4 inhibitors correlates with inhibition of the PDE4 enzyme in its low- 
and high-affinity conformations respectively.
To summarise, though PDE4 inhibitors block T cell proliferation their effect is transitory. 
This may be due to both a lack of adenylyl cyclase stimulation and activation of signalling 
pathways that are insensitive to the inhibition of PDE4. Indeed, inhibition of T cell activity 
by PDE4 inhibitors does not correlate with inhibition of PDE4 enzyme, in its low-affinity 
state, but with inhibition of a high-affinity binding pocket on the enzyme, the function of 
which is unknown. In contrast to the effect on proliferation, inhibition of PDE4 activity does 
inhibit T cell cytokine release at all stages following T cell activation. This cytokine 
inhibition shows no Thl/Th2 bias and in particular indicates that PDE4 inhibitors completely 
inhibit TNF-a production.
Chapters 3 and 4 have discussed the effect of inhibiting PDE4 function in human monocytes 
(antigen-presenting cells) and T lymphocytes. The conclusions drawn from this work 
indicate that PDE4 inhibitors are potent blockers of cytokine production, particularly TNF-a. 
In the remaining chapters of the thesis another class of signal transduction inhibitor will be 
used in an attempt to block the function of leukocytes. These inhibitors are selective for the 
Src kinase family of enzymes, members of which play a role in signalling through multi-
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subunit receptor complexes. Chapter 5 will concentrate on the consequences of inhibiting Src 
kinase in human T cells activated through the T cell receptor.
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Evaluation of the effect of inhibition of Src kinase enzymes 
on human T cell function
5.1 Introduction
Immunosuppressive drugs have radically altered the treatment of organ transplantation. The 
drug cyclosporin A (CsA), which has proved very effective as an immunosuppressive agent, 
was the first drug in a class of relatively inexpensive small molecule inhibitors of T cell 
activation and function. Due to CsA’s dose limiting side-effects other
immunosuppressive drugs have emerged that have sought to replace it. Many of these are 
biological inhibitors of T cell function, such as those that block activation of the IL-2 
receptor alpha chain ^^ =287-289 though effective in certain circumstances, their wide 
spread use has been limited by their cost. This has stimulated the search for new drugs that 
can block signal transduction pathways emanating from the T cell receptor.
The Src kinase Lck, as indicated in Chapter 1, plays a key role in mediating signals 
transduced through the T cell receptor. Lck has a restricted pattern of expression, being 
mainly expressed in cells of haematopoietic origin and along with another Src family 
member, Fyn, it plays a critical role in mediating phosphorylation of proteins recruited to the 
TCR ^^ :29i;292 ^Ithough inhibitors of Lck currently exist (Chapter 1.5.2), they are limited in 
both their potency and selectivity for Lck over other tyrosine kinase enzymes. The work in 
this chapter has aimed, by utilising a panel of novel chemical inhibitors of Src family 
kinases, to assess whether inhibition of selected Src kinases inhibits T cell function in an in 
vitro assay system.
95
Chapter 5
5.2 Results
5.2.1 The effect of Src kinase inhibitors on human PBMC proliferation induced 
by mitogenic stimuli
A novel series of chemical inhibitors (refer to Chapter 2.2.2) of the Src kinase family of 
enzymes (abbreviated to CT-SKI) was synthesised by the medicinal chemistry department, 
Celltech, UK. The selectivity of these compounds for the Src kinase family of enzymes was 
tested using a panel of in vitro enzyme assays. Table 5.1 shows the IC50 values for six Src 
kinase inhibitors against Lck, Lyn and Fyn (Src kinase family members) as well as ZAP-70, 
protein kinase C (PKC), epidermal growth factor receptor (EGFR), Csk and cdc2. The 
known Src kinase inhibitor PP2 was included to act as a reference standard. All six 
inhibitors tested were potent Lck inhibitors, each having IC50 values for the inhibition of Lck 
of less than 5nM. These inhibitors showed weak activity against ZAP-70 and PKC and an 
improved selectivity against EGFR and Csk as compared to PP2.
Table 5.1: IC50S of different Src kinase inhibitors for a panel of different kinase 
enzymes.*
Compound Lck Zap-70 PKC EGFR Csk cdc2 Fyn Lyn
PP2 173 >10000 8900 700 281 ND ND 51
CT5102 4.0 ND ND ND 1166 579 8 ND
CT5215 3.5 >10000 1531 606 330 9036 61 21
CT5263 4.0 ND 3590 631 330 1292 8 ND
CT5264 3.9 9209 1270 2938 126 >10000 24 15
CT5269 1.1 >10000 >10000 3155 86 8463 13 13
CT5276 3.0 ND 2245 795 135 6277 11 ND
* All values are expressed as nM ICso’s. Values are the mean of five separate experiments. ND = not 
determined.
Figure 5.1 shows the effect of three Src kinase inhibitors, CT5102, CT5125 and CT5269 on 
human PBMC proliferation induced by 0KT3. At a fixed concentration of 400nM, CT5269 
inhibited PBMC proliferation by 65% when measured after 72 hours, CT5215 inhibited 30% 
of PBMC proliferation measured after 72 hours and CT5102 did not inhibit PBMC 
proliferation at the concentration tested. CT5269, which was the most potent of the three
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inhibitors tested, inhibited 0KT3 stimulated PBMC proliferation in a dose-dependent 
manner, fig 5.2. The IC50 of CT5269 was 130 ± 34nM. The other two inhibitors tested also 
inhibited OKT3 induced proliferation in dose-dependent manner (data not shown).
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Figure 5.1: The effect of Src kinase inhibitors on the proliferation of human PBMC 
induced by 0KT3. PBMC were pre-treated with 400nM of the Src kinase inhibitors for 30min, prior to 
stimulation with 0KT3 (40ng ml '). Proliferation was measured at different times after stimulation of PBMC. 
Values are mean of triplicates ± SD and are representative of three separate experiments.
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Figure 5.2: The effect of CT5269 on the proliferation of human PBMC activated by 
OKT3. PBMC were pre-treated with the concentrations of CT5269 indicated for 30min, prior to stimulation 
with 0KT3 (40ng mP'). Proliferation was measured 48h post-stimulation with 0KT3. Values are expressed as a 
percentage inhibition of 0KT3 only stimulated cultures. Values are the mean of three separate experiments ± 
SEM.
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A group of ten related Src kinase inhibitors were tested for their capacity to inhibit 0KT3 
and MLR induced proliferation of human PBMC. Figure 5.3 indicates that the compounds 
blocked OKT3-more potently than MLR-induced proliferation. The mean IC50 value for the 
compounds, was 480nM for 0KT3 and 2,000nM for MLR, these differences were 
statistically significant, p<0.008. Figure 5.4 shows the correlation of the inhibition of Lck 
(expressed as an IC50) with the inhibition of 0KT3 induced PBMC proliferation (expressed 
as an IC50) and the inhibition of an MLR (expressed as an IC50) for fourteen Src kinase 
inhibitors. When 0KT3 and Lck were correlated, the correlation was good (r^=0.853) and 
the result was significant (p<0.0001). However, when the MLR and Lck were correlated the 
correlation was poor (r^=0.113) and the result not significant (p=0.241).
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Figure 5.3: The effect of Src kinase inhibitors on the proliferation of human PBMC 
induced by OKT3 and in a MLR. PBMC were pre-treated with Src kinase inhibitors for 30 min prior to 
stimulation. Proliferation was measured 48h after stimulation with 0KT3 and 5d after stimulation in the MLR. 
IC50 values for each compound were obtained from dose response curves. Values are mean of three separate 
experiments, errors are not shown. A straight line indicates the mean of all separate points.
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Figure 5.4.; Correlation of inhibition of Src kinase enzyme activity with inhibition of 
human PBMC proliferation induced by 0KT3 and in a MLR. PBMC were pre-treated with 
Src kinase inhibitors for 30min, prior to stimulation with either 0KT3 (40ng ml'h or an equal number of 
mismatched irradiated PBMC in the case of the MLR. IC50 s for each inhibitor were obtained 48h after 
stimulation of PBMC with 0KT3 and 5d after stimulation in the MLR. Values are the mean of three separate IC50 
determinations and are plotted without errors.
5.2.2 The effect of the Src kinase inhibitor CT5269 on T cell cytokine production
The Src kinase inhibitor CT5269 was evaluated for its effect on cytokine production from 
0KT3 stimulated human PBMC. Figure 5.5a shows that, at a fixed concentration of 500nM, 
CT5269 blocked 92.3% of IL-2 produced, as measured by area under the curve. The 
inhibition of IL-2 production was maintained over the course of the experiment.
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Figure 5.5: The effect of CT5269 on the synthesis of IL-2, IFN-y and IL-4 by PBMC 
stimulated with OKT3. PBMC were pre-treated with 500nM of CT5269 for 30 min, prior to stimulation 
with 0KT3 (40ng ml"')- IL-2 (A), IL-4 (B) and IFN-y (C) were measured in cell free culture supernatants at 
different times following stimulation with 0KT3. Values are the mean of three separate experiments ± SD.
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CT5269 was also evaluated for its effect on IL-4 production. Figure 5.5b shows that, like 
the effect on IL-2, CT5269 blocked 93% of IL-4 produced, as measured by area under the 
curve. Likewise the inhibition of IL-4 was maintained over the course of the experiment.
Finally, CT5269 was evaluated for its effect on IFN-y production from 0KT3 stimulated 
human PBMC. Figure 5.5c shows that CT5269 blocked IFN-y production by 72%, as 
measured by area under the curve. This inhibition of IFN-y production was maintained over 
the course of the experiment.
To test if inhibition of IL-2, IL-4 and IFN-y production was dose-dependent, CT5269 was 
titrated from 20nM to 5pM and the percentage inhibition of cytokine production measured. 
Figure 5.6 shows that CT5269 dose-dependently inhibited IL-2, IL-4 and IFN-y production. 
The respective ICso’s were 150nM for IL-2 and IL-4 and 300nM for IFN-y. Although there 
was a trend suggesting that CT5269 was a weaker inhibitor of IFN-y production this was not 
statistically significant, p= 0.879 when comparing IL-2 with IFN-y.
5.2.3 The effect of Src kinase inhibitors on IL-2 production from human PBMC
activated by either phorhol ester plus calcium ionophore or OKT3
A panel of thirty one related Src kinase inhibitors were chosen, which had a wide variation in 
their potency against isolated Src kinase enzymes. Figure 5.7 shows the correlation of the 
inhibition of Lck, (expressed as an IC50) with the inhibition of 0KT3 induced IL-2 
production (expressed as an IC50), and the inhibition of PMA and ionomycin-induced IL-2 
production (expressed as an IC50), for all thirty one compounds. The inhibition of 0KT3 
induced IL-2 production and Lck showed good correlation (r^=0.914) which was significant 
(p<0.0001). However, when inhibition of PMA/ionomycin induced IL-2 production and Lck 
were correlated the correlation was poor (r^=0.110) and not significant (p=0.08).
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Figure 5.6: Titration o f the effect o f CT5269 on the synthesis o f IL-2, IFN-y and IL-4 by 
PBM C Stimulated with OKT3. PBMC were pre-treated with CT5269 at the concentrations indicated for 
30 min prior to stimulation with 0KT3 (40 ng ml '). Cytokine levels were measured 48 h after stimulation. 
Cytokine production was expressed as a percentage inhibition of total cytokine produced from 0KT3 stimulated 
PBMC cultures only. Values are the mean of three separate experiments ± SD.
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Figure 5.7: Correlation o f inhibition of Src kinase enzym e with inhibition o f IL-2 
production from human PBMC stimulated with OKT3 and PM A/ionomycin. PBMC were 
treated with the Src kinase inhibitors for 30min, prior to stimulation with either 0KT3 (40ng ml ') or PMA (1 p,g 
ml ') and ionomycin (10 ng ml"'). The IC50S of each inhibitor were obtained 48h after stimulation o f PBMC with 
either 0KT3 or PMA and ionomycin. Values are the mean of three separate IC50 determinations and are plotted 
without errors.
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5.2.4 The effect of the Src kinase inhibitor CT5269 on IL-2 receptor expression 
and IL-2 amplified proliferation in OKT3 stimulated human PBMC
Src kinase inhibitors were tested for their ability to block the expression of CD25 on 0KT3 
activated human CD3 positive T cells. Figure 5.8 indicates that Src kinase inhibitors 
CT5102, CT5264 and CT5276 were effective inhibitors of CD25 expression. Their IC50 
values being 900nM, 750nm and 400nm, respectively. The inhibition of CD25 expression 
was seen at all time intervals following OKT3 activation (data not shown).
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Figure 5.8: The effect of Src kinase inhibitors on the expression of CD25 (IL-2Ra 
chain) on human PBMC stimulated with OKT3. PBMC were pre-treated with Src kinase inhibitors 
for 30 min before stimulation with OKT3 (40 ng ml h- IL-2Ra chain (CD25) expression was measured 48 h after 
stimulation. CD25 expression was calculated as a percentage of CD25 mean expression levels on CD3^VCD25 
double positive cells stimulated with 0KT3 alone. Values are the mean of three separate experiments ± SD.
The ability of IL-2, added after TCR engagement, to reverse the inhibitory effect of CT5269
on proliferation was examined. Figure 5.9 shows the effect of CT5269 (500nM) in the
presence of increasing concentrations of hr IL-2. In the absence of IL-2 CT5269 inhibited
58.7 ± 15.3% of OKT3 induced proliferation. As the concentration of IL-2 was increased,
the inhibitory effect of CT5269 was reversed. The highest concentration of IL-2 (lOng ml'^)
completely reversed the inhibition caused by 500nM of CT5269.
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Figure 5.9: The effect of CT5269 on the proliferation of human PBMC induced by 
OKT3 and the addition of exogenous human recombinant IL-2. PBMC were preincubated 
with 500nM of CT5269 for 30min, prior to stimulation with 0KT3 (40ng ml *)- Four hours after stimulation 
PBMC were treated hy the addition of human recombinant IL-2 at the concentrations indicated. Proliferation was 
measured 72h after 0KT3 stimulation. Where a zero is indicated on the X-axis this refers to the percentage 
inhibition of CT5629 without the presence of exogenous IL-2. Data is represented as the percentage inhibition of  
0KT3 stimulated cultures. Values are the mean of three separate experiment ± SEM.
5.3 Discussion
The results in this chapter report the effect of a new class of Src kinase inhibitor on T cell 
function. These compounds were shown to be more potent than first generation inhibitors 
such as Genistein and WIN61651 They also improved upon second generation
inhibitors, such as pyrazolopyrimidines (PPl and PP2) which until now were the most 
potent and specific inhibitors of the Src kinase family of enzymes.
This new class of Src inhibitor (abbreviated to CT-SKI, for Celltech Src kinase inhibitor) 
was shown to have little activity against other enzymes important to T cell receptor 
activation (e.g. PKC and ZAP-70) and showed selectivity of inhibition over the regulatory 
kinase Csk. This was in contrast to PPl/2 which showed equal activity against Src and Csk. 
This distinction between the two classes of compound may be important, as inhibition of Csk
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may counteract any inhibitory effect towards Src kinases, Lck and Fyn, in T cell signalling 
It was confirmed that CT-SKI acted specifically to block phosphorylation of Lck and Fyn 
(auto-phosphorylation) in the T cell line E6.1 stimulated by cross-linking CD3 using an anti- 
CD3 antibody (data not included). The calcium flux induced in such cells was also blocked 
these effects correlated with inhibition of isolated Src kinase enzyme (data also not 
included).
In order to study their effect at the cellular level, CT-SKI were tested in human in vitro T cell 
activation assays. Since T cell clonal expansion (i.e. proliferation) is an important step in the 
immune response mediated by T cells, CT-SKI were tested for their ability to interfere with 
this process. When T cells were activated through the T cell receptor, using cross-linking 
anti-CD3 antibodies, CT-SKI completely blocked cellular proliferation. It was noted, 
however, that when compared to inhibition of enzyme activity (e.g. Lck) CT-SKI potency 
was shifted by at least two orders of magnitude. When CT-SKI were tested in other models 
of T cell activation, such as the MLR, their ability to block proliferation was considerably 
weaker. This is in contrast to CsA which inhibits with an equal inhibitory potency 0KT3-, 
PHA-and MLR-induced proliferation When the inhibition of proliferation induced by 
0KT3 and MLR were analysed, inhibition of 0KT3-mediated proliferation but not MLR, 
correlated with inhibition of the activity of the Src enzyme p56Lck. These findings may 
indicate that separate signalling cascades may be activated by the different stimuli, 0KT3 
and MLR, whose requirement for Src kinases may differ.
Since proliferation is a multifactorial readout involving the activation and co-ordination of 
many genes and proteins, an earlier readout of cellular activation was chosen to test the 
effect of CT-SKI. T cell specific cytokines, such as IL-2, are inducible and highly regulated 
and also important in the proliferative response. CT-SKI were thus employed to block 
cytokine production from 0KT3-stimulated T cells. CT-SKI were potent inhibitors of 
cytokine production and their effects were the same regardless of the time point when 
cytokine production was measured. The CT-SKI, CT5269, at a dose which inhibited
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approximately 50% of 0KT3 induced proliferation, completely blocked the production of 
both IL-2 and IL-4. The effect of CT5269 on IFN-y synthesis was also potent, though it was 
weaker than on the other two cytokines tested. This may be due to the production of IFN-y 
by non-T cells, e.g. NK cells, which may be refractory to the effects of Src kinase inhibitors. 
These effects were in contrast to those observed with the pyrazolopyrimidine compound, 
PPl, which acted differentially on Th cytokines, inhibiting IFN-y production and augmenting 
IL-4 production
CT-SKI have thus been shown to inhibit proliferation and IL-2 production under the same 
conditions. Since IL-2 production can act to amplify proliferation it is important to inhibit 
this pathway, since failing to do so may negate any inhibitory effects on the TCR pathway. 
To rule out a non-specific suppressive effect on IL-2 production, CT-SKI were tested using 
alternative stimuli to activate IL-2 production. When PBMC were stimulated with PMA and 
ionomycin, which are known to activate signalling at the level of PKC and calcium, CT-SKI 
were unable to block the production of IL-2. Inhibition of PMA/ionomycin induced IL-2 
production by CT-SKI did not correlate with inhibition of Src, which is in contrast to 
inhibition of OTK3-induced IL-2 production which showed good correlation. This evidence 
would suggest that CT-SKI act to block IL-2 production at a point above PKC/calcium and 
would be expected if these inhibitors blocked Src kinase activity at the level of the TCR.
To localise the point of action of the inhibitors, assays were set up utilising stimuli that acted 
at different levels along the signalling cascade. Since CT-SKI were ineffective at inhibiting 
proliferation in an allogeneic MLR, but inhibited 0KT3 stimulated proliferation and IL-2 
production, the role of IL-2 receptor signalling was investigated in more detail. IL-2 receptor 
expression (IL-2 receptor a, P and common y-chains) is required for full IL-2 signalling, so 
the effect of CT-SKI on IL-2 receptor a  chain was measured. CT-SKI inhibited IL-2 
receptor a  expression in an equivalent manner to their effect on proliferation. This indicates 
that IL-2 receptor (a chain) expression may be dependent on active Src enzyme.
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The final link in the signal transduction pathway from TCR through production of IL-2 and 
expression of IL-2 receptor is IL-2 binding and signalling through its receptor. If CT-SKI 
failed to block this pathway, this may limit their efficacy in blocking IL-2 driven 
proliferation. There is evidence in the literature that protein tyrosine kinases (PTK) are 
activated when IL-2 binds its receptor These PTK’s include the Src kinase, Lck 
To test CT-SKI in IL-2 receptor-dependent T cell activation, an IL-2 driven model of 
proliferation was established. In 0KT3 stimulated PBMC, exogenous IL-2 was added four 
hours after stimulation and its effect on proliferation measured. The addition of IL-2 under 
such circumstances reversed, in a dose-dependent manner, the inhibitory effect of CT-SKI. 
This is in accordance with the known role of Lck in IL-2 receptor signalling which is thought 
to act in parallel with Jak3 (Janus kinase 3)/STAT (signal transducer and activator of 
transcription), but is not involved in STAT activation
To conclude, CT-SKI appear to be potent inhibitors of mitogen-stimulated T cell activation. 
However, when other stimuli are used, as in the case of the MLR, they are less potent. This 
shift in potency may represent the activation of distinct signalling pathways which may be 
Src-independent. In addition CT-SKI potency shows considerable drift going from the 
isolated enzyme to cell functional assays. This may be due to a number of factors, such as 
poor cell penetration, protein binding or more likely high (mM) intracellular ATP 
concentrations High ATP concentrations are likely to alter the potency of CT-SKI, as 
these compounds were discovered to be ATP-competitive (data not shown). In light of these 
studies, it could be suggested that CT-SKI would not make ideal immunosuppressive agents 
and Lck is not be a good therapeutic target for immunosuppression. Despite this, their 
capacity to block T cell cytokine production and proliferation may indicate that they can act 
in an immunomodulatory role, and further investigation, particularly of their effect in vivo, 
will be needed to verify this function. The final results chapter of this thesis will discuss the 
effect of inhibiting Src kinase enzymes in mast cells activated through the high-affinity IgE 
receptor. This chapter will also investigate the role of phosphodiesterase enzymes in IgE- 
dependent signalling.
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Evaluation of the effect of inhibition of Src kinase and PDE 
enzymes on mast cell function
6.1 Introduction
Mast cells have long been recognised as critical effector cells of the allergic inflammatory 
response When they act in an unregulated or dysfunctional manner, they can contribute 
to the pathogenesis of a number of diseases such as asthma, fibrosis, autoimmunity, 
neoplasia and inflammatory bowel disease amongst others 3os-3i9^  Studies investigating 
the function of human mast cells have relied heavily upon the recovery of cells from 
cadaverous tissue. However, these cells are particularly heterogeneous in their phenotype 
and function according to anatomical location Current techniques of purifying mast
cells from CD34 positive precursors have yielded large numbers of homogenous cells that 
have enabled an insight to be gained into both the function and development of these cells
323-325
As the understanding of mast cell biology has increased, so too has the understanding of the 
molecular basis of mast cell activation and degranulation. The high-affinity IgE receptor 
(FceRI) is the central molecule involved in mast cell activation in allergic inflammation 
108:326 Yhe rapid degranulation of mast cells in response to allergens is mediated by the 
aggregation of surface bound IgE (bound to FceRI) by multivalent antigen The 
consequence of these actions is ultimately the release and synthesis of histamine, 
prostaglandins, leukotrienes, proteases and cytokines 3^2;320;327-33i
Activation of FceRI receptors on the surface of a mast cell initiates a complex signalling 
cascade. The Src family kinase Lyn is one protein involved in FceRI-mediated signalling. 
Lyn, when activated by the phosphatase CD45, phosphorylates the ITAM’s contained within 
the P and y chains of the FceRI receptor, and is a critical controlling step in the activation
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of FceRI Evidence for the involvement of Lyn in FceRI signalling comes from animals 
models in which Lyn activity has been abolished (Lyn ''' mice) Mast cells from these 
animals have impaired protein tyrosine phosphorylation and calcium mobilisation when 
activated via the FceRI. In rat basophilic leukaemia-2113 (RBL-2H3) cells a kinase inhibitor 
with specificity for the Src kinase family of enzymes, blocked activation by cross-linked IgE 
Other critical tyrosine kinases involved in mast cell signalling include Syk a member 
of the Zap70 protein family and Bruton’s tyrosine kinase which, may be a substrate of Lyn 
and has both redundant and opposing functions to Lyn in mast cells
Another key molecule involved in regulating FceRI signal transduction is the second 
messenger cAMP Elevated intracellular cAMP is a potent suppresser of mast cell 
degranulation Stimulation of Gs-coupled receptors or direct stimulation of adenylyl 
cyclase can suppress FceRI signalling. Phosphodiesterases have been shown to control 
cAMP levels in mast cells and the pan-specific phosphodiesterase inhibitor 3-isobutyl-1- 
methylxanthine (IBMX) has been shown to block FceRI activation However the
specific phosphodiesterase thought to control cAMP levels in human mast cells is unknown, 
as both PDE3 and PDE4 specific inhibitors have no effect upon mast cell degranulation
The aim of the work contained within this chapter was to discover which key intracellular 
targets, when blocked, could therapeutically modulate the activation of mast cells stimulated 
through the high-affinity IgE receptor. Using cord blood derived mast cells (as a model of 
IgE-dependent activation) a unique set of chemical inhibitors were used to probe FceRI 
signalling. These inhibitors had selectivity for Src family kinase and phosphodiesterase type 
7 (PDE7) and were used to elucidate the role of these proteins in mast cell activation.
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6.2 Results
6.2.1 The generation of human mast cells from cord blood mononuclear cell 
precursors
Human mast cells were derived from cord blood mononuclear cells by growing them in the 
presence of SCF (Stem cell factor) at a concentration of 4.3nM, IL-6 at a concentration of 
2.3nM and PGE2 at a concentration of 300nM. The method is derived from Saito et al and 
is detailed in chapter 2.3.10. The ability of these cord blood-derived mast cells to proliferate 
in culture was measured over a 45-day period. Figure 6.1 indicates that, by day 15, cell 
number had increased by 177 ± 22%. From day 15 onwards cell numbers started to decline 
and by day 45 in culture 28 ± 9% of original cell numbers remained.
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Figure 6.1: The effect of SCF, IL-6 and PGE2 on cord blood mononuclear cell survival.
30 X 10  ^Cord blood PBMC were treated with SCF (4.3nM), IL- 6  (2.5nM) and PGE2 (300nM) in weekly doses. 
Viable cells were counted at the times indicated by their ability to exclude trypan blue. The values shown are the 
mean of five separate experiments ± SEM.
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6.2.2 The phenotypical analysis of human mast cells derived from human cord 
blood mononuclear cell precursors
Cord blood mononuclear cells cultured with SCF, IL-6 and PGE2 were monitored using a 
FACScalibur flow cytometer, fig 6.2. Forward light scatter (which was taken as an indicator 
of cell size) and side light scatter (which was taken as an indictor of cell granularity) were 
measured by flow cytometry for a period of 14 weeks. These measurements began after 6 
days in order to eliminate contaminating cells, e.g. lymphocytes, from the plots. By day 20 
the cells had formed into a single agranular population that was termed, immature cord 
blood-derived mast cells (IcbMC). This population is indicated on the day 27 plot of fig 6.2 
by an oval gate. IcbMC persisted until day 62 as a minor population. By day 34 in culture, 
the IcbMC population had started to split into another more granular population. These cells 
were termed cord blood-derived mast cells (cbMC), this population is indicated on the day 
62 plot of fig 6.2 by a circular gate.
These two populations, IcbMC and cbMC, were analysed using flow cytometry for the cell 
surface expression of a panel of chemokine receptors. Figure 6.3 shows that IcbMC 
expressed the CC chemokine receptors CCR2 and CCR5 but did not express the chemokine 
receptors CCRl, CCR3 and CCR6. Expression of CCR2 and CCR5 progressively increased 
from day 13 to day 62. Weak expression of CCR6 was observed in some experiments, 
though this expression was variable.
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Figure 6.2: The light scatter properties of cord blood mononuclear cells treated with 
SCF, IL- 6  and PGE2 . Cord blood PBMC were treated with SCF (4.3nM), IL- 6  (2.5nM) and PGE2 (300nM) 
in weekly doses. At the times indicated (day represented in the top left-hand comer of each plot) cells light 
scattering properties were analysed using flow cytometry. The data was expressed as plots o f forward scatter 
(FSC or size) versus side scatter (SSC or granularity). The plots shown consist o f at least 5000 events and the 
data shown is representative of five separate experiments.
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Figure 6.3: The expression of CCRl, CCR2, CCR3, CCR5 and CCR6  on immature 
cord blood derived human mast cells (IcbMC). immature cord blood derived mast cells (IcbMC), 
were defined according to their unique light scattering properties, as analysed using flow cytometry techniques 
(see figure 6.2). IcbMC were stained with antibodies that recognised human CCRl, CCR2, CCR3, CCR5 and 
CCR6 , represented by a red line. IcbMC were also stained with irrelevant isotype matched antibodies, represented 
by a green line. Data was plotted as overlaid histograms, each plot consists of at least 3000 events. The data 
shown is representative of five separate experiments.
IcbMC were also tested for the expression of CXC chemokine receptors. Figure 6.4 shows 
that IcbMC expressed the CXC chemokine receptors CXCR2, CXCR3 and CXCR5 but did 
not express the CXC chemokine receptors CXCRl and CXCR4. Expression of both CXCR3 
and CXCR5, though consistently detectable, was weaker than the expression of the CC 
chemokine receptors CCR2 and CCR5 upon the same cells. Expression of CXCR3 and 
CXCR5 progressively increased from day 13 to day 62, in a similar fashion to the expression 
of CCR2 and CCR5. The expression of CXCR2 on IcbMC was transitory; CXCR2 levels 
peaked after 27 days in culture and had decreased by 62 days in culture.
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Figure 6.4: The expression of CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 on 
immature cord blood derived human mast cells (IcbMC). immature cord blood derived mast 
cells (IcbMC), were defined according to their unique light scattering properties, as analysed using flow 
cytometry techniques (see figure 6.2). IcbMC were stained with antibodies that recognised human CXCRl, 
CXCR2, CXCR3, CXCR4 and CXCR5, represented by a red line. IcbMC were also stained with irrelevant 
isotype matched antibodies, represented by a green line. Data was plotted as overlaid histograms, each plot 
consists of at least 3000 events. The data shown is representative of five separate experiments.
Mature cbMC were also analysed for the expression of CC and CXC chemokine receptors. 
cbMC were assessed for the expression of chemokine receptors after 49 and 62 days in 
culture respectively. Figure 6.5, shows that cbMC did not express any of the CC chemokine 
receptors; CCRl, CCR2, CCR3, CCR5 and CCR6 nor did they express any of the CXC 
chemokine receptors; CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5.
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Figure 6.5; The expression of CCRl, CCR2, CCR3, CCR5, CCR6 , CXCRl, CXCR2, 
CXCR3, CXCR4 and CXCR5 on mature cord blood derived mast cells (cbMC). Cord
blood derived mast cells (cbMC), were defined according to their unique light scattering properties, as analysed 
using flow cytometry techniques (see figure 6.2). cbMC were stained with antibodies that recognised human 
CCRl, CCR2, CCR3, CCR5, CCR6 , CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5, represented by a red line. 
cbMC were also stained with irrelevant isotype matched antibodies, represented by a green line. Data was plotted 
as overlaid histograms, each plot consists of at least 3000 events. The data shown is representative of five 
separate experiments.
6.2.3 The functional responses of human mast cells derived from cord blood 
mononuclear cell precursors
Figure 6 .6  indicates that cbMC (as defined in chapter 6.2.2) were found to contain 
histamine. Cells cultured for at least 70 days with SCF, IL-6 and PGE2, contained 110 ± 37 
ng ml of histamine per lO'^  cells (11 ± 3.7 pg ml of histamine per cell).
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Figure 6.6; The histamine content of cord blood derived human mast cells, l x 1 0  ^ cbMC 
were harvested after 70 days in culture (with SCF/IL-6 /PGE2) and lysed with 0.1% triton X-100. Histamine levels 
were determined in cell free culture supernatants by El A. Each point is a mean of four separate values, each point 
represents a separate experiment. A straight line indicates the mean of all experiments.
cbMC (henceforward ‘cbMC’ will refer to cord blood mononuclear cells that have been 
cultured with SCF, IL-6 and PGE2 for at least 70 days) when challenged with human IgE and 
an anti-human IgE antibody, released histamine, fig 6.7a. The release of histamine was 
specific and dose-dependent, 1 pg ml of IgE protein and 5 pg ml of anti-IgE antibody 
inducing a 6-fold increase in histamine release compared to cells treated with 5 pg ml of 
anti-IgE antibody alone. cbMC also synthesised peptido-leukotrienes when challenged with 
human IgE and an anti-IgE antibody, fig 6.7b. The synthesis of leukotrienes was specific and 
dose-dependent, 1 pg ml of IgE protein and 5 pg ml of anti-IgE antibody inducing a 
58-fold increase in leukotriene synthesis compared to cells treated with 5 pg ml of anti IgE 
antibody alone.
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Figure 6.7: Dose-dependent release of histamine and synthesis of peptido-leukotrienes 
by cord blood derived human mast cells exposed to human IgE and anti-IgE
antibodies. cbMC were pre-treated with or without human IgE (1 pg ml for Ih prior to stimulation with a 
mouse anti-human IgE antibody at the concentrations indicated. Histamine (A) and peptido-leukotrienes (B) were 
measured after 30 min in cell free culture supernatants by El A. Values are in triplicate ±  SD and the experiment 
is representative of three separate experiments.
Stem cell factor (10 ng ml when incubated with cells for one hour prior to culture, 
augmented the IgE-dependent release of histamine and synthesis of leukotrienes, fig 6.8. 
SCF augmented the release of histamine by 4-fold and leukotriene synthesis by 8 fold. cbMC 
when stimulated with SCF, IgF and an anti-IgF antibody preferentially synthesised 
leukotriene C4 (LTC4) in preference over prostaglandin D2 (PGD2). In three separate 
experiments the ratio of LTC4 to PGD2 varied from 9 to 19 fold, fig 6.9.
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Figure 6.8: The release of histamine and synthesis of peptido-leukotrienes by cord 
blood derived human mast cells exposed to human IgE, anti-IgE and stem cell factor.
cbMC were pre-treated with or without human IgE (1 jig ml ~‘) for Ih prior to stimulation with a mouse anti­
human IgE antibody (5 pg ml in the presence or absence of SCF (10 ng ml “*). Histamine and peptido- 
leukotrienes were measured after 30 min in cell free culture supernatants by El A. Values are in triplicate ± SD 
and the experiment is representative of three separate experiments
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Figure 6.9: The production of LTC4  and PGD2  by cord blood derived mast cells 
stimulated with human IgE, anti-IgE antibodies and SCF. cbMC were pre-treated with human 
IgE (1 pg ml for Ih prior to stimulation with a mouse anti-human IgE antibody (5 pg ml “h and SCF (10 ng 
ml "')• LTC4 and PGD2 were measured after 30min in cell free culture supernatants hy ElA. Values are in 
triplicate ± SD. N.B. CD015-CD017 refers to separate cord blood cultures from different donors.
6.2.4 The effect of agents that elevate cAMP on the functional responses of 
human mast cells derived from cord blood mononuclear cell precursors 
Figure 6.10 shows that forskolin (a direct adenylyl cyclase activator) dose-dependently 
inhibited the IgE-dependent release of histamine from cbMC. 25pM of forskolin inhibited 
100% of the specific histamine released. Figure 6.11 indicates that IB MX did not inhibit 
IgE-dependent histamine release from cbMC. Even at concentrations up to 500pM IB MX 
was unable to block histamine release. Two phosphodiesterase inhibitors, Trequinsin 
(PDE3 selective inhibitor) and RP7340I '^ ’^^ '^^ (PDE4 specific inhibitor) both failed to inhibit 
the IgE-dependent release of histamine from cbMC, fig 6.12. When Trequinsin and RP73401 
were both added to cbMC, they synergistically inhibited the IgE-dependent release of 
histamine. Figure 6.13 indicates that IpM of RP7340I and lOpM of Trequinsin inhibited 
44% ± 1% of the specific histamine released from cbMC.
120
Chapter 6
110
100
90
80
70
60
50
40
30
20 -0— Forskolin 
□  Anti-IgE -t- SCF 
A Medium
10
0
10 10000 1000001 100 1000
Concentration of Forskolin (nM -1)
Figure 6.10: The effect of forskolin on the release of histamine from cord blood derived
human mast cells exposed to human IgE, anti-IgE antibodies and SCF. cbMC were pre­
treated with human IgE (1 |iig ml ”') and forskolin (at the concentrations indicated) for Ih prior to stimulation 
with a mouse anti-human IgE antibody (5 p,g ml and SCF (10 ng ml Histamine was measured after 30 min 
in cell free culture supernatants by EIA. Values are in triplicate ± SD and the experiment is representative of three 
separate experiments.
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Figure 6.11: The effect of IBMX on the release of histamine from cord blood derived
human mast cells exposed to human IgE, anti-IgE antibodies and SCF. cbMC were pre­
treated with human IgE (1 (ig ml and IBMX (at the concentrations indicated) for Ih prior to stimulation with a 
mouse anti-human IgE antibody (5 p.g ml ~‘) and SCF (10 ng ml '*). Histamine was measured after 30 min in cell 
free culture supernatants by EIA. Values are in triplicate ± SD and the experiment is representative of three 
separate experiments
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Figure 6.12: The effect of the PDE3 selective inhibitor Trequinsin and the PDE4 
specific inhibitor RP73401 on the release of histamine from cord blood derived human 
mast cells exposed to human IgE, anti-IgE antibodies and SCF. cbMC were pre-treated with 
human IgE (1 pg ml "*) and Trequinsin or RP73401 (at the concentrations indicated) for Ih prior to stimulation 
with a mouse anti-human IgE antibody (5 pg ml and SCF (10 ng ml "*). Histamine was measured after 30 min 
in cell free culture supernatants by EIA. Values are in triplicate ± SD and the experiment is representative of three 
separate experiments
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Figure 6.13: The effect of the PDE3 inhibitor Trequinsin in combination with the PDE4 
inhibitor RP73401 on the release of histamine from cord blood derived human mast
cells exposed to human IgE, anti-IgE antibodies and SCF. cbMC were pre-treated with human 
IgE (1 pg ml "*), RP73401 (IpM) and Trequinsin (at the concentrations indicated) for Ih prior to stimulation with 
a mouse anti-human IgE antibody (5 pg ml “*) and SCF (10 ng ml “*). Histamine was measured after 30 min from 
cell free culture supernatants by EIA. Values are in triplicate ± SD and the experiment is representative of three 
separate experiments.
122
Chapter 6
6.2.5 The effect of Src kinase and PDE 7 inhibitors on the functional responses 
of human mast cells derived from cord blood mononuclear cell precursors
A series of structurally similar inhibitors of the enzymes Lyn and/or PDE7, were used in 
these studies. These compounds; CT5474, CT5733, CT5651, CT5982, CT5227, CT5473, 
CT6236, CT5215, CT5378 and CT5605 are described in more detail in chapter 2.2.2. Table
6.1 shows the selectivity for inhibition of the enzymes PDE7, Lck, Lyn, PDE3, PDE4 and 
PKC by these compounds. This series of compounds contained inhibitors of Lyn, which had 
no inhibitory activity against PDE7 e.g. CT5227. The series also contained inhibitors of 
PDE7, that had no inhibitory activity against Lyn e.g. CT5982 and inhibitors of both PDE7 
and Lyn e.g. CT5474.
Table 6.1: The IC50S of a series of structurally related compounds for the inhibition of 
the in vitro enzyme activity of PDE7, Lck, Lyn, PDE3, PDE4 and PKC.*
Inhibitors PDE7 Lck Lyn PDE3 PDE4 PKC
CT5215 13,300 ND 21 ND ND ND
CT5227 13,300 6 11 13,300 ND 1872
CT5378 ND ND 5.5 ND ND ND
CT5474 15 2.7 2.9 13,300 123 10,000
CT5475 2811 10,000 ND ND ND ND
CT5605 13,300 ND 1273 ND ND ND
CT5651 4 165 191 13,300 164 10,000
CT5733 12 708 1287 6500 504 10,000
CT5982 13 10,000 10,000 1100 359 10,000
CT6236 117 13,000 13,000 13,000 13300 ND
* All values are expressed as nM ICggS. Values are the mean of three separate experiments (standard deviations 
are not shown). ND = not determined.
Eight of the Src kinase and PDE7 inhibitors were tested for their ability to inhibit IgE- 
dependent histamine release and leukotriene synthesis from cbMC, table 6.2. The IC50 
values for the compounds varied in potency from 38nM to lOpM for inhibition of histamine 
release and from lOnM to lOpM for the inhibition of leukotriene synthesis. The same eight 
compounds were also tested for their ability to block histamine release from rat pleural mast
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cells that had been stimulated with cross-linking anti-IgE antibodies. Table 6.2 shows that 
the IC50 values for these compounds ranged in potency from llOnM to lOpM for the 
inhibition of histamine release.
Table 6.2: IC5 0 S of Src kinase and PDE7 inhibitors for inhibition of
histamine/leukotriene production by cbMC and histamine production by rat pleural 
mast cells.*
Compound
Mean IC50 
(nM) histamine 
release (cbMC)
SEM
±
Mean IC50 (nM) 
leukotriene 
synthesis (chMC)
SEM
±
Mean IC50 
(nM) histamine 
release (Rat)
SEM
±
CT5227 198.7 114.7 190 130.6 350 47.3
CT5378 37.7 21.8 10 / 453.4 153.8
CT5474 82 47.3 125 61.2 110 55.4
CT5475 98.7 56.9 80 16.3 1883 573.2
CT5651 266.7 154 250 40.8 2353 613.9
CT5733 1267 731.3 725 224.5 5367 1374
CT5982 6000 3464 6500 2857.7 5160 1642
CT6236 10000 5774 10000 0 10000 0
* cbMC were pre-treated with human IgE (1 pg ml and the compounds preincubated for Ih prior to 
stimulation with a mouse anti-human IgE antibody (5 pg ml “*) and SCF (10 ng ml "*). Histamine and peptido- 
leukotrienes were measured after 30 min from cell free culture supernatants by EIA. Rat pleural mast cells were 
pre-treated with rat IgE (2 pg ml “*) and the compounds indicated for Ih prior to stimulation with a sheep anti-rat 
IgE antibody (1 pg ml ”*). Histamine was measured after 30 min from cell free culture supernatants by EIA. 
Values are the mean o f three separate experiments ±  SEM.
The inhibition of histamine release from cbMC by CT5227, CT5474, CT5651, CT5733, 
CT5982, CT5378 and CT6236 was correlated with inhibition of the Src kinase enzyme Lyn, 
fig 6.14. There was a good correlation between these two inhibitory activities (Spearman’s r 
= 0.964) and the result was significant (p=0.003). Figure 6.14 also shows the correlation of 
the inhibition of leukotriene synthesis with inhibition of Lyn for the same panel of 
compounds. The correlation between these two inhibitory activities was good (Spearman’s r 
= 0.964) and the result was significant (p=0.003).
The inhibition of histamine release from cbMC by the compounds CT5227, CT5474, 
CT5475, CT5651, CT5733, CT5982, and CT6236 was also correlated with inhibition of the 
phosphodiesterase enzyme, PDE7, figure 6.15. There was no correlation between these two 
inhibitory activities (Spearman’s r = -0.286) and the result was not significant (p=0.556).
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Figure 6.15 also shows the correlation of the inhibition of leukotriene synthesis with 
inhibition of PDE7 for the same panel of compounds. There was no correlation between 
these two inhibitory activities (Spearman’s r = -0.351) and the result was not significant 
(p=0.444). To investigate if inhibition of PDE4 correlated with inhibition of mast cell 
degranulation, five compounds that were tested for PDE4 inhibition were correlated with 
inhibition of mast cell histamine release. There was no correlation between these two 
activities (Spearman’s r =0.700) and the result was not significant p=0.233, (data not shown).
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Figure 6.14: Correlation of inhibition of histamine release and leukotriene synthesis 
from cord blood derived mast cells stimulated with IgE, anti-IgE antibodies and SCF,
with inhibition of p56^^” for a series of structurally related inhibitors. cbMC were pre­
treated with human IgE (1 pg ml and the compounds; CT5227, CT5474, CT5474, CT5651, CT5733, CT5982, 
CT5378 and CT6236 for Ih prior to stimulation with a mouse anti-human IgE antibody (5 pg ml "*) in the 
presence of SCF (10 ng ml "*). Histamine and peptido-leukotrienes were measured after 30 min from cell free 
culture supernatants by EIA. IC50 values obtained from this data were plotted against IC50 values obtained for the 
inhibition of p56^^" in in vitro  enzyme assays. This data is the mean of three separate experiments (errors not 
shown).
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Figure 6.15: Correlation of inhibition of histamine release and leukotriene synthesis 
from cord blood derived mast cells stimulated with IgE, anti-IgE antibodies and SCF,
with inhibition of P D E 7  for a series of structurally related inhibitors. cbMC were pre-treated
with human IgE (1 pg ml and the compounds; CT5227, CT5474, CT5474, CT5651, CT5733, CT5982, 
CT5378 and CT6236 for Ih prior to stimulation with a mouse anti-human IgE antibody (5 pg ml “') in the 
presence of SCF (10 ng ml Histamine and peptido-leukotrienes were measured after 30 min from cell free 
culture supernatants by EIA. IC50 values obtained from this data were plotted against IC50 values obtained for the 
inhibition of PDE7 in in vitro enzyme assays. This data is the mean of three separate experiments (errors not 
shown).
The inhibition of histamine release from rat pleural mast cells by the compounds CT5227, 
CT5474, CT5651, CT5733, CT5982, CT5378 and CT6236 was correlated with inhibition of 
the Src kinase enzyme Lyn, fig 6.16. The correlation between these two inhibitory activities 
was good (Spearman’s r = 0.929) and highly significant (p=0.007). The inhibition of 
histamine release from rat pleural mast cells by the same panel of compounds was also 
correlated with their inhibition of the phosphodiesterase enzyme PDE7, fig 6.16. In contrast
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the correlation between these two inhibitory activities was poor (Spearman’s r = -0.357) and 
not significant (p=0.444).
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Figure 6.16: Correlation of inhibition of histamine release and leukotriene synthesis 
from rat pleural mast cells stimulated with rat IgE and anti-rat IgE antibodies, with 
inhibition of p56^ "^ and PDE7 for a series of structurally related inhibitors. Rat pleural 
mast cells were pre-treated with IgE (2 pg ml ~*) and the compounds; CT5227, CT5474, CT5651, CT5733, 
CT5982, CT5378 and CT6236 for Ih prior to stimulation with a sheep anti-rat IgE antibody (1 pg ml “ )^. 
Histamine levels were measured after 30 min from cell free culture supernatants by EIA. IC50 values obtained 
from this data were plotted against IC50 values obtained for the inhibition of p56^^ and PDE7 in, in vitro  enzyme 
assays. This data is the mean of three separate experiments (errors not shown).
The compounds CT5227, CT5733 and CT5982 (which represented potent, intermediate and 
weak inhibitors of IgE-dependent mast cell degraunlation), were examined for their ability to 
inhibit both histamine release and peptido-Ieukotriene synthesis from cbMC stimulated with 
PMA and ionomycin. None of these compounds inhibited the release of histamine and
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synthesis of leukotrienes, with the exception of the compound CT5733, which at a 
concentration of lOjuM inhibited 45% ± 9.5% of leukotriene synthesis, fig 6.17.
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Figure 6.17: The effect of Src/PDE7 inhibitors on histamine release and peptido- 
Ieukotriene synthesis from cord blood derived mast cells exposed to PMA and 
ionomycin. cbMC were incubated with CT5227, CT5733 and CT5982 at the concentrations indicated for 30 
minutes prior to stimulation with PMA (1 pg ml “‘) and ionomycin (10 ng ml “*). Histamine and peptido- 
leukotrienes were measured after 30min in cell free supernatants by EIA. Values are shown in triplicate ± SD and 
the experiment is representative of three separate experiments.
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6.3 Discussion
In order to study the effect of signal transduction inhibitors on mast cell function it was 
essential to obtain large numbers of purified cells. This need was met by deriving mast cells 
from CD34 positive precursors harvested from human cord blood. Cord blood-derived mast 
cells (cbMC) were characterised to ensure they were phenotypically and functionally 
representative of human mast cells. cbMC proliferated in response to high doses of the 
cytokines SCF and IL-6 in the presence of PGE2. cbMC, after this initial period of 
proliferation formed a distinct agranular population as defined by their light scattering 
properties using flow cytometetry. This population termed IcbMC divided into another 
separate and more granular population at around 4 weeks. These granular cells increased in 
number relative to IcbMC and by week 8 were the dominant population. These cells were 
deemed mature mast cells and were termed cbMC.
cbMCs were extensively characterised to ensure that they phenotypically and functionally 
resembled human mast cells. Thirty separate cord blood cultures were used to characterise 
mast cell responses prior to use in this thesis. cbMC after 10 weeks in culture, contained 
levels of histamine similar to those found in human lung mast cells and cord blood-derived 
mast cells described in the literature ^^"^=324:346^ These cells released histamine and synthesised 
peptido-leukotrienes when challenged with cross-linked human IgE but not IgE alone. In 
accordance with other studies SCF augmented this response In addition, cbMC also 
synthesised LTC4 in preference to PGD2, which may indicate the up-regulation of the 5- 
lipoxygenase-synthase pathway Although cbMC were found to express mast cell 
tryptase, technical difficulties precluded the measurement of mast cell chymase. However, 
cbMC did not, using light microscopy, resemble basophils nor did they express any basophil 
specific markers (data not shown). cbMC, thus behaved like human mast cells with respect 
to their functional activation using cross-linked IgE as an activating agent.
At the beginning of this project little was known of how mast cell precursors or mature mast 
cells migrate to the sites of allergic inflammation. To investigate this the expression of
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chemokine receptors on differentiating and mature cord blood mast cells was studied. 
Evidence that mast cells express chemokine receptors has until recently been limited. Human 
mast cells were found to migrate, but not degranulate, in response to monocyte 
chemoattractant protein-1 (MCP-1) and RANTES (regulated upon activation normal T cell 
expressed and secreted) indicating that they express chemokine receptors The mast
cell-like cell line HMC-1 expresses functional CXCRl and 2 though there is no
evidence for the expression of such receptors on primary cells.
During the course of this thesis a paper by Ochi et al supported some of the findings 
contained within this chapter. Ochi et al reported that cord blood derived mast cells express 
the chemokine receptor CCR3, a chemokine implicated in the pathogenesis of asthma. 
Subsequently, fully functional CCR3 was found to be expressed on human mast cells that 
stained positive for tiyptase/chymase The findings of Ochi et al, also indicated that 
immature cord derived mast cells express functionally active C-C chemokine receptors 
CCR3 and 5 and CXC chemokine receptors CXCR2 and CXCR4.
Mast cells used in this study were also found to express a unique repertoire of chemokine 
receptors. IcbMC, which were less granular than fully mature mast cells and did not act as 
functional mast cells (data not shown), expressed the CC chemokine receptors CCR2 and 5 
and the CXC chemokine receptors CXCR2, 3 and 5. IcbMC did not express the CC 
chemokine receptors CCRl, 3, or 6 nor the CXC chemokine receptors, CXCRl and CXCR4. 
This pattern of expression differed from that reported by Ochi et al who found expression 
of CCR3, CCR5, CXCR2 and CXCR4 on immature cells. Mature granular mast cells 
(detected from 5 weeks onwards) did not express the CC chemokine receptors CCRl, 2, 3, 5 
and 6 nor did they express the CXC chemokine receptors CXCRl, 2, 3, 4 or 5. These 
findings are broadly in line with those described by Ochi et al though they did find that 
mature mast cells expressed CCR3, a finding that could not be replicated in the present 
study.
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These findings implicate a wide variety of chemokine receptors in the trafficking of mast 
cell-committed precursors to sites within the body. The expression of CCR2, CCR5, 
CXCR2, CXCR3 and CXCR5 receptors on mast cells precursors may mean they can migrate 
to many different sites within the body. This pattern of receptor expression has not been 
documented on haematopoetic cells. The lack of chemokine receptors on mature mast cells is 
contrary to that reported by Ochi et al, who found expression of CCR3. These differences in 
receptor expression may relate to the use of IL-10 in preference to PGE2 as a differentiating 
factor. This may have induced the preferential expression of CCR3 on mast cells. For 
instance, it has been reported that different cytokines such as IL-4, IL-5 and IFN-y can 
influence the differentiation of mast cells from their committed precursors More
studies are needed to determine how these cytokines can influence the chemokine receptor 
expression on committed mast cell precursors and whether these processes occur in vivo.
Elevated levels of cAMP in cultured human mast cells correlate with the inhibition of 
mediator release and cytokine production The granular cbMC used in these studies were 
shown to be sensitive to the elevation of cAMP. The adenylyl cyclase activator, forskolin, 
inhibited IgE-mediated mast cell activation in accordance with the literature The
question of which PDE controls cAMP in mast cells is unclear. Although PDE3 and 4 have 
been shown to be expressed in mast cells the addition of specific PDE3 and PDE4 
inhibitors was unable to block IgE-induced histamine release. In addition, IBMX did not 
inhibit histamine release from cbMC, in contrast to other experimental findings but
inhibitors of PDE3 and PDE4, when added together, did have a small synergistic inhibitory 
effect on histamine release at high concentrations. This effect has been observed with human 
mast cells using the mixed PDE3/4 inhibitor Benzafentrine This indicates that inhibition 
of PDE4, currently a therapeutic target for intervention in asthma does not control
FceRI induced degranulation of mast cells and is, in contrast to FceRI induced degranulation 
in other cells such as basophils, PDE4-insensitive This may imply that basophils and 
cbMC differ in their expression or utilisation of PDEs. These findings, along with reports in 
the literature, have led to the proposal that a PDE other than PDE3 or 4 must control cAMP
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levels in mast cells. Inhibition of this PDE would control mast cell degranulation in response 
to IgE. One such candidate is PDE7, a cAMP selective PDE, that is thought to play a role in 
T cell activation Until now no potent and specific PDE7 inhibitors have been
available to test whether PDE7 plays a role in mast cells.
Using a series of Celltech inhibitors, the role of both Src kinase and PDE7 could be 
determined in mast cell activation. This series of inhibitors were potent and specific for Src 
kinase, Lyn without showing significant activity for PDE3, 4 and PKC (activity against 
PDE3,4 or PKC may inhibit mast cell degraulation). The inhibition of Lyn (as a 
representative Src kinase) but not PDE7 was able to control the activation of cbMC 
stimulated via the FceRI receptor. Lyn kinase inhibitors controlled the IgE-mediated release 
of histamine and the de novo synthesis of leukotrienes. Under the same conditions low nano­
molar inhibitors of PDE7 failed to inhibit the release of histamine and synthesis of 
leukotrienes. The inhibitor effects were not restricted to cord blood-derived mast cells as 
inhibition of Lyn, but not PDE7 also correlated with inhibition of histamine release from rat 
pleural mast cells. The effect was probably not due to a synergistic blockade of PDE3 and 4 
as the most potent dual PDE3 and 4 inhibitor, CT5982, was a weak suppresser of mast cell 
activation. The effects of these inhibitors were confined to signalling pathways upstream of 
those activated by PMA and ionomycin.
This study has confirmed that Src kinases play an important role in FceRI signal 
transduction. Studies using another Src kinase inhibitor, PPl, showed inhibition of markers 
of cellular activation in RBL (rat basophillic leukaemic cell line) cells activated through the 
FceRI receptor During this thesis it emerged that the dominant role thought to be played 
by Lyn in FceRI signalling may be incorrect. Work using Lyn negative mice indicates that 
Lyn does not play such a central role in FceRI mediated degranulation To explain why 
CT-SKI inhibited FceRI-dependent mast cell degranulation it may be that as well as 
inhibiting Lyn, other tyrosine kinases critical to FceRI signalling are also blocked by these
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inhibitors. Two such candidates Syk and Btk may account for the effects seen. Syk activity 
when absent, as in the case of the Syk deficient cell line (RBL-2H3), completely abolishes 
FceRI induced degranulation and cytokine synthesis. When Btk’s activity is abolished, 
together with Lyn, profound inhibition of mast cell degranulation is seen When Btk alone 
is absent from mast cells the synthesis of cytokines is impaired but when Lyn alone is
absent from mast cells cytokine synthesis can be increased Studies of the effect of
inhibitors on mast cell cytokine production may delineate Lyn- and Btk-selective action of 
inhibitors.
Future work using these chemical inhibitors will be required to profile them against a panel 
of critical kinases involved in FceRI activation. These inhibitors are likely to be pan-specific 
inhibitors of the Src family of kinases (as indicated by their inhibition of the related Src 
kinase Lck), whose family members Lyn, c-Src and c-Yes are all activated upon cross- 
linking the FceRI Indeed, these inhibitors may mediate their effects by the concomitant 
inhibition of Lyn, Src and Yes in the same cells. A full understanding of these inhibitors 
profile against other key kinases, along with an understanding of their effects on other 
cellular phenomenon such as calcium mobilisation and cytokine production will be required 
to fully interpret their mechanism of action and possible therapeutic potential as anti-allergic 
drugs.
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General discussion
7.1 Introduction
Inflammation under normal circumstances is a protective phenomenon, but can be 
responsible for an enormous amount of morbidity and mortality worldwide. Infectious 
diseases, cardiovascular diseases, neuro-degenerative disorders, cancer and the many 
idiopathic chronic inflammatory conditions (asthma, rheumatoid arthritis etc.) all have 
inflammatory components which, if they could be blocked, would have therapeutic benefit. 
Inflammatory diseases have been the subject of study for well over a century and since the 
end of the second world war there has been an enormous effort made to understand these 
diseases at levels from the whole animal to the individual protein. More than 50 years of 
intensive research have made us realise the immense complexity of the inflammatory process 
and how deeply it is woven into the fabric of the individual. This has been brought into focus 
by the recent discoveries of the Toll interleukin-1 receptor domain which may be traced back 
through our genetic history for over 2 billion years
How can one envisage controlling, for therapeutic benefit, this ancient and multifaceted 
protective mechanism? One hypothesis, that has been the subject of ongoing examination for 
the past two decades, is that cytokines represent a major control point in inflammation. 
When this thesis began the hypothesis that inhibition of particular cytokines could be of 
therapeutic use in controlling inflammation had not been formally tested. However, in the 
past few years sufficient clinical data has accrued to support the hypothesis that blockade of 
TNF-a has therapeutic benefit. The methods used to block this cytokine include the use of 
neutralising chimaeric anti-TNF antibodies and soluble TNF receptor-Fc fusion proteins 
These macromolecular medicines are proving efficacious but may prove a mere stopgap 
before the introduction of small molecule drugs, which will provide the same end result but 
interfere, with different aspects of the control of the inflammatory process.
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It is likely, given that the cytokines appear to make multi-point attachments with their 
receptors, that small molecule inhibitors of individual cytokines will prove difficult to 
produce. This leaves the intracellular signalling processes driven by cytokines and the 
interactions which induce the transcription of pro-inflammatory cytokine genes, as 
therapeutic targets. In this thesis the hypothesis under test is that blockade of specific 
intracellular signalling systems can inhibit cytokine synthesis or cytokine-driven patho- 
mechanisms.
This project has focused on two intracellular signalling enzyme classes which, when 
inhibited, may regulate the production of cytokines by leukocytes. Potent and selective 
inhibitors of phosphodiesterases and Src tyrosine kinases have been used to block the 
activity of these enzymes in leukocytes and in turn used to discover the role these proteins 
play in regulating cytokine production. Since a detailed discussion has accompanied each 
chapter, this final section will provide an abbreviated review of the findings of the thesis, 
comment on their implications and on further work that is indicated by the studies described.
7.2 Inhibition of the PDE4 enzyme
The PDE4 enzyme has a well defined role in regulating cytokine production i49;i76;2oo;269 
Inhibiting PDE4 in monocytic cells greatly suppresses their ability to produce the pro- 
inflammatory cytokine TNF-a The ability of PDE4 inhibitors to block TNF-a production 
is thought to involve the elevation of intracellular cAMP. This method of suppressing TNF-a 
has been shown to be dependent upon elevating the level of the anti-inflammatory cytokine 
IL-10 as IL-10 is a natural regulator of TNF-a production However, studies using 
PDE4 inhibitors have indicated that blockade of TNF-a can be both-dependent or- 
independent of IL-10 production ^^ :^205;24i has led to confusion over the exact way in 
which PDE4 inhibitors regulate monocyte synthesis of TNF.
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Chapter 3 of this thesis supports the hypothesis that the suppression of monocyte TNF-a 
production by PDE4 inhibitors is not due to the elevation of IL-10 synthesis. To explain why 
conflicting reports suggested both IL-10-dependent and-independent mechanisms of TNF-a 
inhibition, it was proposed that studies comparing the effects of PDE4 inhibition on murine 
and human monocytic cells may not have taken into account the heterogeneous nature of 
monocytes when interpreting data.
In order to understand why different results using PDE4 inhibitors have been obtained it was 
necessary to study the effect of inhibiting PDE4 on cytokines other than TNF-a. It was 
discovered that inhibition of PDE4, in LPS activated human PBMC, resulted in a distinct 
pattern of cytokine inhibition as shown in table 7.1.
Table 7.1: PDE4-mediated inhibition of LPS induced human PBMC cytokine 
production. *
Cytokine PDE4 inhibitor hr IL-10
TNF-a 4-++-h +++-1-
IL-1 a +4-+ ND
IL-ip -H- 4—H"
IL-6 - -
IL-8 - ND
* ND, indicates measurements not determined. + indicates inhibition and -  indicates no effect. hrIL-10 indicates 
the effect of Ing ml'* of hrIL-10 on LPS induced cytokine production.
As can be seen from the table PDE4 inhibitors mediated strong suppressive effects on both 
TNF and IL-1, an effect similar to the addition of exogenous IL-10 to LPS stimulated 
cultures. An interesting finding was the discovery that IL-1 a  was inhibited to a greater 
extent than IL-p. Both IL-1 a  and IL-1 (3 are synthesised as precursors and secretion of mature 
protein is dependent upon calpain and caspase-1, respectively Apart from the
requirement of these enzymes, the secretion pathways that lead to the release of IL-1 a  and 
IL-ip remains largely unknown. It may be that these pathways interact with the PDE4 
enzyme differently. Future experiments will need to dissect apart these two pathways and
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measure, for instance, the effect of inhibiting PDE4 activity on calpain and caspase-1 
activity. Also, inhibition of PDE4 did not result in the inhibition of IL-6 or IL-8 in vitro. This 
suggests that neither IL-6 nor IL-8 lie on a pathway that is regulated by PDE4.
Using neutralising anti-IL-10 receptor antibodies, it was determined that PDE4 inhibitors did 
not mediate the inhibition of TNF via the production of IL-10. Indeed PDE4 inhibitors were 
found to suppress IL-10 production when measured early on after LPS stimulation. This 
could conceivably be due to the feedback mechanisms between TNF and IL-10 as it is 
known that when TNF production is suppressed, it can counteract the signals that induce IL- 
10 expression
Monocytes are heterogeneous cells and the relative expression of two surface proteins, CD 14 
and CD 16, has proved useful in determining different monocyte subsets The expression 
of CD 16 on CD 14 positive monocytes and macrophages correlates with downregulation of 
the expression of both IL-10 and PDE4 it was discovered that both activating stimuli 
and PDE4 inhibitors can alter monocyte phenotype, fig 7.1.
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Figure 7.1: The effect of different stimuli on monocyte/macrophage maturation. PCS and
to a lesser extent LPS upregulate the expression of CD 16 on macrophages as they mature from human peripheral 
blood precursors. The expression of CD 16 on LPS but not PCS stimulated macrophages was blocked by 
inhibiting the enzyme PDE4. In contrast, LPS plus IPN-y suppressed the expression o f CD 16 and increased the 
expression of CD 14 on macrophages.
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Monocytes stimulated with LPS or LPS plus IFN-y, when compared, showed altered 
regulation of IL-10 by PDE4 inhibitors, table 7.2.
Table 7.2: Comparison of PDE4-mediated inhibition of LPS and LPS plus IFN-y 
induced human PBMC cytokine production. *
Cytokine LPS LPS plus IFN-y
T N F -a -H-4-+ 4-4-4-
IL-1 a +-H- ND
IL-ip 4-4- ND
IL-6 - ND
IL-8 - ND
IL-10 not detected Î Î
IL-12 ND ++++
* ND, indicates measurements not determined. + indicates inhibition, -  indicates no effect and T indicates 
stimulation.
This table indicates that PDE4 inhibitors show altered regulation of the key inflammatory 
cytokine IL-10 when stimulated with LPS with and without IFN-y. It was noted that PDE4 
inhibitors increased IL-10 production only in PBMC stimulated with LPS plus IFN-y. 
However despite elevating IL-10, PDE4-mediated inhibition of both TNF-a and IL-12 was 
found to be independent of IL-10 production. This may mean that PDE4-mediated inhibition 
of TNF-a is due to a direct effect on TNF-a production, which may for instance be due to 
regulation of TNF-a at a transcriptional level
At the beginning of this thesis it was assumed by many that PDE4 inhibitors clearly elevated 
cAMP in monocytes and so, like other agents that elevate cAMP, inhibited TNF-a 
production via an increase in IL-10. In consideration of this, early attempts during this thesis 
were made to show that PDE4 inhibitors could augment LPS induced IL-10 production. This 
hypothesis proved unworkable. To reconcile these findings with studies that clearly showed 
that PDE4 inhibitors elevated IL-10 it was proposed that the phenotype of the
monocytes used in these studies could account for the different effects of PDE4 inhibitors on 
IL-10 synthesis. Since it was known that CD16 positive macrophages differ compared to
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CD 16 negative macrophages in their regulation of cytokines and phosphodiesterases, factors 
that alter CD 16 expression could alter the effect of PDE4 inhibitors upon cytokine 
production. Indeed it was discovered that in CD 16 negative monocytes (stimulated with LPS 
plus IFN-y) PDE4 inhibitors could upregulate IL-10 production. Further studies are required 
to examine if CD 16 negative cells stimulated with LPS alone also regulate IL-10 in the same 
way as cells stimulated with LPS plus IFN-y. It would also be of interest to determine if cells 
from different species and anatomical sites, that are both CD 16 positive and CD 16 negative, 
regulate IL-10 the same way in response to PDE4 inhibitors. To know why PDE4 inhibitors 
act differently in different monocyte subsets, apart from the possible dysregulation of PDE4 
protein expression, it is important to know if PDE4 inhibitors block interactions other than 
the hydrolysis of cAMP. For instance, it is known that PDE4 interacts with important 
signalling enzymes such as MAP kinase and Src kinase but it is not known if these 
interactions are functionally relevant with respect to the signalling cascade nor if PDE4 
inhibitors can disrupt such interactions.
7.3 Inhibition of PDE4 in T ceils
The work reported in chapter 4 strongly implicates PDE4 inhibitors as being antagonistic to 
Thl mediated inflammation, exemplified by their inhibition of pro-inflammatory cytokine 
production by activated monocytes. In addition, it was shown that PDE4 inhibitors were 
equally effective at counteracting Th2 driven immune responses These effects may, in 
part, be due to the action on cells such as eosinophils which may be critical to the
pathogenesis of particular disease models. However, it is unclear whether PDE4 inhibitors 
differentially effect either Thl or Th2 cytokine production In chapter 4 of this thesis it
was hypothesised that PDE4 inhibitors have the potential to be both immunosuppressive 
and/or immunododulatory to T cells. To test if either or both of these hypotheses were 
correct the effect of inhibiting PDE4 on T cell proliferation and cytokine production was 
measured.
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PDE4 is an enzyme that is expressed in many cells, including T cells. Since elevating cAMP 
can control T cell responses, an agent that can induce such an elevation would be a useful 
immunosuppressive drug. Work reported in this thesis has shown that PDE4 inhibitors can 
elevate cAMP levels in activated T cells. Despite this, PDE4 inhibitors were weak 
suppressants of T cell proliferation. These weak effects do not correlate with inhibition of the 
PDE4 enzyme in its low-affmity conformation but correlate with inhibition of the PDE4 
enzyme in its, alternate, high-affmity conformation. The significance of these conformations 
is unclear but many of the side-effects of PDE4 inhibitors, e.g. the induction of emesis 
have correlated with inhibition of the enzyme in its high-affinity state. The effect on 
proliferation is in contrast to the effect on T cell cytokine production which was found to 
correlate with inhibition of the PDE4 enzyme in its low-affmity state The weak 
suppressive effect of PDE4 inhibitors on proliferation showed no bias to antigens that primed 
for Thl or Th2 responses, nor to the stimulus used to induce proliferation. Interestingly 
however, it was shown that the potency of PDE4 inhibitors at suppressing T cell proliferation 
could be enhanced by addition of exogenous PGE2. Since PDE4 protein expression may 
regulate PGE2 levels it has been suggested that the anti-proliferative effect of PDE4 
inhibitors is due to PGE2 This may indeed be the case, however in these studies PGE2 
was used at a dose that activated adenylyl cyclase but did not inhibit proliferation. To use an 
analogy, if inhibiting PDE4 is the equivalent of putting a plug in a bath, adenylyl cyclase is 
the equivalent of turning on the tap. Thus, if activated T cells have a decreased rate of cAMP 
synthesis then PDE4 inhibitors will not be able to maintain high cAMP levels. Indeed it was 
shown during this thesis that cAMP levels were greatly diminished 24 hours after activation, 
even in cells treated with high doses of PDE4 inhibitor.
In contrast to the inhibition of T cell proliferation PDE4 inhibitors were more effective at 
blocking cytokine production. The effects of inhibiting PDE4 on a number of T cell 
functions are compared in table 7.3.
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Table 7.3: PDE4-mediated inhibition of T cell activation. *
Response Stimulus 24hrs 48hrs
Proliferation Con A +++ +
Proliferation Con A + PGEz +-H- +++
IL-2 Anti-CD3 *f++ ND
IL-4 Anti-CD3 +4-4- +++
IFN-y Anti-CD3 +++ +++
TNF-a Anti-CD3 ++++ ++++
CD25 expression Anti-CD3 ++ -
* ND, indicates measurements not determined. + indicates inhibition and -  indicates no effect.
PDE4 inhibitors blocked the expression of both Thl (IFN-y) and Th2 (IL-4) cytokines to the 
same extent indicating that in in vitro human cultures PDE4 inhibitors do not favour 
inhibition of either Thl or Th2 cytokines. Under the same experimental conditions TNF-a 
production was completely blocked by PDE4 inhibitors. Although these studies were 
performed on mixed cell populations the TNF-a produced under such conditions could be 
completely blocked by the action of cyclosporin A indicating that T cells were the sole 
source of cytokine production. If these findings can be extended to purified T cell cultures 
then this may indicate that unlike all other T cell responses, TNF-a production in T cells is 
largely regulated by PDE4. The inhibition of T cell PDE4 activity results in a spectrum of 
responses, ranging from the strong inhibition of cytokines such as TNF-a to the weak 
inhibition of T cell proliferation and CD25 expression. As some of these processes correlate 
with inhibition of the PDE4 enzyme in either one or other of its conformational states it may 
be of importance to investigate what factors can regulate PDE4 enzyme conformation. Such 
as the divalent cation magnesium and the interaction of protein kinase A (PKA) with the 
PDE4 enzyme Understanding how such factors can regulate the PDE4 enzyme at the 
cellular level may explain the range of effects mediated by inhibiting PDE4 and how the 
compartmentalisation of responses can exist within the same cell.
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7.4 Inhibition of Src kinase enzymes
Inhibition of kinase enzymes has until recently been of limited use as a therapeutic tool to 
treat disease. The complexity and supposed redundant nature of kinase enzymes has held 
back the development of kinase inhibitors. This has all changed with the introduction of 
Gleevec an inhibitor of Bcr-Abl (Abelson tyrosine kinase) for the treatment of patients 
with CML (chronic myeloid leukaemia). This inhibitor has not only introduced the 
possibility of kinase inhibitors as effective treatments in cancer but has invoked a 
reassessment of kinase enzymes as targets in other non-cancerous diseases. In the second 
part of this thesis the activity of another class of signalling enzyme, Src tyrosine kinase, was 
inhibited in human T and mast cells. Since Src kinases are recruited to multi-chain immune 
recognition receptors, e.g. the T cell and high-affinity IgE receptors, they represent attractive 
targets to modulate immune responses. Such an undertaking required potent and specific 
chemical inhibitors. Through its medicinal chemistry department, Celltech (Slough, UK) 
developed a series of small molecule inhibitors of Src kinase. Although selectivity for 
individual Src kinase members was not achieved, a series of inhibitors were produced that 
specifically blocked Src kinases over other critical intracellular signalling enzymes. These 
small molecules improved upon existing pyrazolopyrimidine inhibitors of Src kinase As 
well as showing increased potency against Src enzymes, Celltech kinase inhibitors do not 
inhibit Csk, a kinase that can also regulate Src activity. This chemical series also contained 
molecules designed to inhibit a novel PDE, PDE7. These compounds were used to probe the 
function of both Src kinase and PDE7 in activated T and mast cells.
It was proposed that because Src kinase enzymes (Lck and Fyn) are implicated in TCR 
signalling, inhibiting their enzymatic function may block signalling through the T cell 
receptor. The data presented in chapter 5 indicates that Src kinase inhibitors were potent at 
suppressing T cell activation directed through the T cell receptor using anti-CD3 as a 
stimulus. This inhibition was exemplified by showing that inhibition of isolated Src kinase 
enzyme correlated with inhibition of anti-CD3-mediated T cell proliferation. This 
suppression was manifested as an inhibition of cellular proliferation, inhibition of the
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synthesis of both Thl and Th2 cytokines and inhibition of IL-2 receptor expression. 
However, when more complex antigen driven systems of T cell activation, such as the MLR, 
were used to activate T cells, Src kinase inhibitors were less effective. This implies that 
during antigen-driven proliferation other signalling pathways are activated that are Src 
kinase-independent. It was hypothesised that since responses such as the MLR are dependent 
upon IL-2 to amplify proliferative signals signalling through the IL-2 receptor may be a 
Src-independent event. It was found that inhibition of anti-CD3 induced proliferation caused 
by blocking Src kinase activity could be short circuited by adding exogenous IL-2. This 
indicates that signalling through the IL-2 receptor does not critically require Src tyrosine 
kinases. To further define the point of action of the inhibitors, IL-2 production was activated 
below the level of the TCR using PMA and ionomycin (which act at the level of PKC and 
calcium signalling). Src inhibitors did not block IL-2 induced proliferation under such 
conditions suggesting that their activity can be localised to the part of the signal pathway 
downstream of the TCR but upstream of PMA and ionomycin.
More work is needed to define how antigen and mitogen driven systems differ in their 
requirement for Src kinases. It is not understood which (apart from signals that are forced 
through the IL-2 receptor) pathways activated by antigen are Src-independent. The complex 
response initiated by T cell recognition of antigen, i.e. antigen processing and presentation, 
TCR recognition of peptide and clonal expansion, means there are many co-stimulatory 
signals feeding into the T cell. Understanding the effect that inhibiting Src kinase has on 
events such as the production of cytokines or expression of activation markers may reveal 
possible Src-dependent-and-independent pathways. This however may be an academic 
exercise, as it is emerging that Src kinases do not represent suitable immunosuppressive 
targets as their inhibition is unable to block antigen-driven T cell proliferation. Instead, it 
may be of benefit to evaluate the ability of these compounds to modulate immune responses. 
Studies in vivo using models of inflammation and immune activation may be modulated by 
Src kinase inhibitors, especially if they are dependent upon overexpression or disregulation 
of T cell cytokines.
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7.5 Inhibition of Src kinase and PDE enzymes in mast cells
Mast cells are recognised to be involved in allergic inflammation via activation of their high- 
affinity IgE receptors. Activation of these receptors results in the recruitment of many 
protein tyrosine kinases to the receptor complex and distinguishing which PTKs are crucial 
to activation is important in establishing therapeutic targets that can modulate mast cell 
function. The final results chapter introduced the hypothesis that inhibiting Src kinase 
enzymes may modulate acute mast cell responses, in particular the ability of mast cells to 
produce histamine and leukotrienes.
To perform these studies it was necessary to develop a model system of human mast cell 
activation. Human mast cells were generated from CD34 positive progenitors by stimulation 
with a cocktail of IL-6, SCF and PGE2. Such cells were phenotypically and functionally 
similar to human tissue mast cells. As a consequence of the phenotypic analysis of these 
cells it emerged that, as cells mature from their progenitors, they express a distinct repertoire 
of chemokine receptors. Parallel to these studies, Ochi et al also reported the expression 
of chemokine receptors on such mast cells. The similarities and differences between the two 
studies are summarised in fig 7.2.
The importance of these findings is yet to be fully understood, but differences between this 
and Ochi et aVs work infer that the cytokines used to induce mast cell maturation may affect 
chemokine receptor expression. Indeed it is already known from work by other groups that 
cytokines such as IL-4 and-5 can influence the phenotype of mature mast cells differentiated 
from cord blood precursors
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Figure 7.2: Chemokine receptor expression on cord blood derived m ast cells, it is proposed 
that as mast cells mature from CD34 positive precursors they express distinct chemokine receptor repertoire. 
Agents such as PGE2 and IL-10 can promote the alternative expression of chemokine receptors in the presence of 
SCF and IL-6. PGE2 promotes the expression of CCR2, CXCR3 and CXCR5 where as IL-10 promotes the 
expression of CCR3 and CXCR4. PGE2 is unable to induce mature mast cells to express chemokine receptors, 
however IL-10 (plus SCF and lL-6) can induce the expression of CCR3
In cord blood-derived mast cells elevation of intracellular cAMP was able to inhibit mast cell 
degranulation. As the PDE responsible for controlling mast cell cAMP was unknown, a 
panel of specific inhibitors to various members of the PDE family were used to identify the 
PDE responsible. No role could be ascribed to PDE3, 4 or 7 in FceRI-dependent activation 
of mast cells but the ability of PDE3 and 4 inhibitors to partially inhibit mast cell 
degranulation suggests a complex regulation of cAMP by PDEs in the mast cell. This may be 
why pan-specific inhibitors of PDEs were unable to control cord-blood derived mast cell 
degranulation. However pan-specific PDE inhibitors did block degranulation of mast cells 
recovered from human tissue More studies are needed to ascertain which PDEs are
expressed in cord-blood mast cells and to uncover what factors regulate PDE activity in 
tissue mast cells.
In fully functional mast cells, Src kinase inhibitors blocked the release of histamine and 
synthesis of leukotrienes, in response to IgE but not other downstream activators (e.g. PMA
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and ionomycin). These effects correlated with inhibition of isolated Src kinase enzymes. In 
addition, these inhibitors also blocked rat pleural mast cell degranulation activated by cross- 
linked IgE. From studies using mice in which Lyn has been functionally deleted it is 
apparent that the regulation of FceRI by Src kinases is complex. In such mice deletion of 
Lyn alone does not inhibit mast cell degranulation To reconcile the effect of Celltech Src 
kinase inhibitors with the Lyn knockout mouse data, it must first be shown that these 
inhibitors do not inhibit Btk or Syk, as inhibition of either or both of these kinases could also 
inhibit FceRI-induced degranulation This would then narrow the effect down to the 
Src kinases; Lyn, Src or Yes (all shown to be present in mast cells ^^ °). Mutant FceRI 
positive cell lines (such as PT-18, a Lyn/Src deficient cell line ^^ °), which are positive for 
only one kinase would allow the role of each kinase to be assessed individually. It would be 
logical to test the effect of Celltech Src kinase inhibitors in such cells.
More work is also needed to define the effect of these compounds on other mast cell 
responses such as calcium influx or synthesis of cytokines in response to activation. Albeit, 
these Src kinase inhibitors represent an attractive starting point for a drug discovery 
programme aimed at developing Src kinase family specific inhibitors that can inhibit IgE- 
dependent mast cell degranulation. If these aims were met, then these current molecules, in 
their capacity to act as validating tools, would prove very useful.
7.6 Conclusions
In summary, these studies reinforce the premise that PDE4 inhibitors may be therapeutically 
beneficial for treating inflammatory diseases and can almost be called steroid-like in terms of 
their general broad suppressive qualities, particularly their suppression of cytokine 
production. Src kinase inhibitors, on the other hand, though less useful in suppressing T cell 
proliferation may be therapeutically useful in suppressing T cell cytokine production or mast 
cell activation. Though no role was found for PDE7 in mast cells activated through FceRI, 
potent PDE7 inhibitors may be useful in determining the role of this PDE in other cells. In
147
Chapter 7
particular, PDE7 is thought to be involved in signalling through the TCR complex but as 
yet little evidence has supported this role.
This thesis has stimulated research on many fronts and has in particular emphasised the 
complexity of even simple in vitro assays, particularly with respect to the regulation of 
cytokines. Toward the end of this thesis a new method for analysing cytokine production 
became available. This technique using fluorescent polystyrene beads, has enabled the 
quantification of multiple analytes (in this case cytokines), measured simultaneously from 
the same sample Such a method will allow the measurement of many (up to 100) 
different cytokines from a sample. The application of such technology to understand the 
interplay of cytokines in simple in vitro systems, such as the LPS activation of monocytes, 
may be helpful in understanding how inhibition of single cytokines (e.g. TNF) affect other 
cytokines within a network. These methods are currently being applied to profiling the effect 
of drugs, such as PDE4 inhibitors, with the hope that they will reveal a unique fingerprint of 
cytokine inhibition. The usefulness of this technique has yet to be fully realised but 
preliminary work during this thesis has suggested that such experiments are possible and 
may allow a greater insight into the mechanism of action of cytokine inhibitors.
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